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Analysis of the Role of bHLH/PAS  
Proteins in Aryl Hydrocarbon Receptor Signaling 
Edward J. Dougherty 
ABSTRACT 
 The aryl hydrocarbon receptor (AHR) is a basic helix-loop-helix PER/ARNT/SIM 
(bHLH-PAS) transcription factor that binds ligands typified by 2,3,7,8-
tetracholordibenzo-p-dioxin, translocates to the nucleus, dimerizes with the aryl 
hydrocarbon nuclear translocator (ARNT) and associates with specific cis xenobiotic 
response elements to activate transcription of genes involved with xenobiotic metabolism.  
AHR-mediated signal transduction has been evaluated thoroughly in the C57BL/6J 
mouse model system.  This model system, however, may not be the most accurate model 
for human comparisons as the AHRb-1 allele carried by C57BL/6J contains a point 
mutation that prematurely truncates the receptor at 805 amino acids, while the AHRb-2, 
rat, and human AHR all contain an additional 42-45 amino acids at their carboxy-
terminus that have 70% identity.  This carboxy-terminal region could be functionally 
significant and the analysis of AHR-mediated signal transduction in the rat, human, or 
other mouse strains may better represent the physiology of the AHR pathway.   
ARNT is another member of the bHLH-PAS family of proteins that is essential in 
several distinct signal transduction pathways mediated by its dimerization with a variety 
of bHLH-PAS proteins.  Several isoforms of ARNT have been identified in mammalian 
 xv
and aquatic species.  While ARNT and ARNT2 exhibit >90% amino acid identity in the 
bHLH and PAS domains, gene knock-out of either ARNT or ARNT2 results in 
embryonic/perinatal lethality characterized by distinct phenotypes.  This suggests that 
neither protein can compensate fully for the loss of the other.  Since overlapping tissue 
specific expression of ARNT and ARNT2 does exist, but neither ARNT can compensate 
fully for loss of the other, this suggests that the two proteins have distinct functions in the 
presence of various dimerization partners.   Thus, the focus of these studies is to examine 
the discrepancies between the rat, human, or AHRb-2 possessing the extended carboxy-
terminal region and that of the AHRb-1 and also to examine the role of both ARNT and 
ARNT2 during AHR-mediated signal transduction.  
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Chapter One 
Introduction 
 
1.1 AHR and ARNT History 
The aryl hydrocarbon receptor (AHR) was initially described as a heritable simple 
autosomal dominant trait, designated the Ah locus that conferred the ability to induce aryl 
hydrocarbon hydroxylases by polycyclic aromatic hydrocarbons in the C57BL/6N mouse 
(Gielen et al., 1972).  Response to polycyclic hydrocarbons, as measured in vitro by 
increased rate of formation of benzo[a]pyrene metabolites through an increase in aryl 
hydrocarbon hydroxylase activity had been determined by administration of aromatic 
hydrocarbon ligands such as 3-methylcholanthrene and benzo[a]pyrene.  This response 
was not seen in the DBA/2N, DBA/2J, AKR/N, or NZW/BLN mice, now known to carry 
the AHRd low affinity ligand binding allele (Poland and Glover, 1974; Poland et al., 
1976; Poland et al., 1994).  It was later described that 2, 3, 7, 8-tetrachlorodibenzo-p-
dioxin (TCDD) was approximately 30,000 times as potent as 3-methylcholanthrene as an 
inducer for hepatic aryl hydrocarbon hydroxylase activity in the rat and could elicit 
induction of aryl hydrocarbon hydroxylase activity in the previously “nonresponsive” 
DBA/2N mice as well as in the "responsive" C57BL/6J mice (Gielen and Nebert, 1972).  
Intraperitoneal or topical administration of TCDD to mice also led to an induction of aryl 
hydrocarbon hydroxylase activity and the formation of new cytochrome P1-450 in the 
 2
liver, bowel, lung, kidney and skin as well as induction of 7-ethoxycoumarin O-
demethylase (EROD) activity in the liver and kidney and hepatic p-nitroanisole O-
demethylase and 3-methyl-4-methylaminoazobenzene N-demethylase activity to a similar 
magnitude in either the "nonresponsive" or “responsive” mice (Poland and Glover, 1974).  
Thus, it was demonstrated that the genetically nonresponsive mice had the structural and 
regulatory genes necessary for aryl hydrocarbon hydroxylase induction, but possessed a 
defect that failed to recognize less potent inducers.   
The regulatory product of the Ah locus was then shown to be a soluble protein 
that specifically bound [3H]-TCDD with high affinity with rank-ordered binding affinities 
for various ligands that correlated to their relative potencies to induce aryl hydrocarbon 
hydroxylase activity (Legraverend et al., 1982; Poland et al., 1976). Though the AHR 
was initially described as cytosolic, it has since been shown that the subcellular location 
of the endogenous complex may be cell/receptor dependant and the AHR has been found 
in the cytoplasm and nucleus and may exhibit dynamic nucleocytoplasmic shuttling 
(Pollenz and Dougherty, 2005; Pollenz et al., 1994).  In any case, there is no apparent 
difference in the ability of the AHR to serve as a ligand-activated transcription factor 
from either subcellular compartment.  
While the AHR has been shown to be activated by a variety of polycyclic and 
halogenated hydrocarbons, the identity of an endogenous ligand remains controversial, 
though several endogenous and alternate exogenous ligands have been suggested 
including: 2-(1'H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), a 
compound found predominantly in the preliminary testes and lung, equine estrogen 
equilenin, tryptophan products, dietary polyphenols,  prostaglandins, indirubin and indigo, 
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biliverdin and bilirubin (Adachi et al., 2001; Gouedard et al., 2004; Henry et al., 2006; 
Jinno et al., 2006; Oberg et al., 2005; Phelan et al., 1998a; Seidel et al., 2001; Song et al., 
2002; respectively).  However, while these endogenous compounds have been shown to 
bind the AHR, little has been done to assess whether the AHR functionally binds these 
compounds in vivo. 
The aryl hydrocarbon receptor nuclear translocator (ARNT) protein was initially 
proposed to function in the nuclear translocation of the aryl hydrocarbon receptor (AHR) 
protein.  This assumption was based on the observation that mutant hepatoma cells 
deficient in AHR-mediated induction of the target gene, cytochrome P450 1A1 
(CYP1A1), did not exhibit an increase of AHR in nuclear extracts following treatment 
with ligand as was seen in wild-type cells, and this lack of nuclear accumulation of AHR 
in response to ligand could be rescued by genomic DNA coding for ARNT (Hankinson, 
1979; Hoffman et al., 1991; Legraverend et al., 1982; Okey et al., 1980; Reyes et al., 
1992; Whitlock and Galeazzi, 1984).  These studies also established that ARNT was a 
basic helix-loop-helix protein, as was the AHR, and that ARNT served as a 
heterodimerization partner for the AHR and was a necessary component of the DNA 
binding AHR complex (Burbach et al., 1992; Ema et al., 1992; Hoffman et al., 1991; 
Reisz-Porszasz et al., 1994; Reyes et al., 1992). Using immunohistochemical techniques, 
it was later determined that ARNT was constitutively nuclear and played no role in 
ligand-mediated translocation of the AHR since nuclear translocation of the AHR 
occurred following ligand binding even in ARNT deficient cells, and that this 
translocation was not detected in nuclear extracts since the AHR lacked the ability to bind 
DNA in the absence of ARNT (Holmes and Pollenz, 1997; Pollenz et al., 1994).     
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Since the initial cloning of AHR and ARNT, it has been demonstrated that the 
both proteins are members of the class VII helix-loop-helix superfamily of transcriptional 
regulators, which are classified by the presence of a basic region prior to the HLH 
domain (bHLH) as well as the PER/ARNT/SIM (PAS) domain (Sablitzky 2005).  These 
bHLH/PAS proteins can be further divided into two main groups: one which contains the 
ARNT proteins: ARNT (HIF-1β), ARNT2, BMAL1 (ARNT3, MOP3, JAP3, ARNTL1, 
TIC), and BMAL2 (ARNT4, ARNTL2, MOP9) and one which contains the hypoxia-
inducible factor 1 family (HIF-1α, HIF-2α, HIF-3α), the hypoxia-like factor (HLF), the 
single-minded proteins (SIM1, SIM2), and the AHR (Barrow et al., 2002; Drutel et al., 
1996; Hirose et al., 1996; Hogenesch et al., 1997; Hogenesch et al., 2000; Ikeda and 
Nomura, 1997; Ikeda et al., 2000; Maemura et al., 2000; Okano et al., 2001; Takahata et 
al., 1998; Wolting and McGlade, 1998) (Tables 1.1, 1.2).  These proteins generally 
appear to function through heterodimerization of members of the first group with 
members of the second group, though homodimerization of ARNT has also been 
suggested.  Together, these proteins are involved with the regulation of a variety of 
signaling pathways ranging from angiogenesis, vasculogenesis, xenobiotic metabolism, 
and hypoxic response to developmental pathways wherein each dimer associates with 
specific cis acting DNA elements to regulate target genes (Crews, 1998; Ema et al., 
1996a; Ema et al., 1997; Furness et al., 2007; Kewley et al., 2004; Whitelaw et al., 1993) 
(Figure 1.1).  
  Interestingly, while many of ARNT's interactions with various dimerization 
partners have been established both in vitro and in vivo, as have the more recently  
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Table 1.1: Summary of ARNT cloning. 
ARNT Type, the ARNT group to which each clone has the highest identity; Clone, the 
original name ascribed to the individual cDNA during the cloning of each gene; Species, 
the origin of the cDNA library or EST database used in the generation of probes.    
* Tian,H., Russell,D.W. and McKnight,S.L., Unpublished Direct Submission to NCBI 
database 10-JUN-1996. 
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Table 1.2: Amino acid identity comparisons of murine ARNT types and across 
ARNT isoform domains. 
 
 
 
Numbers represent the percent identities between compared proteins using the 
CLUSTALW (Slow/Accurate, Gonnet) method (MEGALIGN, DNAstar, Madison, WI) 
with a PAM250 residue weight table.  A, Identity among murine ARNT types. Accession 
numbers were: mARNT (U10325), mARNT2 (D63644), mARNT3 (AB014494), 
mARNT4 (AY005163). B, Identity among murine ARNT protein domains. 
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Figure 1.1: Overview of known cellular pathways requiring ARNT or ARNT2 in 
mammals. Protein•protein interactions between the ARNT proteins and their 
dimerization partners that have been functionally and biochemically established both in 
vitro and in vivo are indicated by solid thick arrows, while interactions that have been 
established either in vitro or in vivo are indicated by solid thin lines, and presumed 
interactions are shown with dashed arrows.  Also shown are the gene regulatory 
sequences to which the heterodimers/homodimers bind: XRE: xenobiotic response 
element; HRE: Hypoxia response element; CME: central midline enhancer, with the 
bolded sequence representing the portion of the regulatory sequence that is recognized by 
ARNT/2.  Below these sequences are the some of the target genes of the 
heterodimers/homodimers that have been assessed and their overall physiological role.  
 8
discovered ARNT3 and ARNT4 proteins’ roles in circadian rhythm regulation with 
Clock, the physiological roles of ARNT2 remain less clear.   
 
1.2 AHR and ARNT Domains 
These proteins are modular, and their common characteristics are the bHLH 
domains and the PAS domains that are distal to the bHLH motif.  Through mutation and 
deletion analyses, the basic domain of these proteins has been shown to be critical for 
DNA binding whereby 2-4 basic residues appear to make direct contact with DNA (in the 
AHR and ARNT respectively) while other basic residues may make contact with the 
phosphodiester backbone (Bacsi and Hankinson, 1996).  In the AHR, tyrosine 9 (Y9) and 
arginine 39 (R39) appear to be essential for AHR contact with the DNA, while other 
residues of the basic region maintain α-helical structure and make contact with the 
phosphodiester backbone (Bacsi and Hankinson, 1996).  Interestingly, the basic region of 
ARNT more closely resembles the basic region found in leucine zipper-HLH proteins 
such as TFEB, USF, c-Myc and Max than the basic region of the AHR (Sogawa et al., 
1995).  This basic region has been shown to be critical for binding to the E-box half site 
GTG, whereby during AHR signaling, four residues are critical for contact with DNA 
(H94, E98, Rl0l, and R102), which correspond in position to essential residues found in 
the bHLH proteins USF and MAX and are conserved across all characterized ARNT 
proteins (Bacsi and Hankinson, 1996; ED, unpublished observations).  Though these 
mutational analyses focused on XRE binding ability of the AHR•ARNT complex as the 
endpoint and have not included other ARNT types (ARNT2/3/4), each ARNT protein 
appears to associate with the GTG half-site regardless of its dimerization partner, while 
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the partner provides the specificity for enhancer binding (Ebert et al., 1995; Fujisawa-
Sehara et al., 1986; Hapgood et al., 1989; Paul and Ferl, 1991; Semenza et al., 1994; 
Swanson et al., 1995; Wharton and Crews, 1993; Wharton et al., 1994). 
The HLH motif consists of two amphipathic α-helices connected by a variable 
loop and appears to serve as a surface for protein-protein interactions and is also 
responsible for positioning the α-helix of the basic domain within the major groove of B-
DNA to allow for specific interactions between the DNA binding protein and the target 
response elements (Anthony-Cahill et al., 1992).   Deletion of either helix has been 
shown to abolish dimerization (Reisz-Porszasz et al., 1994). 
The PAS domain, named for the first three proteins found to exhibit this 
conserved sequence (PER/ARNT/SIM) is found in numerous proteins that are involved 
with detection of environmental cues and stress response (Gu et al., 2000).  However, 
while this domain has a high level of identity between the ARNT and ARNT2 proteins, 
there is less than 20% identity in this region between the PER, ARNT, and SIM proteins 
themselves (Gu et al., 2000; Huang et al., 1993).  Therefore, the PAS domain is 
characterized by an approximately 100 amino acid hydrophobic-rich region, which is 
further characterized by a highly degenerate ~50 amino acid repeat with an invariant 
phenylalanine, histidine, and aspartic acid at positions 1, 41, and 44 respectively within 
the PAS domain repeat (Huang et al., 1993; Nambu et al., 1996).  Both the AHR and all 
ARNT proteins appear to contain two PAS domains termed PAS A and PAS B.  In each 
case, the PAS domain appears to provide specificity for dimerization, may also provide 
the specificity for the protein binding of the adjacent HLH domain, and may enable 
transcription following DNA binding (Chapman-Smith et al., 2004; Dolwick et al., 1993; 
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Jain et al., 1994; Lindebro et al., 1995; Pongratz et al., 1998; Reisz-Porszasz et al., 1994; 
Whitelaw et al., 1994; Zelzer et al., 1997).   In addition, it has been suggested that the 
PAS A domain is critical for DNA binding and protein-protein interactions and 
contributes directly to AHR•ARNT XRE binding (Chapman-Smith et al., 2004; 
Chapman-Smith and Whitelaw, 2006; Pongratz et al., 1998).   Similarly, the PAS B 
domain has been implicated in contributing to the heterodimerization potential and 
stability of ARNT and HIF-1α/HIF-2α through interactions occurring via the PAS B 
central β-sheet, and mutations in this region have been suggested to affect the 
transcriptional ability of the overall heterodimer (Card et al., 2005; Erbel et al., 2003).  
For the AHR, the PAS domain appears to have additional functions including Hsp90-, 
XAP2-, and ligand-binding (Dolwick et al., 1993; Jain et al., 1994; Reisz-Porszasz et al., 
1994; Whitelaw et al., 1994).  It has also been suggested that the PAS domain for the 
AHR contains a repressor region, since Ah receptor lacking this region exhibits 
constitutive activity (CAR mutant), though it is now known that it is the presence of 
Hsp90 bound to the receptor by the PAS domain that prevents DNA binding from 
occurring (Antonsson et al., 1995; Heid et al., 2000; Whitelaw et al., 1994).  
The AHR and ARNT proteins also each contain a putative nuclear localization 
site (NLS).  While the AHR may be cytoplasmic, nuclear, or shuttling through the 
cytoplasm and nucleus based on the receptor species, ARNT appears to be constitutively 
nuclear (Pollenz and Dougherty, 2005; Pollenz et al., 1994).  In the AHR, the NLS is a 
single basic region (RKRRKPVQK) located at the NH-terminus that is capable of 
recognizing the importin proteins necessary for nuclear translocation following ligand 
binding, however, the AHRb-1 appears to exist in a conformation whereby the NLS is 
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exposed only after a conformational change following ligand binding, resulting in the 
nuclear import of the AHR (Holmes and Pollenz, 1997).   
The AHR also contains a leucine-rich nuclear export site (NES) located within the 
HLH helix 2 region amino acids 63-71 (LDKLSVLRL).  Leucine to alanine scanning 
mutagenesis of leucines 66 and 71 of the putative AHR NES revealed that alanine 
substitutions at these residues resulted in a protein with reduced function in dimerization 
to ARNT and binding to DNA (Pollenz and Barbour, 2000).  In these same studies, 
mutagenesis of leucine 69 did not impact function with regard to ARNT dimerization or 
DNA binding, yet resulted in a protein that was incapable of nuclear export suggesting 
that AHR defective in nuclear export can remain functional during ligand mediated gene 
induction.  
The ARNT proteins also each contain a putative nuclear localization site (NLS) 
and appear to be localized to the nucleus, though it has been suggested that partial 
cytoplasmic localization may be occurring in certain cell types or during developmental 
periods (Eguchi et al., 1997; Holmes and Pollenz, 1997; Ikeda and Nomura, 1997; Ikeda 
et al., 2000; Jain et al., 1998; Pollenz et al., 1994; Sadek et al., 2000; Schoenhard et al., 
2002).  In the ARNT and ARNT2 proteins, this NLS is bipartite, consisting of two basic 
domains separated by an acidic region spacer (RXXKRRSGXDFDDEXXXXXKFXR) 
that are capable of interacting with the proteins of the nuclear pore targeting complex for 
efficient nuclear localization (Eguchi et al., 1997).  Deletion of this region, however, 
results in a cytosolic protein that remains capable of interacting with the AHR (Holmes 
and Pollenz, 1997; Song and Pollenz, 2003).   ARNT3 and ARNT4 both contain a short 
basic NLS (RKRK), though the ARNT3 protein also appears to contain two nuclear 
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export sites (NES) located in the PAS domains that allow for dynamic nucleocytoplasmic 
shuttling of this ARNT isoform (Ikeda et al., 2000; Kwon et al., 2006; Schoenhard et al., 
2002). 
Deletion and mutational analysis has also defined regions in the carboxy-terminus 
of the AHR that are important in transactivation including an acidic domain, a proline-
rich domain, and a serine-rich region as well as a glutamine rich region in ARNT (Jain et 
al., 1994; Ko et al., 1996; Ko et al., 1997; Li et al., 1994; Pollenz et al., 2005; Whitelaw 
et al., 1994) (Figure 1.2).  In the AHR, loss of the proline and serine rich regions by 
truncation reduces the transactivation ability of the AHR as measured by a marked 
reduction of CYP1A1 protein following treatment with TCDD compared to full length 
AHR, while additional loss of the acidic region ablated all apparent transactivation ability 
(Pollenz et al., 2005).    
The carboxy-terminal portion of the ARNT, ARNT2, and ARNT3 proteins also 
appears to contain a transactivation domain and a glutamine-rich region has been 
demonstrated to have functional significance in both ARNT and ARNT2, while ARNT3 
appears to have an acidic region important to its transactivation potential when partnered 
to HIF-1α (Corton et al., 1996; Li et al., 1994; Takahata et al., 1998).  In contrast, the 
carboxy-terminal portion of ARNT4 has been shown to be dispensable for luciferase 
reporter transcription in the presence of Clock (Schoenhard et al., 2002).  In the case of 
ARNT, reports of the functional role of the carboxy-terminal portion as a transactivation 
domain during AHR signaling have shown conflicting results.  Studies performed by Li 
et al. (1994) demonstrated that deletion of the glutamine-rich region of the ARNT  
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Figure 1.2: Domain structures of the AHR (b1 allele) and ARNT. Thin horizontal 
lines indicate domain regions; bold lines indicate functional regions for the AHR.  NLS, 
nuclear localization signal; NES, nuclear export signal; b, basic region; HLH, helix-loop-
helix; PAS A and PAS B, PER/ARNT/SIM homology regions; PAC, PAS associated 
carboxy-terminal region; TAD, transactivation domain. Numbers under each box 
represent amino acids.  
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transactivation domain (TAD) by truncation resulted in decreased CAT activity 
controlled by a TCDD-responsive enhancer when ARNT deficient (c4) hepatoma cells 
were cotransfected with ARNT and reporter vectors.  In contrast, studies by Corton et al. 
(1996) using a Gal4 hybrid approach demonstrated that loss of the ARNT TAD through 
truncation resulted in no change in overall a CAT activity reporter under the control of 
multiple Gal4 upstream activating sequences.  Thus, in contrast to the studies by Li et al., 
the studies by Corton et al. suggest that the ARNT TAD has minimal impact on 
transactivation of the AHR•ARNT complex, and suggest that during AHR signaling, the 
AHR itself provides the functional TAD within the AHR•ARNT complex while the 
ARNT TAD is silent (Corton et al., 1996; Li et al., 1994).   
However, the studies by Corton et al. (1996) also suggested that the strength of 
the ARNT TAD may be cell specific, since the ARNT TAD appeared to exhibit the same 
properties as the well-characterized VP16 TAD in COS-1 cells, but exhibited ~10 fold 
weaker activity in hepatoma ARNT deficient (c4) cells.  In separate studies, the AHR and 
ARNT TAD showed equal transactivation ability in Hepa-1, CHO, and COS-7 cells, 
while the ARNT TAD appeared to be much weaker than the AHR TAD in HepG2 cells 
when recombined with the glucocorticoid receptor DNA binding domain and used to 
drive reporter activity controlled by a glucocorticoid receptor responsive enhancer 
(Whitelaw et al., 1994).  Since the studies by Li et al. (1994) also employed the ARNT 
deficient c4 cells, cell-specificity of the ARNT TAD cannot explain the discrepancies 
between these and other studies and since all studies described herein employed 
transiently transfected cells with no immunohistochemistry to support population wide 
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transfection, more thorough studies were later conducted in this area using stably 
transfected cells (Ko et al., 1996).  Using retrovirally transfected truncated ARNT cDNA 
in ARNT deficient (BPrc1, LA-II) mouse hepatoma cells, these studies showed that in 
vivo, the ARNT TAD is dispensable for  TCDD-induced CYP1A1 induction and that the 
AHR when dimerized with ARNT supplies the dominant TAD (Ko et al., 1996; Whitlock 
and Galeazzi, 1984).  While reporter studies have also been performed using ARNT2-4, 
similar evaluations using stably transfected cells have not yet been performed using these 
ARNT proteins nor have such studies examined the contribution of the ARNT TAD in 
other ARNT requiring pathways (Cowden and Simon, 2002; Hirose et al., 1996; 
Takahata et al., 1998). 
 
1.3 AHR Proteins 
AHR-mediated signal transduction has been evaluated thoroughly in the 
C57BL/6J mouse model system that carries the AHRb-1 allele.  While this allele has been 
the most studied, it may not be the most appropriate choice for study as it is clearly the 
outlier amongst the AHR alleles as well as amongst Ah receptors from other species 
including the rat and human.  The AHRb-1 is found in the C57, C58, and the MA/My 
strains where it exists as a ~95kDa (805 amino acid) cytosolic receptor, which does not 
appear to be shuttling through the nucleus endogenously (Poland et al., 1994; Pollenz and 
Dougherty, 2005).  The AHRb-2 found in the BALB/cBy and C3H strains exists as a 
~104kDa (848 amino acid) receptor that is primarily nuclear, though capable of 
nucleocytoplasmic shuttling.  Additionally, the AHRb-3 is a~105kDa (883 amino acid) 
receptor allele found in mus caroli, mus spretus, and the MOLF/Ei strains, while the 
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AHRd allele found in the AKR, DBA/2, and 129 strains is a ~104kDa (848 amino acid) 
receptor.  Collectively, these alleles differ by only 8 point mutations in the initial 805 
amino acid open reading frame and by the presence of additional 43-78 amino acids in 
the carboxy-terminus of the Ahb2, Ahb3, and Ahd receptors.  Of these 8 point mutations 
found amongst the murine AHR alleles, the AHRb-1 accounts for more than half, resulting 
in a receptor that binds Hsp90, XAP2, and ligand more avidly and is more stable than the 
other mouse allelic receptors (Figure 1.3, Table 1.3).  These discrepancies support the 
idea that the AHRb-1 is the outlier.  The amino terminal halves of these AHR alleles are 
identical except for 1 amino acid change in the second PAS box (isoleucine to methionine 
at position 324) with the remaining mutations present in the carboxy-terminus.  
Interestingly, these mutations are generally outside of the characterized functional 
domains with the exception of the PAS box mutation (324) and a serine to asparagine 
mutation in the acidic portion of the transactivation domain, yet these receptors have a 
varying degree of activity following ligand binding.  Though the AHRd differs from the 
AHRb-2 by only three amino acids, it is nonresponsive to low affinity ligands, unlike the 
AHRb-2.  This loss of function has been attributed to the alanine to valine mutation at 
position 375, which occurs immediately distal to the ligand-binding domain (Poland et 
al., 1994).  Furthermore, the AHRb-1 is truncated when compared with Ah receptors 
found in other mammalian species, containing a point mutation that prematurely truncates 
the receptor at 805 amino acids, while the AHRb-2, rat, and human AHR all contain an 
additional 42-45 amino acids at their carboxy-terminus that have 70% identity (Figure 
1.3).  As this additional carboxy-terminal sequence is present in the other AHR alleles as  
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Figure 1.3: Protein sequence alignment of various AHR c-termini.   Carboxy-terminal alignment of AHR proteins from amino acid 
position 800 to termination in Mus musculus C57BL/6J (Ahb1 allele); Mus musculus BALB/c (Ahb2 allele); Mus musculus DBA/2J 
(Ahd allele); the chicken Gallus gallus; Homo sapiens, and Rattus norvegicus.  Proteins were aligned by using the CLUSTALW 
(Slow/Accurate, Gonnet) method (MEGALIGN, DNAstar, Madison, WI) using a PAM250 residue weight table. 
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Table 1.3: Amino acid changes among the first 805 amino acids of murine AHR 
alleles. 
 
 
Full length AHR proteins were aligned from the murine strains: C57BL/6J (Ahb-1 allele); 
C3H (Ahb-2 allele); MOLF/Ei (Ahb-3 allele); and DBA/2J (Ahd allele).  Proteins were 
aligned by using the CLUSTALW (Slow/Accurate, Gonnet) method (MEGALIGN, 
DNAstar, Madison, WI) using a PAM250 residue weight table.  Point mutations 
occurring in the first 805 amino acids between proteins are shown in bold.  Numbers 
above each column represent the amino acid location within the open reading frame.   
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well as across species and is reasonably conserved in sequence, it is reasonable to assume 
that this sequence may be functionally relevant. 
Several orthologs of the AHR have also been identified in other mammalian, 
invertebrate, aquatic and avian species including Mesocricetus auratus, Gallus gallus, 
Cavia porcellus, Cricetulus griseus, the rabbit Oryctolagus cuniculus, the seal Phoca 
siberica, the North Atlantic right whale Eubalaena glacialis, the clam Mya arenaria, the 
zebra mussel Dreissena polymorpha, the sea lamprey Petromyzon marinus, the common 
tern Sterna hirundo, the common cormorant Phalacrocorax carbo, the Asian malaria 
mosquito Anopheles stephensi, Drosophila menologaster, and Carnorhabditis elegans 
(Bennett et al., 1996; Butler et al., 2001; Emmons et al., 1999; Hahn et al., 2004; Jensen 
and Hahn, 2001; Karchner et al., 1999; Kim and Hahn, 2002; Korkalainen et al., 2001; 
Meyer et al., 2003; Powell-Coffman et al., 1998; Roy and Wirgin, 1997; Satoh et al., 
2003; Takahashi et al., 1996; Tanguay et al., 1999; Walker et al., 2000; Yasui et al., 
2004; Figure 1.4).  Many more AHR proteins have also been predicted in silico based on 
genomic sequencing data (www.ensembl.org), though have not yet been evaluated in 
vivo.  Interestingly, the function of the AHR in response to xenobiotics appears to be 
well-conserved across many of these species.   However, the AHR proteins from several 
invertebrate species appear to be developmentally regulated, lacking constitutive 
expression and exhibiting a lack of ligand binding (Butler et al., 2001; Emmons et al., 
1999; Powell-Coffman et al., 1998). 
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Figure 1.4: AHR protein dendogram.  Full-length proteins were aligned by using the 
CLUSTALW (Slow/Accurate, Gonnet) method (MEGALIGN, DNAstar, Madison, WI) 
using a PAM250 residue weight table.  The horizontal distance to the subclusters 
corresponds to degree of amino acid substitutions among members.  References are as 
follows: (Abnet et al., 1999; Bennett et al., 1996; Butler et al., 2001; Carver et al., 1994a; 
Emmons et al., 1999; Hahn et al., 2004; Jensen and Hahn, 2001; Karchner et al., 1999; 
Kim and Hahn, 2002; Korkalainen et al., 2001; Meyer et al., 2003a; Nene et al., 2007; 
Powell-Coffman et al., 1998; Roy and Wirgin, 1997; Satoh et al., 2003; Takahashi et al., 
1996; Tanguay et al., 1999; Walker et al., 2000; Yasui et al., 2004) 
 
Amino acid substitutions x100
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1.4 AHR-Mediated Signaling 
The current model of AHR-mediated signal transduction in mammals 
hypothesizes that the AHR in its unliganded state exists in a ~280 kDa multimeric 
complex consisting of two molecules of Hsp90, the immunophilin-like protein XAP2  
 (XAP, AIP, ARA9), and p23 (Chen and Perdew, 1994; Gu et al., 2000; Petrulis and 
Perdew, 2002; Pollenz et al., 2002; Whitlock, 1999).  Once activated by ligand, the AHR 
translocates to the nucleus where it dissociates from the Hsp90 complex and forms a 
dimer with ARNT via its bHLH domains by an unknown regulatory step that may 
involve a phosphorylation event on the AHR following nuclear import (Heid et al., 2000; 
Pollenz et al., 1994; Pongratz et al., 1998).  The Hsp90-free AHR•ARNT complex is then 
capable of binding the non-canonical E-box like consensus xenobiotic response element 
(XRE, DRE, AHRE, ARE) 5'-T(T/A)GCGTG-3', associating with numerous coactivators 
such as members of the 160 family (SRC-1, SRC-2, SRC-3), RIP140, CoCoA, and p300, 
and regulating the transcription of phase I metabolizing enzymes including the 
monooxygenase CYP1A1, NAD(P)H:quinone oxidoreductase, alcohol dehydrogenase, 
and aldehyde dehydrogenase, along with phase II  conjugation enzymes including 
glutathione-S-transferase Ya, UDP-glucoronosyltransferase, and N-acetyltransferases that 
are important in the metabolism of drugs, steroids, and toxins (Denison et al., 1988; 
Hankinson, 2005; Hapgood et al., 1989).  The AHR is then targeted for degradation by an 
unknown mechanism that terminates at the 26-S proteasome (Pollenz, 1996; Pollenz, 
2002).  It must be noted, however, that this description is simplified and there are several 
unknowns throughout this pathway such as the regulation of each step in the pathway, the  
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Figure 1.5: Schematic of the AHR signaling pathway. In brief, ligands such as 
halogenated aromatic hydrocarbons (HAHs), polychlorinated biphenyls (PCBs), 
polyaromatic hydrocarbons (PAHs) enter a cell, bind to the AHR complex leading to a 
conformational change of the receptor, which then translocates to the nucleus and 
heterodimerizes with ARNT.  The AHR•ARNT complex then associates with xenobiotic 
response elements with the core sequence 5’-TNGCGTG to regulate phase I and phase II 
metabolizing enzymes, typified by CYP1A1.  The AHR is then targeted for degradation 
via the 26S proteasome. 
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involvement of specific coactivators and coregulators and the precise mechanism behind 
the degradation of the AHR (Figure 1.5). 
 
1.5 AHR Associated Proteins 
The heat shock protein 90 family (Hsp90a and Hsp90b in the human, Hsp84 and 
Hsp86 in the mouse) is a group of highly conserved and highly expressed chaperone 
proteins implicated in the maintenance of proper protein folding and prevention of 
protein aggregation with a variety of intracellular receptors (Hickey et al., 1989; Moore et 
al., 1989).  The AHR appears to have equal affinities for either Hsp90 type (Chen and 
Perdew, 1994; Czar et al., 1994), and this association is essential for agonist-induced 
AHR signaling in vivo since Hsp90's association with the AHR, as well as with the 
glucocorticoid receptor (GR) and MyoD, has been correlated to the receptor's ability to 
maintain proper conformation and to bind ligand (Carver et al., 1994b; Evans, 1989; 
Hutchison et al., 1994; Schmidt et al., 1996; Shue and Kohtz, 1994; Whitelaw et al., 
1995).  Preceding ligand binding, Hsp90 appears to hold the AHR in a conformation 
capable of binding ligand while repressing the ability of the receptor to bind DNA.  
However, it has also been suggested that Hsp90 is necessary only for the initial folding of 
the AHR, since in the presence of salt conditions that result in the disassociation of the 
existing AHR from the Hsp90 complex leads to Hsp90-free AHR that remains capable of 
binding ligand (Heid et al., 2000; Phelan et al., 1998b; Whitelaw et al., 1994).   The 
affinity of Hsp90 for the AHR has been correlated to the phosphorylation status of three 
serine residues within Hsp90 (S225 and S254 for Hsp90b and S230 in Hsp90a 
[equivalent to S225 of Hsp90b]) that occur within the charged linker domain that 
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associates with the AHR (Chen and Perdew, 1994; Ogiso et al., 2004).  Interestingly, in 
these studies, mutation of the potential phosphorylation sites S225 and S254 to alanines 
increased both the affinity of AHR for Hsp90 as well as the transactivation activity of the 
AHR as measured by a luciferase reporter following treatment with 3-methycholanthrene 
compared to glutamine substitutions at these residues, suggesting that phosphorylation 
status of Hsp90 may play a role in modulating AHR signaling (Ogiso et al., 2004). 
XAP2 is a ~37kDa protein that contains three regions of homology to the 
tetratricopeptide (TPR) motif found in the FKBP12 and FKBP59 and FKBP52 
immunophilins, which act as molecular chaperones in steroid receptor signaling, targeting 
steroid receptors to the nucleus.  Unlike immunophilins, however, XAP2 does not 
associate with immunosuppressive drugs like FK506 (Tacrolimus, Fujimycin), but 
appears to associate with the AHR through this drug-binding (FK) domain and with 
Hsp90 via its TPR domain (Carver et al., 1998; Ma and Whitlock, 1997).  Also, XAP2 
does not appear to be involved in maturation of the AHR, but can modulate AHR activity 
in that overexpression of XAP2 has been suggested to increase response to aryl 
hydrocarbon hydroxylase inducers without appearing to alter the affinity of the AHR for 
TCDD (Carver et al., 1998; Ma and Whitlock, 1997).   Reduction of XAP2 by siRNA 
appears to result in the transformation of the AHR from a statically cytoplasmic receptor 
to one capable of undergoing dynamic nucleocytoplasmic shuttling (Pollenz et al., 2006).  
Furthermore, following ligand activation of the AHRb-1, XAP2 remains associated with 
the receptor following nuclear translocation and may serve to inhibit transformation of 
the AHR complex to the ARNT dimerized form (Pollenz and Dougherty, 2005; Pollenz et 
al., 2005).   Phosphorylation of XAP2 has not been implicated in modulation of AHR 
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function; however, mutation of S53 to alanine appears to inhibit the ability of XAP2 to 
enter the nucleus (Dull et al., 2002).   
P23 is a 23-kilodalton Hsp90 binding protein that appears to serve several roles in 
AHR signaling including stabilization of the AHR-Hsp90 complex, assistance of nuclear 
translocation, and recruitment of XAP2 to the AHR complex (Kazlauskas et al., 2001). 
Similar to its role in glucocorticoid receptor signaling, p23 appears to be important for 
proper maturation of the latent AHR complex, allowing for a stable complex capable of 
binding ligand, heterodimerizing with ARNT and subsequently binding DNA.  These 
hypotheses stemmed from observations demonstrating that loss of p23 from crude 
reticulocyte extracts resulted in a diminished DNA binding shift in electrophoretic 
mobility shift assays, while the presence of p23 appeared to enhance AHR•ARNT 
heterodimerization in an Hsp90-dependent manner (Shetty et al., 2003).  This 
enhancement by p23 was also seen by others and therefore, p23 has been suggested to be 
an important enhancer of AHR signaling, though ultimately not necessary for AHR 
function (Cox and Miller, 2003).  Similar results were also seen with another Hsp90 
binding protein cyclophilin 40 (CyP40), suggesting that other proteins may also be 
involved with the formation/stability of the latent AHR complex (Shetty et al., 2004).  
 
1.6 Degradation of the AHR 
Agonist binding to the AHR results in degradation of the receptor following DNA 
binding, but not of the complex’s components: ARNT, XAP2, or Hsp90 (Cioffi et al., 
2002; Giannone et al., 1998; Pollenz, 2002; Roman and Peterson, 1998; Roman et al., 
1998).  Following TCDD binding, the AHRb-1 is rapidly depleted by >60-80% within 4-6 
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hours of treatment in numerous cell culture models and does not return to basal levels as 
long as ligand is present in the media (Pollenz, 1996; Reick et al., 1994).  This 
degradation is even more rapid with the Ahb-2, human or rat receptors, depleting by 90-
100% within 2 hours of treatment (Pollenz and Dougherty, 2005).  In either case, this 
degradation has been  demonstrated to occur via the 26S proteasome complex since pre-
treatment with the proteasome inhibitors MG-132 or lactacystin prior to treatment with 
agonist blocks degradation of the receptor, while pre-treatment with inhibitors of calpain, 
serine, or cysteine proteases nor lysosomal proteases cannot (Davarinos and Pollenz, 
1999; Ma and Baldwin, 2000; Wentworth et al., 2004).   
As such, several studies have suggested that the AHR is ubiquitinated, though 
none demonstrated definitive evidence of such events and at this time no E3 ligase has 
been demonstrated to be involved in the degradation of the AHR (Ciechanover, 2005; 
Kazlauskas, 2000; Ma and Baldwin, 2000).  Furthermore, ligand-dependant degradation 
can also be blocked by pre-treatment with the transcription inhibitor actinomycin D (AD) 
or the translation inhibitor cycloheximide (CHX) without affecting nuclear localization or 
DNA binding of the receptor, suggesting that both active transcription and translation are 
necessary for ligand-induced degradation of the AHR (Pollenz et al., 2005).   
Carboxy-terminally truncated Ah receptors as well as those defective in DNA 
binding or ARNT dimerization similarly exhibit a low level of degradation following 
treatment with TCDD albeit a much lower level of degradation than that seen in wild 
type; however, this degradation cannot be blocked by either AD or CHX, suggesting that 
this loss is not representative of the typical degradation seen following ligand binding 
with the wild-type receptor (Pollenz et al., 2005). 
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It also appears, however, that the AHR is capable of being degraded by a second, 
distinct pathway that does not require ligand binding.  This pathway is typified by 
treatment with geldanamycin (GA), a benzoquinone ansamycin capable of binding to the 
ATP-binding pocket of Hsp90 and thereby likely altering the conformation of the Hsp90 
associated AHR to allow for nuclear translocation of the receptor and its subsequent 
degradation without disruption of the AHR complex itself and, importantly, without 
DNA binding or subsequent gene induction (Chen et al., 1997; Meyer et al., 2003b; Song 
and Pollenz, 2002).  This second pathway is characterized by a rapid and robust 
degradation profile (>80% within 1 hour) that also appears to occur via the 26S 
proteasome and can be blocked by MG-132 or lactacystin (Song and Pollenz, 2002).  
Though treatment with GA results in a rapid nuclear translocation of the AHR as does 
ligand-binding, further studies suggest this mode of degradation can occur in either the 
cytoplasm or nucleus (Song and Pollenz, 2002).  Additionally, degradation of the AHR 
via GA cannot be blocked by treatment with either AD or CHX, suggesting that multiple 
mechanisms exist for the degradation of the receptor, though both terminate at the 26S 
proteasome (Pollenz et al., 2005). 
 
1.7 Consequences of AHR Degradation or Overexpression 
 Studies have shown that a single oral dose of TCDD can lead to sustained 
depletion of AHR proteins in the liver, spleen, thymus, and lung in vivo and that such a 
depletion correlates with reduction in TCDD-mediated reporter gene expression in 
mammalian culture cells following a second dose of TCDD (Pollenz et al., 1998).   The 
importance of this loss is underscored by the variety of physiological defects seen in 
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AHR-/- mice (Andreola et al., 1997; Fernandez-Salguero et al., 1995; Gonzalez et al., 
1995; McDonnell et al., 1996).  It is important to note that many of the phenotypes seen 
in TCDD-treated mice are similar to those reported for AHR-/- mice that have not been 
exposed to TCDD.  Thus, this loss of AHR may contribute to some of the biological 
effects of xenobiotics.  Degradation of the AHR, therefore, which may be used as a 
means of attenuating the transcriptional response, can have significant repercussions on 
future signaling ability of the AHR pool as well as biological implications.   
Conversely, blockage of degradation by CHX appears to result in potentiation of 
gene induction (superinduction), whereby genes regulated by the AHR are induced to a 
higher level and for a longer period of time (Ma and Baldwin, 2000; Pollenz and Barbour, 
2000).  Induction of CYP1A1 protein in response to TCDD has also been implicated in 
some subsets of the physiological defects associated with TCDD toxicity such as 
pericardial edema and reduced blood flow (Teraoka et al., 2003).  Furthermore, 
constitutive activation of the AHR in the CAR mutant lacking a ligand-binding domain 
led to proliferation of stomach tumors and reduced life span (Andersson et al., 2002).  
Together, these data suggest a role for the gene products of AHR-dependant signaling in 
mediating the toxic effects of TCDD. 
 
1.8 Mammalian ARNT Isoforms 
Several isoforms of ARNT have been identified in mammalian species and have 
been grouped into four ARNTs: ARNT (HIF-1B), ARNT2, ARNT3 (BMAL1, MOP3, 
JAP3, ARNTL1, TIC) and ARNT4 (BMAL2, ARNTL2, MOP9, CLIF) (Table 1.1).  
ARNT appears to be ubiquitously expressed, while ARNT2 has been described primarily 
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in the kidneys and central nervous system (Abbott and Probst, 1995; Aitola and Pelto-
Huikko, 2003; Hirose et al., 1996; Jain et al., 1998).  A more recent study, however, has 
demonstrated that mRNA for both ARNT and ARNT2 is co-localized in many murine 
peripheral organs and neuronally derived tissue, suggesting that the distribution of 
ARNT2 may not be as restricted as previously described (Aitola and Pelto-Huikko, 
2003).  ARNT3 and ARNT4, on the other hand, were initially characterized by Northern 
blot analysis as being expressed only in the skeletal muscle, heart, and brain, with high 
expression in the suprachiasmatic nucleus (SCN) (Hogenesch et al., 1997; Ikeda and 
Nomura, 1997; Ikeda et al., 2000; Okano et al., 2001; Takahata et al., 1998), though other 
studies have reported more ubiquitous expression of ARNT3 including high levels 
detectable in the liver, kidney, lung, skeletal muscle pancreas, stomach, and testis, and a 
varied expression of ARNT4 differing between splice variants (Ikeda et al., 2000; 
Schoenhard et al., 2002; Wolting and McGlade, 1998).  Given that the ARNT3 and 
ARNT4 proteins appear to be primarily involved with circadian rhythm signaling and are 
expressed in an oscillatory manner, it is likely that expression would be seen not only in 
the SCN, which acts as the central pacemaker, but also in the heart, kidney, liver, and 
other tissues that have peripheral clocks (Kohsaka et al., 2007; Maemura et al., 2007).  
Additionally, since the expression of these proteins oscillates, it is expected that detection 
of these proteins in vivo would differ based on the central clock time.  Therefore, studies 
were carried out to examine the time course of expression of both ARNT3 and ARNT4 in 
the zebrafish in several tissues (Cermakian et al., 2000).  These studies revealed that 
mRNA for both ARNT3 and ARNT4 can be detected in the zebrafish brain, pineal gland, 
eye, heart, liver, spleen, and testis depending on the physiological time point evaluated, 
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suggesting a ubiquitous, but oscillatory expression pattern for these proteins in vivo that 
was asynchronous between ARNT3 and ARNT4.  Since it has been suggested that 
expression of ARNT also oscillates on a circadian rhythm in several tissues, similar 
studies to those performed on ARNT3 and ARNT4 should be considered for ARNT and 
ARNT2 to fully evaluate tissue distribution of these proteins in vivo (Garrett and 
Gasiewicz, 2006; Richardson et al., 1998). 
In contrast to mammalian systems, expression of ARNT2 is markedly different 
amongst several fishes and avian species; however, ARNT2 in Xenopus has also been 
characterized as being highly expressed in the brain and kidneys with low or absent levels 
in other tissues as has been described in mammalian systems.  In contrast, the marine 
teleost, Fundulus heteroclitus, appears to predominantly express a form of ARNT that is 
ARNT2-like (fhARNT2), resembling mouse ARNT2 (83%) more highly than mouse 
ARNT (63%), and surprisingly, more highly than rainbow trout ARNT (rtARNTb, 54%) 
as well (Powell et al., 1999).  These studies showed that fhARNT2 was detectable in the 
liver, gill, ovary, and brain and was the only detectable form of ARNT (Powell et al., 
2000; Powell et al., 1999).  Similarly, studies identifying expression of ARNT proteins in 
the zebrafish, Danio rerio, have identified an ARNT2 (zfARNT2b) that had a high level 
of identity when compared to fhARNT2 (80%) and mouse ARNT2 (82%), but had low 
identity with mouse ARNT (59%) and rtARNTb (52%; Tanguay et al., 2000).  
Expression of zfARNT2b was detected to high levels in the brain, eye, gill, skin, and 
skeletal muscle with low or undetectable levels in the liver, heart, and kidney (Andreasen 
et al., 2002; Tanguay et al., 2000).  ARNT2 has also been described as being the 
predominant ARNT form in the common cormorant, Phalacrocorax carbo with high 
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levels of mRNA detected in the liver, kidney, brain, muscle, heart, lung, spleen, 
testis/ovary, eye, stomach, and intestine (Lee et al., 2007).   Taken together, these studies 
suggest a different functional role of ARNT2 in these species.   
It is important to note, however, that the majority of studies examining the tissue 
distribution of the ARNT proteins have focused primarily on mRNA expression patterns 
through Northern blot analysis or whole mount in situ hybridization with little  
examination of endogenous protein expression and more thorough protein studies are 
missing from the current literature.   Furthermore, numerous splice variants have been 
identified for each ARNT type and appear to exhibit different tissue distributions, which 
may also confound these characterizations (Drutel et al., 1996; Ikeda and Nomura, 1997; 
Korkalainen et al., 2003; Pollenz et al., 1996; Prasch et al., 2006; Tanguay et al., 2000; 
Wang et al., 1998; Wilson et al., 1997; Yu et al., 1999). 
Interestingly, while ARNT and ARNT2 exhibit >90% and >80% amino acid 
identity between the bHLH and PAS domains respectively (Figure 1.6), gene knock-out 
of either ARNT or ARNT2 results in embryonic/perinatal lethality characterized by 
distinct phenotypes.  This suggests that neither protein can compensate fully for the loss 
of the other.  The lack of compensation may be due to differences in tissue specific 
expression, discrepancies in the level of protein expression, or biochemical differences 
that influence gene activation.  While ARNT is known to have a more ubiquitous 
expression pattern than ARNT2, mRNA for the two genes is clearly co-expressed to 
some degree in many tissues, though the ratio of ARNT:ARNT2 proteins in these tissues 
is unknown (Table 1.4). Since overlapping tissue specific expression of ARNT and  
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Figure 1.6: Homology between ARNT and ARNT2 domains.  Thin lines indicate 
domain regions.  NLS, nuclear localization signal; b, basic region; HLH, helix-loop-helix; 
PAS A and PAS B, PER/ARNT/SIM homology regions; TAD, transactivation domain. 
Numbers under each box represent amino acids.  Thick lines represent regions of 
homology with the numbers representing the percent identity. 
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Table 1.4: mRNA expression for mARNT and mARNT2 in murine peripheral 
organs and central nervous system at postnatal day 1.5.  
 (Adapted from: Aitola and Pelto-Huikko, 2003). 
  
+ indicates the level of mRNA expression; +, low but positive signal; ++, weak positive 
signal, +++, strong positive signal. 
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ARNT2 does appear to exist, but neither ARNT can compensate fully for loss of the 
other, this suggests that the two proteins have distinct functions in the presence of various  
dimerization partners. Furthermore, the co-expression of ARNT and ARNT2 and the 
potential impact each may have on the other in terms of signal transduction has not been 
fully explored to date. 
 
1.9 ARNT Isoforms from Other Species 
Several orthologs of the ARNT proteins have also been identified in other 
mammalian, invertebrate, aquatic and avian species including Drosophila melanogaster, 
Caenorhabditis elegans, Xenopus laevis, the yellow fever mosquito Aedes aegypti, the 
common cormorant Phalacrocorax carbo, the chicken Gallus gallus, the domestic cow 
Bos taurus, the rabbit Oryctolagus cuniculus, the crustacean Daphnia magna, the killifish 
Fundulus heteroclitus, the zebrafish Danio rerio, and the rainbow trout Oncorhynchus 
mykiss (Lee et al., 2007; Nene et al., 2007; Pollenz et al., 1996; Powell-Coffman et al., 
1998; Powell et al., 1999; Prasch et al., 2006; Rowatt et al., 2003; Smith et al., 2001; 
Sonnenfeld et al., 1997; Takahashi et al., 1996; Tanguay et al., 2000; Tokishita et al., 
2006; Walker et al., 2000).  Many more ARNT proteins have also been predicted in silico 
based on genomic sequencing data (www.ensembl.org), though have not yet been 
evaluated in vivo.  Phylogenetically, the ARNT proteins appear to be divided into two 
major clades: one containing the BMAL type ARNT3 and ARNT4 proteins and one 
containing the ARNT and ARNT2 type proteins (Figure 1.7).  Consistent with the 
evolutionary timeline, the mammalian, avian, and amphibian ARNT proteins grouped  
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Figure 1.7: ARNT protein dendogram.  Full-length proteins were aligned by using the 
CLUSTALW (Slow/Accurate, Gonnet) method (MEGALIGN, DNAstar, Madison, WI) 
using a PAM250 residue weight table.  The horizontal distance to the subclusters 
corresponds to degree of amino acid substitutions among members.  Cavia porcellus 
ARNT (AB263100) and Mesocricetus auratus ARNT (AB263099) sequences were 
unpublished direct submissions to the NCBI database by Kawanishi,M., Sakamoto,M., 
Shimohara,C. and Yagi,T. 19-JUN-2006.  Mammalian, avian, and amphibian ARNT 
proteins grouped together, as did the ARNT2, ARNT3, and ARNT4 proteins.  ARNT 
proteins from piscine and invertebrate species also primarily grouped together as 
ancestors to the ARNT/ARNT2 split.  Exceptions (Daphnia magna ARNT2 and 
Antheraea pernyi ARNT) are denoted by an asterisk. 
Amino acid substitutions x100
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together, while the ARNT proteins from piscine and invertebrate species also primarily 
grouped together as ancestors to the ARNT/ARNT2 event.  The ARNT2 proteins also 
grouped together as did the BMAL type ARNT3 and ARNT4 proteins with few 
exceptions. 
 
1.10 ARNT-Dependent Signaling 
The ARNT protein was initially proposed to function in the nuclear translocation 
of the AHR protein (Hoffman et al., 1991; Reyes et al., 1992).  It was later determined 
that ARNT was constitutively nuclear, playing no role in the ligand mediated 
translocation of the AHR (Holmes and Pollenz, 1997; Pollenz et al., 1994).  ARNT is 
now known to act as a dimerization partner essential in several distinct signal 
transduction pathways each of which are mediated by ARNT's dimerization with a 
variety of bHLH-PAS proteins such as the aryl hydrocarbon nuclear receptor (AHR), the 
hypoxia-inducible factor 1 family (HIF-1α, HIF-2α, HIF-3α), the hypoxia-like factor 
(HLF), the single minded proteins (SIM1 and SIM2), or ARNT itself; however, each 
dimer associates with specific cis acting DNA elements to regulate genes (Figure 1.1).  
Thus, ARNT is considered a master regulator required for response to hypoxia, 
angiogenesis, xenobiotics, and in various developmental pathways.   
 
1.10.1 AHR Signaling 
In response to xenobiotics typified by 2,3,7,8 tetrachlorodibenzo-p-dioxin, ARNT 
dimerizes with the liganded AHR and binds the asymmetric xenobiotic response element 
(XRE: 5'T T/A GCGTG) enhancer sequences to regulate a battery of phase I and II  
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metabolizing enzymes that include CYP1A1, glutathione-S-transferase Ya, and 
NAD(P)H:quinone oxidoreductase as previously described (Hapgood et al., 1989; 
Hoffman et al., 1991; Ma, 2001; Ramadoss et al., 2005; Safe, 2001). 
Interestingly, analysis of the role of ARNT2 in AHR-mediated signaling is less 
clear and studies examining the ability of ARNT2 to function during AHR signaling have 
been sparse and conflicting.  The initial evaluation of the mouse ARNT2 clone included 
XRE driven luciferase reporter studies, in which it was determined that ARNT2 appeared 
to be able to compensate for loss of ARNT in AHR signaling (Hirose et al., 1996).    
However, recently Sekine et al. (2006) have hypothesized that ARNT2 does not dimerize 
with the AHR because it contains a proline and not a histidine residue at amino acid 352 
within the PAS B domain.  This hypothesis is based on the observation that all 
characterized mammalian ARNT2 proteins contain a proline residue in the PAS B 
domain while the homologous position in ARNT proteins contains a histidine residue.  
Therefore, studies were initiated in which the histidine at amino acid 378 in the PAS B 
region of ARNT was mutated to a proline causing the ARNT to have greatly reduced 
ability to function in AHR-mediated signaling that was similar to that observed with wild 
type ARNT2.  Interestingly, while the histidine to proline mutation in the Sekine et al. 
study affected the transcriptional ability of ARNT•AHR heterodimers, the transcriptional 
ability of ARNT•HIF-1α heterodimers remained unaffected, although the ARNT 
interactions of either AHR or HIF-1α appear to be mediated by the same domains.  
However, the studies did not directly evaluate the role of the P352 in ARNT2 function by 
converting it a histidine and producing a protein capable of functioning in AHR-mediated 
signaling.  Thus, the mechanism that underlies the lack of ARNT2 function in AHR-
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mediated signaling in vivo is currently undefined.  Further studies assessing the potential 
roles of ARNT2 in AHR signaling should be considered. 
 The BMAL type ARNT proteins do not appear to be involved with AHR 
signaling.  Although, ARNT3 was initially demonstrated to coimmunoprecipitate with the 
AHR using in vitro expressed and activated proteins, it was also determined that ARNT3 
did not appear to associate with the AHR in a yeast two-hybrid system and also did not 
appear to be able to substitute for ARNT in ARNT-deficient c4 hepatoma cells to 
regulate an XRE controlled reporter (Hogenesch et al., 1997; Takahata et al., 1998).   
 
1.10.2 Hypoxic Signaling 
Under hypoxic conditions, ARNT binds with the bHLH/PAS protein hypoxia-
inducible factor (HIF) -1α, -2α, -3α, which are constitutively degraded under non-
hypoxic conditions, to mediate gene regulation through binding to hypoxia response 
elements (HRE: 5'T/GACGTG) in specific genes involved with vascularization and 
glucose transport such as erythropoetin (EPO), vascular endothelial growth factor 
(VEGF), and glucose-transporter-1 (GLUT-1) (Maxwell et al., 1997; Poellinger and 
Johnson, 2004; Semenza, 2007; Semenza et al., 1997; Wood et al., 1996).  However, 
since the angiogenic deficits seen in HIF-/- animals are more severe than those seen in 
ARNT-/- animals, it is likely that other protein(s) can partially substitute for loss of ARNT 
during hypoxic signaling (Iyer et al., 1998; Ryan et al., 1998). 
 Thus, the suggestion that ARNT2 may be this protein is provided by evidence that 
HRE controlled genes such as VEGF are still able to be regulated during development in 
areas where ARNT2 mRNA is known to be present, such as the neural tube (Maltepe et 
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al., 1997).  Furthermore, ARNT2 has been shown to be able to substitute for ARNT in 
regulation of a HRE controlled reporter in ARNT-deficient cells (Sekine et al., 2006). 
ARNT3 was originally demonstrated to associate with HIF-1α and HLF by yeast-
two hybrid screens and gel shift assays and could substitute for ARNT in ARNT-
deficient c4 hepatoma cells to regulate an HRE controlled reporter (Hogenesch et al., 
1997; Takahata et al., 1998).  However, it was later shown that ARNT3 did not appear to 
be participating in hypoxic response since ARNT3 could not complement hypoxia-
mediated signaling in ARNT-/- ES cells and ARNT3-/- embryos lacked angiogenic defects 
similar to those seen in ARNT-/- ,  ARNT2-/- or HIF1-/- animals, though the ubiquitous 
expression pattern of ARNT would likely limit potential angiogenic defects resulting 
through loss of ARNT3 since ARNT would be present to complement hypoxic signaling 
(Cowden and Simon, 2002; Kozak et al., 1997; Maltepe et al., 2000; Maltepe et al., 1997; 
Ryan et al., 1998).  Similarly, ARNT4 has been shown to be competent to participate in 
hypoxic signaling in Hep3B cells by regulating an HRE controlled reporter (Hogenesch 
et al., 2000). Further biochemical studies using endogenously expressed proteins should 
be carried out to continue to assess the potential interactions of ARNT2-4 with the HIF 
family of proteins.  
 
1.10.3 SIM1/SIM2 Interactions 
The single-minded protein, first identified in Drosophila, is another bHLH/PAS 
transcription factor that controls the development of the neurons and glia in the central 
nervous system by regulating target genes that repress neuroectodermal genes and 
activate CNS midline genes (Nambu et al., 1991; Sonnenfeld et al., 1997; Thomas et al., 
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1988).  The mammalian orthologs Sim1 and Sim2 are also expressed in the developing 
CNS and appear to similarly regulate mammalian CNS development by regulating genes 
controlled by central midline enhancing elements (CME: G/ATACGTGA; Michaud and 
Fan, 1997; Nambu et al., 1991; Sonnenfeld et al., 1997; Swanson et al., 1995; Wharton 
and Crews, 1993).   Since all ARNT proteins appear to be expressed in the brain along 
with the Sim proteins (Sim1, Sim2), all ARNT proteins would appear to have the 
potential to interact with Sim in vivo.  Interestingly, ARNT, ARNT2, and ARNT3 have 
all been shown to interact with Sim1 by co-immunoprecipitation, while the potential 
interactions of ARNT4 with Sim remain unexplored (Michaud et al., 2000).   
In Drosophila, mutations in ARNT (tango) result in defects in CNS midline and 
tracheal development (Sonnenfeld et al., 1997).  In the mouse, the interactions of ARNT 
with SIM1 are suggested by neural tube defects seen in ARNT knockout animals and 
have been supported with biochemical analyses including co-immunoprecipitation, yeast 
two-hybrid, and electrophoretic mobility shift assays using CME oligos  (Ema et al., 
1996; Kozak et al., 1997; Probst et al., 1997).  Furthermore, expression of Sim1 appears 
to inhibit TCDD-dependent reporter activity in Hepa-1 cells as well as the DNA binding 
activity of the AHR•ARNT complex in vitro, suggesting that Sim1 is able to sequester 
ARNT away from the AHR (Probst et al., 1997).  ARNT•Sim2 interactions have also 
been shown via co-immunoprecipitation and CME reporter assays, though these dimers 
lack transcriptional ability, and Sim2 appears to function as a dominant negative 
regulator (Moffett and Pelletier, 2000; Moffett et al., 1997). 
Along these lines, the interactions of ARNT2 with SIM are implied by the similar 
phenotype of SIM-/- and ARNT2-/- animals in the failure to develop specific 
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neuroendocrine lineages in the paraventricular (PVN) and supraoptic nuclei (SON) of the 
hypothalamus (Hosoya et al., 2001; Michaud et al., 2000; Wines et al., 1998).  In support 
of this, ARNT2 and Sim1 expression appears to be co-localized in the PVN/SON, while 
ARNT levels are low or absent (Michaud et al., 2000).  Furthermore, these studies also 
demonstrated that both Sim1 and ARNT2 appear to function in maintaining the 
expression of Brn2 in the PVN/SON, which in turn, controls the differentiation of cells 
expressing vasopressin, oxytocin, and corticotropin-releasing hormones.  Thus, since 
ARNT2 and Sim1 are co-localized spatially and temporally, exhibit similar phenotypes, 
and appear to control the same developmental processes, it is likely that they are partners 
in vivo, while interactions of other ARNT proteins with Sim1 in other tissues or with 
Sim2 remain unexplored possibilities.  
 
1.10.4 Circadian Signaling 
The BMAL type ARNT proteins, ARNT3 and ARNT4, are currently believed to 
be primarily involved in the maintenance of circadian rhythms since targeted disruption 
of ARNT3 in the mouse results in the abolishment of circadian rhythm maintenance 
under constant darkness (Bunger et al., 2000).  During Clock/ARNT3/4 signaling, Clock 
and ARNT3/4 when temporally co-expressed form a heterodimer that associates with E-
box response elements (5’CACGTG) to regulate target genes involved with circadian 
signaling such as the period (Per) family of genes, the cryptochrome (Cry) genes, and 
vasopressin, leading to gradual accumulation of the Per protein in the cytoplasm.   In 
turn, Per, along with timeless (Tim) interact with Cry to inhibit transcription by the 
Clock/ARNT3/4 complex as a negative feedback loop. The interactions of both ARNT3 
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and ARNT4 with Clock have been well established biochemically and several excellent 
reviews detail these studies and the Clock pathway (Gekakis et al., 1998; Gu et al., 2000; 
Maemura et al., 2007; Sangoram et al., 1998).   As a result of these analyses, ARNT3 and 
ARNT4 are not believed to be involved with the same array of signaling pathways as 
ARNT and ARNT2. 
 
1.10.5 AINT Interactions 
 While interactions with ARNT proteins with Sim and HIF proteins are critical for 
proper development of the CNS and vasculature, other proteins have been suggested to 
interact with ARNT proteins during specific developmental time points.  One of these 
proteins, the ARNT interacting protein (AINT, TACC3) is a coiled-coil/PAS protein that 
has been shown to interact with both ARNT and ARNT2 in yeast and in vitro (Sadek et 
al., 2000).   These studies showed that overexpression of AINT appears to lead to non-
nuclearization of ARNT and an apparent augmentation of response to hypoxia as 
measured by HRE controlled luciferase reporters in Hepa-1 cells transfected with naked 
vector or AINT.  More recently, it was demonstrated that expression of AINT in vivo 
coincided with high levels of HIF-1α in the neuroepithelium of the neural tube and was 
highly expressed in several areas of rapid cellular proliferation in the developing mouse 
as well as in the ovaries and testes of the adult, suggesting that AINT may be expressed 
as a means to augment cellular proliferation possibly through increasing the 
speed/strength of hypoxic signaling (Aitola et al., 2003).  Non-nuclearization of ARNT 
could also serve to inhibit constitutive ARNT homodimer regulation of genes, which 
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have also been implicated in the regulation of cellular differentiation and proliferation, 
and such studies have yet to be explored.  
 Another protein suggested to interact with ARNT during specific developmental 
time points is the hypoxia-like factor (HLF) (Ema et al., 1997).  In contrast to the hypoxia 
inducible factors, this novel member of the HIF family appears to be expressed under 
normoxic conditions to high levels in the lung, heart, and liver and appears to regulate 
expression of VEGF in an ARNT dependent manner via the previously described HRE.  
 
1.10.6 ARNT Homodimer Interactions 
ARNT has also been implicated in serving as a transcriptional regulator in a 
homodimeric form, based on early studies in which it was demonstrated that during size 
exclusion high performance lipid chromatography of Sf9 whole cell lysates, ARNT was 
eluted as a single peak with a molecular mass of 205 kDa (Sogawa et al., 1995).  These 
studies also demonstrated that ARNT could form homodimers via the HLH/PAS 
domains, had affinity for the core sequence of the adenovirus major late promoter (MLP) 
containing the canonical E-box (5’CACGTG) sequence, and could drive expression of E-
box controlled reporters when produced in vitro similar to the activities of other E-box 
binding proteins MyoD, Max, and USF.  Further studies showed similar results, again 
suggesting that ARNT homodimers could associate with the E-box sequence and could 
competitively displace the c-Myc/Max heterodimer from binding to the E-box, though the 
ability of ARNT to homodimerize may be dependent upon ARNT phosphorylation status 
(Antonsson et al., 1995; Huffman et al., 2001; Levine and Perdew, 2001; Levine and 
Perdew, 2002; Swanson et al., 1995; Swanson and Yang, 1999).  However, physiological 
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target genes for ARNT homodimers remained undescribed until recently when 
microarrays examining differential gene regulation between wild-type Hepa-1 cells and 
their ARNT-deficient variants revealed 27 genes whose expression was upregulated by 
≥1.5-fold in the wild-type Hepa-1 cells, 15 of which had confirmed E-box sequences in 
the 5’ promoter region, including BCL2/adenovirus E1B 19 kDa interacting protein 1 
(NIP3), Serine (or cysteine) protease inhibitor clade E number 1 (PAI1), and N-Myc 
downstream regulated-like (NDR1) (Wang et al., 2006).  Additionally, ARNT 
homodimers have been implicated in the partial regulation of CYP2A5 through 
chromatin immunoprecipitation, electrophoretic mobility shift assays, a liver-specific 
ARNT knockout mouse showing reduced CYP2A5 levels, and mutational analyses in the 
E-box region of the CYP2A5 promoter, though AHR•ARNT dimers have also been 
suggested to participate in the regulation of CYP2A5 expression as well as PAI1 
(Arpiainen et al., 2007; Arpiainen et al., 2005; Son and Rozman, 2002).  In contrast, 
multiple yeast two-hybrid experiments have indicated only weak or absent interactions 
for ARNT homodimers and other studies have failed to detect ARNT homodimerization 
(Hirose et al., 1996; Reisz-Porszasz et al., 1994).  Similarly, the interactions of ARNT2-4 
as homodimers have been examined through yeast two-hybrid systems and have showed 
only weak interactions at best (Hirose et al., 1996; Takahata et al., 1998).  Thus, the 
potential role of ARNT as a homodimeric transcriptional regulator remains controversial 
and though such studies prove difficult, attempts must be made to further explore the 
possibility under physiological conditions.   
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1.11 ARNT Interactions with Transcriptional Repressors 
 Along with ARNT’s interactions with several transcription factors and co-
activators, ARNT proteins also appear to associate with transcriptional repressors such as 
the aryl hydrocarbon receptor repressor, NPAS, and necdin to prevent further PAS 
protein signaling.  Such interactions have not been well-defined and may be important 
feedback or negative regulators of several of the aforementioned pathways. 
 
1.11.1 Aryl Hydrocarbon Receptor Repressor Interactions 
ARNT has also been implicated in binding to the aryl hydrocarbon receptor 
repressor (AHRR), which is upregulated by liganded-AHR•ARNT dimers and 
subsequently appears to be involved with negatively influencing AHR signaling by 
associating with ARNT and binding XREs, thereby preventing association of 
AHR•ARNT dimers (Baba et al., 2001; Kikuchi et al., 2003; Mimura et al., 1997).  
Interestingly, this repression does not appear to require DNA binding by the 
AHRR•ARNT complex and cannot be rescued by additional ARNT expression, 
suggesting that AHRR repression of AHR signaling does not occur through sequestration 
of ARNT, but through alternative protein-protein interactions (Evans et al., 2008).  
Recently, it has been suggested that AHRR plays a role as a tumor suppressor since 
silencing of AHRR in several human malignant tissues led to increased cell growth, while 
exogenous expression of AHRR led to diminished growth, diminished angiogenesis, and 
appeared to confer resistance to apoptotic signals (Zudaire et al., 2008).  AHRR null 
mice, however, exhibited a seemingly contradictory delayed response to carcinogenesis 
in the skin following exposure to benzo[a]pyrene along with increased CYP1A1 mRNA 
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induction in the skin, stomach, and spleen compared to wild-type AHRR mice (Hosoya et 
al., 2008).  Thus, the role of the interaction of AHRR with ARNT remains controversial.  
Future studies should continue to address the potential physiological role of the AHRR 
and should address whether AHRR can interact with other ARNT proteins.  
The ARNT proteins have also been implicated in binding to several repressors 
 
1.11.2 NPAS Interactions 
 ARNT and ARNT2 have been implicated in binding to the neuronal PAS domain 
protein 1 (NPAS), a bHLH-PAS transcriptional repressor expressed in the mouse brain 
following organogenesis that is thought to be involved with nervous system development 
and morphogenesis in the murine lung by regulating genes such as erythropoeitin and 
tyrosine hydroxylase that are involved in hypoxic response (Levesque et al., 2007; 
Ohsawa et al., 2005; Teh et al., 2006).  In these studies, NPAS was shown to be 
cytoplasmic, entering the nucleus via the NLS of ARNT following heterodimerization, 
resulting in binding to enhancer regions and subsequent transrepression of gene targets 
(Teh et al., 2006). In contrast, NPAS2 expressed in the mammalian forebrain appears to 
be CLOCK-like and can interact with ARNT3 to drive expression of PER and CRY, 
showing no transrepression (Franken et al., 2006; Reick et al., 2001; Rutter et al., 2001). 
 
1.11.3 Necdin Interactions 
 Necdin is a member of the melanoma antigen (MAGE) protein family that is 
thought to be a growth suppressor expressed predominantly in postmitotic neurons 
(Kuwako et al., 2004; Maruyama et al., 1991). Recently, a study has implicated necdin as 
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a transcriptional repressor involved with modulation of  ARNT2•SIM1 and ARNT2•HIF-
1α complexes (Friedman and Fan, 2007).  In this study, necdin could be co-precipitated 
with ARNT2 or HIF-1α and appeared to interact with the bHLH of ARNT2 or HIF-1α 
via a 115 residue region in its amino-terminus, resulting in a dramatic repression of 
reporter activity controlled by CMEs.  Interestingly, interaction of necdin with ARNT or 
ARNT3 was not seen in cell culture, suggesting that necdin may specifically act to 
repress the transactivation of ARNT2 containing complexes.  Since studies examining the 
impact of necdin on other bHLH-PAS proteins are relatively non-existent, this avenue 
should be continued as well as the potential repression of target genes by necdin in other 
ARNT2 requiring pathways. 
 
1.12 AHR and ARNT Levels 
The levels of both AHR and ARNT are extremely important to the AHR-signaling 
pathway as it has been characterized.  Calculations of the concentration of AHR and 
ARNT protein in continuous cell culture lines from a variety of species and tissues 
revealed that the levels of ARNT remained relatively consistent between lines, ranging 
from approximately 13,979 molecules of ARNT/cell in MDCK canine kidney cells (94 
fmol/mg lysate) up to 33,445 molecules of ARNT/cell in Hepa-1 mouse hepatoma cells 
(231 fmol/mg lysate; Holmes and Pollenz, 1997).  In contrast, AHR levels in those lines 
showed a much greater range of expression, varying from 4,763 molecules AHR/cell in 
the H4IIE rat hepatoma cells (69.4 fmol/mg lysate) up to 323,004 molecules of AHR/cell 
(2231 fmol/mg lysate; Holmes and Pollenz, 1997).  
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Recent studies have examined the critical importance of these levels by 
modulating the expression of these proteins by siRNA (RSP, unpublished).  While a 
moderate reduction of ARNT levels by siRNA in Hepa-1 cells has little effect on 
CYP1A1 induction following TCDD treatment, a similar reduction of AHR levels by 
siRNA leads to a marked reduction of CYP1A1 levels following TCDD treatment.   
Similarly, overexpression of AHR in Hepa-1 cells can lead to an increased response in 
CYP1A1 induction at the mRNA and protein level following TCDD treatment, 
suggesting that the levels of AHR may be more limiting than the levels of ARNT, even 
though there appears to be ~10x more AHR than ARNT in these lines.   
 
1.13 ARNT Crosstalk 
 Since the ARNT proteins appear to be capable of dimerizing with a variety of 
partners in vivo and appear to be expressed at relatively low levels, it is possible that 
signaling in one pathway requiring ARNT would potentially disrupt/inhibit simultaneous 
signaling of other ARNT requiring pathways (Holmes and Pollenz, 1997).  Several 
studies have addressed these questions, but have reported conflicting results (Chan et al., 
1999; Chilov et al., 2001; Gradin et al., 1996; Lee et al., 2006; Pollenz et al., 1999; Qu et 
al., 2007; Safe and Wormke, 2003; Woods and Whitelaw, 2002). 
 Early studies on hypoxia/AHR crosstalk demonstrated that AHR signaling 
appeared to be reduced following hypoxic signaling induction by cobalt chlorine 
(CoCl2), a known inducer of hypoxia-inducible factor 1α (Gradin et al., 1996).  In these 
studies, HepG2 cells transfected with an XRE controlled luciferase reporter showed 
reduced luciferase activity when treated with both CoCl2 and TCDF, a known AHR 
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ligand, in comparison to those treated with TCDF alone (Gradin et al., 1996).  
Electrophoretic mobility shift assays (EMSA) of nuclear extracts from TCDF treated 
HepG2 cells also showed XRE binding that was reduced when the cells were pretreated 
for increasing time periods with CoCl2 prior to TCDF treatment, suggesting decreased 
recruitment of AHR•ARNT heterodimers to XRE enhancers under hypoxic conditions 
and similar results were seen in EMSAs combining various amounts of in vitro produced 
AHR, ARNT, and HIF-1a in the presence of β-naphthoflavone (Chan et al., 1999).  
Additionally, coimmunoprecipitation studies using in vitro translated AHR, ARNT, or 
HIF-1a demonstrated that coprecipitation of the AHR with ARNT antiserum following 
TCDD treatment was reduced in a concentration dependent manner when HIF-1α was 
added to the activation (Gradin et al., 1996).   However, in neither of these studies was 
ARNT used to rescue AHR signaling during hypoxia. 
 In contrast, studies by Pollenz et al. demonstrated that the physiological 
functional interference between hypoxia and AHR signaling does not appear to occur 
through competition for ARNT (Pollenz et al., 1999).  In these studies, hypoxia did not 
affect the concentration or localization of ARNT, and the ARNT protein sequestered 
during hypoxia was returned to the cellular ARNT pool following hypoxia-driven 
signaling.  Furthermore, under conditions of physiological hypoxia (1% O2), only a small 
fraction of the total cellular ARNT pool (12-15% in Hepa-1 and H4IIE cells respectively) 
was sequestered, suggesting that the remaining ARNT would remain free for other 
ARNT requiring pathways assuming that the entire protein pool is accessible for 
dimerization.  Additionally, the formation of AHR•ARNT heterodimers as measured by 
electrophoretic mobility shift assays of nuclear extracts from four distinct TCDD treated 
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cell lines (Hepa-1, HepG2, MCF, or H4IIE) remained unchanged in comparison to 
normoxic conditions.  Furthermore, these studies indicated that while the level of TCDD 
inducible CYP1A1 protein was decreased under hypoxic conditions, the level of 
CYP1A1 mRNA remained similar regardless of hypoxia, suggesting that reductions in 
CYP1A1 protein levels were distal to the induction of CYP1A1.  Since cellular protein 
synthesis is generally reduced in hypoxic cells, it is likely that reductions in CYP1A1 
protein occurred as a non-specific cellular response to hypoxia rather than a mechanistic 
response resulting from loss of available ARNT.      
 More recent studies on AHR/HIF crosstalk suggest that AHR/HIF crosstalk is 
limited to genes with enhancer regions containing specific regulatory motifs (Lee et al., 
2006).  Using global gene expression patterns derived from high-density oligonucleotide 
arrays of Hep3B cells treated with Me2SO, CoCl2, TCDD, or TCDD and CoCl2, Lee et al. 
identified only 33 target genes affected by co-treatment with TCDD and CoCl2 whose 
expression appeared to be modulated by crosstalk.  However, of these 33 genes, 35% 
were actually upregulated by co-treatment with TCDD and CoCl2, while 38% were 
downregulated by co-treatment with TCDD and CoCl2, and 33% were differentially 
regulated through co-treatment with TCDD and CoCl2 in comparison with either TCDD 
or CoCl2 alone.  Upon evaluating these target gene promoters, the authors found no 
correlation between the types or number of HRE or XRE response elements in the 
putative regulatory regions of these genes and the apparent crosstalk that was observed 
and, instead, determined that the incidence of serum response factor regulatory elements 
(SRE) was more predictive of crosstalk than the number of HRE or XRE sites.  Given 
that the majority of genes evaluated appeared to be unaffected by co-treatment with 
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TCDD and CoCl2 compared with either treatment alone, it is unlikely that treatment with 
either TCDD or CoCl2 resulted in loss of ARNT to the other signaling pathway since 
such a loss would likely have a more global effect on gene regulation by AHR or HIF.  
Furthermore, the co-treatment with TCDD and CoCl2 resulted in an additive effect in 
35% of the 33 affected genes.  Taken together along with the data presented by Pollenz et 
al., these data suggest that in a physiological setting, AHR/HIF crosstalk is limited in 
scope and does not appear to occur through competition for ARNT (Lee et al., 2006; 
Pollenz et al., 1999).    
 In addition to direct competition for ARNT, crosstalk of ARNT-requiring 
pathways may also be occurring indirectly through regulation of bHLH/PAS proteins by 
another bHLH/PAS pathway.  For example, hypoxia has been implicated in the 
modulation of expression of PER and CLOCK in the mouse brain leading to increased 
expression of both PER1 and CLOCK and, similarly, Sim has been shown to attenuate 
regulation of EPO during hypoxia (Chilov et al., 2001; Woods and Whitelaw, 2002).   
 
1.14 AHR and ARNT Defective Hepatoma Cell Lines 
Six benzo[a]pyrene mutant clones (c1-c6) all exhibiting decreased or undetectable 
levels of aryl hydrocarbon hydroxylase inducibility, sparing them from the toxic 
metabolites of reactive benzo[a]pyrene intermediates, were isolated from the Hepa1-c1c7 
mouse hepatoma parental line and characterized (Hankinson et al., 1979; Hankinson, 
1979; Legraverend et al., 1982).  Through somatic cell hybridization, five of these 
mutations were found to be recessive and belong to three complementation groups (c1 
and c5, c2 and c6, and c4), while another was found to be dominant (c3).  The c2 and c6 
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clones were shown to be AHR-deficient (<10% wt) and the c4 clone was later determined 
to be ARNT-deficient (Hankinson, 1979; Hoffman et al., 1991; Legraverend et al., 1982; 
Pollenz et al., 1994).  At the same time, another laboratory group utilized the mouse 
Hepa1-c1c7 cell line to select populations defective in aryl hydrocarbon hydroxylase 
activity (Whitlock and Galeazzi, 1984).  Similarly, their LA-I variant was shown to be 
AHR-deficient, while the LA-II variant was later shown to be ARNT-deficient (Pollenz 
et al., 1994; Reyes et al., 1992).  Since re-introduction of AHR cDNA is known to restore 
TCDD mediated CYP1A1 induction in the c2 and LA-I variants, these variants will be 
used to explore the function of other AHRs (Legraverend et al., 1982).  Similarly, re-
introduction of ARNT cDNA to the c4 or LA-II variants has been shown to restore some 
level of function in terms of AHR- and hypoxia- mediated signaling (Maxwell et al., 
1997; Pollenz et al., 1994).  It is therefore expected that the re-introduction of various 
ARNT constructs, and possibly, ARNT2 should complement AHR and hypoxia signaling 
and would thereby provide a common genetic background to evaluate ARNT and 
ARNT2 function. 
 
1.15 Knockout Animals 
An important tool for examining protein function is targeted disruption of genes 
through homologous recombination using targeting vectors.  With the use of this 
technique, null mice have been generated for the AHR, ARNT, and ARNT2 
independently.  Two separate laboratories have generated AHR null mice (Gonzalez et 
al., 1995; Schmidt et al., 1996).  The resulting AHR-/- mice were demonstrated to be 
viable, though they exhibited a multitude of physiological changes and developmental 
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abnormalities including: reduced liver weight with pronounced fibrosis in the portal tract, 
glycogen depletion, eosinophilia, reproductive defects, and a retarded growth rate 
(Fernandez-Salguero et al., 1995; Schmidt et al., 1996).  A 40-50% neonatal lethality and 
depressed immune systems were also seen in mice generated by the Fernandez-Salguero 
group, but neither was seen in those of Schmidt et al., (1996). As both studies were done 
in C57BL/6J mice, differences between the two are not attributable to genetic 
background; rather, these differences are more likely to be attributable to partial allelic 
inactivation, which was addressed by the Schimdt et al. (1996) group, but not in the study 
by Fernandez-Salguero et al. (1995).  In either case, mice lacking the AHR protein were 
unable to induce wild-type levels of CYP1A1 in response to TCDD administration.  
Additionally, the Fernandez-Salguero AHR-/- mice exhibited a significant decrease in 
CYP1A2 and ΜGT*06, which are constitutively expressed in the wild-type mouse, 
indicating that the AHR is responsible for controlling the basal levels of these enzymes as 
well as for controlling induction of other drug metabolizing enzymes in response to 
ligand (Fernandez-Salguero et al., 1995).  Interestingly, the disruption of the Ah locus 
also led to protection from the harmful effects of TCDD, benzo[a]pyrene, polychlorinated 
biphenyls, and polybrominated biphenyls including protection against thymic atrophy, 
lesions, and disruption of thyroid hormone homeostasis (Fernandez-Salguero et al., 1996; 
Nishimura et al., 2005).   
Null mice have also been generated for the ARNT, ARNT2, and ARNT3 proteins 
independently.  Interestingly, while the ARNT and ARNT2 proteins possess a high 
degree of homology in the functional domain regions, the phenotypes of either null 
animal differ significantly.  For ARNT, two separate laboratories have generated null 
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mice (Kozak et al., 1997; Maltepe et al., 1997).  In both groups, the knockout of ARNT 
proved to be fatal, with animals dying in utero between embryonic day (ED) 9.5 and 
10.5.  As such, the ARNT null animals were examined prior to 10.5 days of gestation in 
an attempt to reveal the underlying cause of death. In the Maltepe line, ARNT-/- animals 
exhibited defective angiogenesis of the yolk sac and branchial arches, stunted 
development and embryo wasting and were generally distinguishable from their 
heterozygous ARNT littermates by ED 8.5-10.5.  The cause of lethality in these animals 
was attributed to the formation of hypoxic/nutrient-deprived cells resulting from an 
inability to promote vascularization for the increasing tissue mass during organogenesis 
due to a loss of ARNT.  To support these data, ARNT-/- animals were shown to have less 
VEGF mRNA in the yolk sac as well as in the embryo overall, with high VEGF mRNA 
appearing to be restricted to areas known to be colocalized with ARNT2 mRNA.  In 
contrast, animals of the Kozak line were indistinguishable from their littermates at ED 
8.5, exhibiting normal vasculogenesis in the yolk sac and embryo.  By ED 9.5, however, 
60% of ARNT-/- animals exhibited developmental delay and/or abnormal phenotypes 
(100% by ED 10.5).  These abnormalities included: neural tube closure defects, forebrain 
hyperplasia, delayed rotation of the embryo, placental hemorrhaging, and visceral arch 
abnormalities, with no defects seen in yolk sac circulation.   However, they postulated 
that the cause of lethality lay with the failure of the embryonic component of the placenta 
to vascularize preventing further development, possibly as a result of loss of ARNT in 
necessary hypoxic response.  These data are supported from evidence that other 
knockouts in which lethality occurs at ED 10.5 were attributed to improper placental 
development (Guillemot et al., 1994; Gurtner et al., 1995).  Loss of ARNT has also been 
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linked to pancreatic-islet dysfunction in type II diabetes (Czech, 2006; Gunton et al., 
2005; Levisetti and Polonsky, 2005). 
ARNT2 knockouts have also been examined by three independent laboratories 
(Hosoya et al., 2001; Keith et al., 2001; Michaud et al., 2000; Wines et al., 1998).  In all 
groups, the knockout of ARNT2 was non-embryonic lethal; instead, ARNT2-/- animals 
died perinatally within two weeks of birth (Hosoya et al., 2001).  Loss of ARNT2 was 
correlated to deficiencies in the formation of specific neuroendocrine lineages in the 
hypothalamus and altered expression of Brn2 in the hypothalamus similar to SIM-/- 
animals, and also exhibited impaired regulation of HIF-1 target genes and thymic defects 
(Keith et al., 2001; Wines et al., 1998).  Attempted double knockouts of ARNT and 
ARNT2 in the mouse were unsuccessful and out of 67 embryos resulting from a crossing 
of heterozygous mutant ARNT-/+, ARNT2-/+ animals embryos, no embryos were found to 
be homozygous double mutants by ED 8.5, and interestingly, only a single embryo was 
found for the ARNT-/+, ARNT2-/- or ARNT-/-, ARNT2-/+ genotype (Keith et al., 2001).  
This suggests that in the mouse, two wild-type alleles of either ARNT or ARNT2 are 
required to prevent resorptions of the embryo and that ARNT and ARNT2 may have 
overlapping functions during early development prior to ED 8.5. 
Conversely, knockout of ARNT3 does not appear to elicit defects in early 
development, but does lead to increased mortality after 26 weeks of age, abolishment of 
circadian rhythm maintenance under constant darkness, and progressive noninflammatory 
arthropathy evidenced by ossification of tendons and ligaments (Bunger et al., 2005; 
Bunger et al., 2000).  In another, independent, ARNT3 knockout mouse, deficiency in 
ARNT3 led to reduced levels of B cells in the peripheral blood, spleen and bone marrow 
 56
and also led to increased mortality around 6 months of age, but was correlated to elevated 
levels of serum glutamic oxaocetic transaminase, serum glutamic pyruvic transaminase, 
and blood urea nitrogen, which are indicators of liver, heart, and kidney damage (Sun et 
al., 2006a; Sun et al., 2006b).  However, pathological assessment of these tissues 
revealed no obvious differences between wild-type and ARNT3-/- mice, suggesting a 
possible loss of function in these tissues rather than tissue damage.  An ARNT4 knockout 
mouse has not yet been evaluated. 
 
1.16 Toxicity of TCDD 
Halogenated aromatic hydrocarbons are widespread environmental contaminants 
that are generally chemically stable, lipophilic, and resistant to degradation.  As such, 
they tend to persist in the environment where they may bioconcentrate and bioaccumulate 
through food webs. While some of these hydrocarbons are directly manufactured such as 
polybrominated biphenyls, some are formed as contaminants in the manufacture of other 
commercial products. TCDD, for example, is formed as a contaminant in the synthesis of 
2, 4, 5-trichlorophenol, which is used in the commercial synthesis of 2, 4, 5-
trichlorophenoxyacetic acid (2, 4, 5-T), a widespread herbicide and defoliant.   
Of the common types, chlorinated dibenzo-p-dioxins, dibenzofurans, 
azo(xy)benzenes, naphthalenes, biphenyls and brominated biphenyls, each has produced 
incidents of poisoning of industrial workers, members of the general population, or farm 
workers (Poland and Knutson, 1982).  All of these aromatic hydrocarbons share similar 
chemical structures and produce similar toxic responses varying in potency (Figure 1.8).   
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Figure 1.8: Structures of common tetra-chlorinated- congeners for various 
halogenated aromatic hydrocarbons.  Shown above are several of the chemical 
structures for various AHR ligands. A, halogenated hydrocarbons.  The toxic isomers are 
halogenated at 3 or 4 of the lateral ring positions with at least 1 ring position that is 
unsubstituted.  Adapted from: (Poland and Knutson 1982). B, polycyclic hydrocarbons. C, 
potential endogenous (indirubin) and dietary (indole-3-carbinol) ligands. 
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The toxic isomers are halogenated at 3 or 4 of the lateral ring positions with at least 1 ring 
position that is unsubstituted (Poland and Knutson, 1982).  
Toxicity resulting from exposure to polycyclic hydrocarbons is mediated by their 
high affinity and saturable binding to the AHR and involves a broad range of adaptive 
and toxic responses including the induction of xenobiotic metabolizing enzymes, such as 
wasting syndrome, tumor production, thymic involution, hepatotoxicity, skin disorders,  
gastric lesions, and alterations in endocrine homeostasis (Poland and Knutson, 1982; 
Sutter et al., 1994).  Exposure to TCDD has also been associated with urinary tract 
hyperplasia, subcutaneous edema, decreased spermatogenesis, decreased testicular 
weight, degeneration of the seminiferous tubules, fetal death and resorptions, fetal 
wastage, and malformations (Kremer et al., 1994; Nebert et al., 1993; Okey et al., 1994; 
Safe et al., 1998). 
 
 1.17 Role of AHR and ARNT in Mediating TCDD Toxicity 
 Recent studies using antisense morpholino oligonucleotides to knock down levels 
of the zebrafish AHR (zfAHR2) protein in vivo have revealed that the AHR is required 
for mediating many endpoints of TCDD toxicity, exhibiting protection against TCDD-
induced toxic endpoints such as reduced blood flow, pericardial edema, and reductions in 
lower-jaw growth (Bello et al., 2004; Carney et al., 2004; Prasch et al., 2003; Teraoka et 
al., 2003).  Reductions of non-functional isoforms of the AHR (zfAHR1) showed no such 
protections.  Similarly, zfARNT1 morphants show complete protection against TCDD-
induced pericardial edema and show partial protection against reduced peripheral blood  
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flow and lower-jaw growth deficiencies (Prasch et al., 2006).  These results have also 
been confirmed with a mammalian model system (Walisser et al., 2004). 
 Interestingly, antisense morpholinos against zfARNT2 indicate that reduced or 
absent levels of ARNT2 provide no protection against TCDD-induced developmental 
toxicity (Prasch et al., 2004a; Prasch et al., 2004b).  In these experiments, both wild-type 
and zfARNT2-/- animals exhibited similar responses to TCDD as measured by the toxic 
endpoints previously described.  Taken together, these data suggest that disruption of 
AHR-mediated signaling provides protection against many of the molecular and 
physiological TCDD-induced toxic endpoints and that the AHR and ARNT1 are essential 
for TCDD toxicity.  Furthermore, these data also suggest that zfARNT2 is not functional 
in TCDD-mediated AHR signaling. 
 While AHR-mediated signaling may be required for many endpoints of TCDD-
induced toxicity, the mechanism(s) for this toxicity is still unknown.  Since the AHR and 
ARNT are transcription factors, it is likely that increased signaling leads to an alteration 
of gene expression resulting in toxicity.  However, while zfCYP1A1 is the well-
characterized of the known TCDD regulated genes, zfCYP1A1 morphants exhibit no 
protection against endpoints of TCDD-mediated toxicity (Carney et al., 2004).  Thus, 
genes involved in mediating such toxicity are as yet unknown. 
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Chapter Two 
Generation and Characterization of Stable Lines Expressing Different Species of AHR 
 
2.1 Rationale for Stable Lines Expressing Different Species of AHR  
The aryl hydrocarbon receptor (AHR) is a basic helix-loop-helix PER/ARNT/SIM 
(bHLH-PAS) transcription factor that binds ligands typified by 2,3,7,8-
tetracholordibenzo-p-dioxin (TCDD), translocates to the nucleus, dimerizes with the aryl 
hydrocarbon nuclear translocator (ARNT) and associates with specific cis acting 
xenobiotic response elements (XRE) to activate transcription of genes involved with 
xenobiotic metabolism and is subsequently degraded.  AHR-mediated signal transduction 
has been evaluated primarily in the C57BL/6J mouse model system.  This model system, 
however, may not be the most accurate model for human comparisons as the AHRb-1 
allele carried by C57BL/6J contains a point mutation that prematurely truncates the 
receptor at 805 amino acids, while the AHR found in other murine strains as well as in 
the rat and human all contain an additional 42-45 amino acids at their carboxy-terminus 
that have 70% identity (Figure 1.3, Table 1.3).  This carboxy-terminal region could be 
functionally significant and the analysis of AHR-mediated signal transduction in the rat, 
human, or other mouse strains may better represent the physiology of the AHR pathway.  
Since the Ah receptors found in mice carrying the Ahb-2 allele, like those found in 
the rat and human, possess a carboxy-terminal region that is more typical across species 
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than the truncated b1 allele, these Ah receptors were chosen to be evaluated in an attempt 
to evaluate a possible functional role for this additional carboxy-terminal sequence.  The 
ability to directly compare the function of these Ah receptors versus that of the AHRb-1 in 
a genetically identical background was essential for delineating possible roles of this 
sequence, since studies using an endogenously expressed AHRb-2 would need to be 
performed in a different cell line than the murine Hepa-1 line used to examine the AHRb-1 
function and therefore could have confounding results due to other genetic variation 
between these lines. Furthermore, the AHRb-2 allele was highly useful in that antibodies 
currently in use by the Pollenz laboratory for the detection of the AHRb-1 allow 
equivalent detection of both proteins since these antibodies were generated against an 
amino-terminal portion of the AHRb-1 which shares 100% identity with the AHRb-2. 
To formally investigate protein-protein associations and degradation patterns of 
the AHRb-2 receptor, and whether the differences seen were due to the receptor itself or 
other cellular factors, stable lines were generated exploiting the LA-I, AHR deficient 
cells as described in Chapter Six.  The use of a genetically identical background to 
examine the function and degradation rate of the AHRb-2 in comparison with the AHRb-1 
provided significant insights into these biological properties of the AHR contributed by 
this functional region.   
 
2.2 Generation of LA-I Lines Expressing the Ahb-1 or Ahb-2 Receptor   
The first step in these studies was the ligation of the various coding regions from 
each cDNA into base and retroviral vectors, as detailed in Chapter Six (Invitrogen; Figure 
2.1). The base vector, pcDNA 3.1 allowed cloned products to be produced through in 
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Figure 2.1: Invitrogen plasmid maps.  Target genes are expressed from the 
cytomegalovirus immediate early (CMV IE) promoter and the plasmids contain both 
neomycin (G418) and ampicillin resistance used for antibiotic selection in eukaryotic and 
prokaryotic cells respectively.  Top: pcDNA 3.1 was used as the base vector for most 
constructs and the T7 promoter exploited for the production of in vitro transcribed and 
translated proteins.  This construct also contains a CMV promoter for in vivo expression 
located upstream of the viral T7 (not shown).  Bottom: pQCXIN and pLNCX2 are 
retroviral vectors optimized to yield high titers.  In pQCXIN, the possibility of promoter 
interference is minimized by expressing the gene of interest along with the neomycin 
resistance gene as a bicistronic transcript by means of an internal ribosomal entry site 
(IRES).  Following transfection of either retroviral vector into packaging cells, the vector 
provides the viral packaging signal (Ψ+), the target gene, and the drug-resistance marker. 
Vectors were obtained from the manufacturer (Invitrogen; Carlsbad, California). 
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vitro transcription and translation reactions.  The initial retroviral vector, pLNCX2, was 
chosen as it allows each of the proteins to be stably integrated into a common genetic 
background under the control of the same promoter.  PCR was used to amplify the cDNA 
coding region as well as to add specific restriction endonuclease sites that were exploited 
for the ligation of the cDNA into the multiple cloning site of pLNCX2.  Alternatively, 
retroviral constructs were also prepared using pQCXIN, a retroviral vector derived from 
pLNCX2 containing an internal ribosomal entry site for bicistronic expression of the 
neomycin resistance and target genes (Invitrogen, Figure 2.1).  Using this vector allows 
for a greater percentage of positive clones following infection with competent virus since 
expression of the neomycin resistance gene for selection in eukaryotic cells is coincident 
with expression of the target cDNA. 
Since neither pLNCX2 nor pQXCIN has an in vitro promoter, retroviral 
constructs were sequenced and tested by transient transfection into the AHR-deficient 
LA-I Hepa-1 variant or in PT67 viral packaging cells derived from an NIH 3T3 line, then 
analyzed by SDS-PAGE and evaluated by Western blotting (Figure 2.2).  Western 
analysis also validated that the molecular mass of each protein is correct.  In either case, 
following transfection of viral packaging cells, viral media was collected and used to 
infect target cells as shown in Figure 2.3 (see also Chapter Six). 
Stable lines surviving a two-week selection in neomycin were then analyzed for 
expression of the target genes by SDS-PAGE and Western blotting (Figure 2.4).   While 
these studies were intended to generate stable lines in the Hepa-1 background expressing 
either the wild-type AHR, the Ahb-2, the human AHR, or the rat AHR, numerous colonies  
surviving neomycin selection following infection with human or rat AHR viral media 
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Figure 2.2: Western analysis of the AHR constructs following transfection into 
AHR-deficient PT67 viral packaging cells.  Equal amounts of total cell lysates from 
independent clones were resolved by SDS-PAGE, blotted, and stained with A-1A anti-
AHR IgG (1.0 µg/ml) and -actin IgG (1:1000).  Reactivity was visualized by ECL with 
GAR-HRP IgG (1:10,000). A, total cell lysates from PT67 viral packaging cells 
transfected with Ahb-2 or Rat AHR. B, total cell lysates from PT67 cells transfected with 
Ahb-1, Ahb-2, rat AHR, or human AHR.  WT, wild-type Hepa-1 cells; PT67, non-
transfected viral packaging cells; B1, PT67 cells transiently expressing the Ahb-1 receptor; 
B2, PT67 cells transiently expressing the Ahb-2 receptor; RAT, PT67 cells transiently 
expressing rat AHR; HU, PT67 cells transiently expressing human AHR.  HU TNT, in 
vitro transcribed and translated human AHR used as a control.  Note that in each case 
PT67 cells express detectable levels of the target AHR. 
B 
A 
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Figure 2.3: Schematic for viral transfection.  (Adapted from Clontech user manual  
PT3132-1).  The viral genes gag, pol and env are required for viral production and are 
absent from the retroviral vector, but are integrated into the genome of the viral 
packaging cells. Following transfection of the retroviral vector into the packaging cells, 
the vector provides the viral packaging signal (Ψ+), the target gene, and the drug-
resistance marker, while the packaging cells provide gag, pol and env to generate 
infection-competent, replication-incompetent virus, which is collected from the cell 
culture media.  This viral media is then used to infect target cells, which are selected for 
infection by culturing in the presence of neomycin.  Resultant colonies are subsequently 
evaluated for expression of the target gene. 
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Figure 2.4: Western analysis of stable line expression of target AHR constructs.  
Equal amounts of total cell lysates from independent clones were resolved by SDS-PAGE, 
blotted, and stained with A-1A anti-AHR IgG (1.0 µg/ml) and -actin IgG (1:1000).  
Reactivity was visualized by ECL with GAR-HRP IgG (1:10,000). A, LA-I clones 
surviving selection after infection with Ahb-2, a truncated AHR (AHRtr), or rat AHR. WT, 
LA-I clones stably expressing the Ahb-1 receptor; B2, LA-I clones stably expressing the 
Ahb-2 receptor; AHRtr, amino-terminally truncated AHR; PT67, non-transfected viral 
packaging cell line; RAT, LA-I clones surviving selection after infection with rat AHR. B, 
LA-I clones surviving selection after infection with human AHR (Hu).  Arrows indicate 
clones that were chosen for future analysis.  Note that each lane represents an 
independent clone.  Also note that several independent clones for both the rat and human 
AHR failed to express the AHR following selection. 
   
A B
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failed to express the desired target genes or expressed these genes at very low levels, 
though the constructs contained the correct sequence and transiently expressed the target 
genes following transient transfections into LA-I cells (Figure 2.2).  Repeated attempts to 
generate the lines by altering the number of rounds of infection with competent virus, the 
confluency of target cells, or by using different lots of competent virus, all resulted in 
colonies that failed to express the target genes at levels detectable with the A1-A AHR 
antibody (Figure 2.4).  Since the Ahb-1 and Ahb-2 lines were easily created, these lines 
became the focus for the following studies.  
Stable lines expressing the Ahb-2 were selected and those that expressed the 
receptor to the same physiological level as the AHRb-1 in WT Hepa-1 cells were chosen 
for future study and are referred to as AHb2 cells (Figure 2.4).  The same process was also 
completed for the AHRb-1 whereby the receptor was re-introduced into the LA-I AHR 
deficient line.  This line, termed hereafter as AHWT, was used as the control for the 
following studies, rather than WT Hepa-1, since these cells have also undergone selection 
and this line is therefore more comparable to other generated stable lines.  Since the 
expression of the AHRb-1 and AHRb-2 were achieved using retroviral vectors which insert 
the target genes directly into the genome, it was possible that insertion of the target genes 
could disrupt the expression of other gene(s) and thus confound the biochemical analyses 
of AHR function.  Therefore, all studies were performed using at least three independent 
AHWT or AHb2 clones to increase the likelihood that the biochemical properties of the 
AHR being evaluated were not resulting from altered expression of other genes impacting 
the AHR signaling pathway.  
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2.3 Reduced Association of XAP2 with Ahb-2 Receptors Expressed in the Hepa-1 
Background Mimics that of Endogenously Expressed Ahb-2 Receptors  
 It has been proposed that XAP2 functions in AHR-mediated signal transduction 
by influencing the stability, shuttling behavior and expression of the AHR (Bell and 
Poland, 2000; Berg and Pongratz, 2002; Carver and Bradfield, 1997; Kazlauskas et al., 
2002; LaPres et al., 2000; Lees et al., 2003; Ma and Whitlock, 1997; Meyer and Perdew, 
1999; Meyer et al., 2000; Meyer et al., 1998; Petrulis et al., 2003; Ramadoss and Perdew, 
2005).  However, these conclusions have been based primarily on the analysis of AHR 
and XAP2 in transient transfection systems.  Thus, there has been minimal information on 
the function of endogenous XAP2 especially as it relates to interactions with AHR 
proteins from species other than the murine C57BL strain.  Interestingly, initial studies 
carried out on mouse Hepa-1c1c7 cells, which express the C57BL Ahb-1 receptor, mouse 
C2C12 myoblasts, which express the Ahb-2 receptor, and rat smooth muscle cells (A7) 
suggested that AHR proteins from non-C57BL species exhibited a reduced association 
with XAP2.  This observation was based on evidence that while Western blot analysis of 
total cell lysates from these lines showed equal levels of endogenous hsp90, p23, and 
XAP2 protein and similar levels of AHR protein, cytosol produced from these lines and 
immunoprecipitated with AHR antibodies as detailed in Chapter Six showed that the 
level of XAP2 co-precipitated with the AHR in the C2C12 and A7 cells was greatly 
reduced in comparison to the Hepa-1 cells (Figure A-1).  In repeated experiments, the 
amount of XAP2 co-precipitated with AHR IgG from A7 and C2C12 cells averaged 15 ± 
7% and 19 ± 6% respectively of the level co-precipitated from Hepa-1 cells.  Since the 
overall level of AHR precipitated from the C2C12 or A7 cells was similar to that from the 
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Hepa-1, and the total cellular levels of AHR and XAP2 were similar, these results 
suggested that the differences in XAP2 association between the Hepa-1 cells and the 
C2C12 or A7 cells may be related to the AHR itself, rather than cellular context. 
Furthermore, recent studies likewise suggest that the human AHR is associated with 
reduced levels of XAP2 when transiently expressed in COS cells (Ramadoss and Perdew, 
2005).   However, since other cellular factors could be contributing to the reduced 
association of AHR and XAP2 in these lines by competing for binding with either protein 
or blocking interaction sites, it was essential to explore these protein•protein interactions 
in a common genetic background. 
  Thus, to further explore the reduced association of XAP2 seen in the C2C12 cells 
carrying the Ahb-2 allele and to determine more definitively whether this reduced 
association between the non-C57BL/6J AHR and XAP2 was receptor or cell specific, 
studies were carried out in the previously described AHWT and AHb2 stable cell lines.  
Figure 2.5 A shows the expression of AHR, hsp90, XAP2, and actin in the parental LA-I 
Hepa-1 variant, the AHWT, and the AHb2 lines.  Importantly, the level of AHR expressed 
in each of the stable cell lines approximates that of the endogenous AHR in wild type 
Hepa-1 cells, and the levels of hsp90 and XAP2 in total cell lysates are also similar.  To 
assess the composition of the unliganded AHR complex, cytosol was generated from two 
independent AHb2 cell lines as well as from the AHWT line and immunoprecipitated with 
antibodies specific to the AHR as previously described.  As shown for the endogenous 
Ahb-1 receptor in Hepa-1 cells, immunoprecipitation of the AHR from the AHWT cells co-
precipitated a high level of XAP2 (Figure 2.5 B).  In contrast, as shown for the  
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Figure 2.5: Analysis of AHR and XAP2 expression and association in stable cell 
lines expressing Ahb-1 or Ahb-2 receptors. Stable cell lines expressing the Ahb-1 (AHWT) 
or Ahb-2 (AHb2) were generated as detailed in Chapter Six.  A, equal amounts of total cell 
lysates from LA-I (LA), Hepa-1 (He), AHWT (WT), or AHb2 (b2) cells were resolved by 
SDS-PAGE, blotted, and stained with A-1A rabbit IgG (1.0 µg/ml), -actin rabbit IgG 
(1:1000), hsp90 rabbit IgG (1:500), or XAP2 mouse IgG1 (1:750). Reactivity was 
visualized by ECL with GAR-HRP or GAM-HRP IgG (1:10,000). B, cytosol was 
prepared from AHWT (WT) or two independent AHb2 (b2) cell lines as detailed. 800 µg of 
cytosol was precipitated with either affinity-pure A1-A IgG (5 µg) or affinity-pure 
preimmune rabbit IgG (5 µg) along with Protein A/G-agarose (25 µl) for 2.5 h at 4 °C 
with rocking. Pellets were washed three times for 5 min each with TTBS supplemented 
with sodium molybdate (20 mM) and then boiled in 30 µl of SDS sample buffer. 15 µg of 
cytosol (input) or 15 µl of the eluted protein were resolved by SDS-PAGE, blotted, and 
stained with A-1A IgG (1.0 µg/ml) or XAP2 mouse IgG1 (1:750). Reactivity was 
visualized by ECL with GAR-HRP or GAM-HRP IgG (1:10,000). Ah, precipitated with 
A1-A IgG; Pi, precipitated with preimmune IgG. The numbers under the XAP2 blot 
represent the percentage of XAP in relation to the level in the AHWT cell line (100%).  
The precipitated IgG band is shown to demonstrate the uniformity of the precipitation 
across all samples.    
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endogenous rat and Ahb-2 receptors, immunoprecipitation of the AHR from both of the 
AHb2 cell lines precipitated significantly lower levels of endogenous XAP2 than the 
AHWT (compare Figures 2.5 B and A-1 B).  Indeed, over several experiments, the average 
amount of XAP2 co-precipitated from the AHb2 cells was 21 ± 8% of the level co-
precipitated from AHWT, which highly mimics the 19 ± 6% seen in the C2C12 cells 
endogenously expressing the Ahb-2 receptor.  Taken together, these studies clearly 
indicate that even in the same genetic background as the Ahb-1, the Ahb-2 receptor exhibits 
a reduced association with XAP2.  Thus, the species of receptor, not the cellular context 
of its expression, appears to determine the level of association with XAP2.  Furthermore, 
since the Ahb-1 and the Ahb-2 exhibit 99% identity of the first 805 amino acids, this 
reduced association is likely to be related to the extended carboxy-terminal region found 
in most species.  However, since XAP2 appears to associate with amino acids 380-419 of 
the PAS B domain of AHR which share 100% identity between the Ahb-1 and Ahb-2 
(Meyer and Perdew, 1999) and not through a carboxy-terminal region of AHR, this 
reduced association is likely due to a conformational change in the AHR resulting from 
the extended carboxy terminus rather than sequence specific differences. 
 
2.4 Ahb-2 Receptor Expressed in the Hepa-1 Background Exhibits Nucleocytoplasmic 
Shuttling 
     The endogenous Ahb-1 receptor is predominantly cytoplasmic in Hepa-1 cells 
when evaluated by immunohistochemistry or confocal microscopy (Pollenz, 1996; 
Pollenz et al., 1994), though exogenous expression of the Ahb-1 receptor in HeLa or COS 
cells is nuclear unless XAP2 is also expressed in the cells (Berg and Pongratz, 2002; 
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Kazlauskas et al., 2000; Kazlauskas et al., 2002; Petrulis et al., 2000; Petrulis et al., 2003).  
Thus, it has been hypothesized that XAP2 inhibits nuclear localization of the unliganded 
AHR complex.  Previous studies have demonstrated that the endogenous Ahb-1 receptor 
in untreated Hepa-1 exhibits a predominantly cytoplasmic location that becomes strongly 
nuclear following exposure to ligand (Pollenz, 1996; Pollenz et al., 1994).   In contrast, 
the endogenous AHR proteins expressed in A7, C2C12, or 10T1/2 embryonic fibroblasts, 
which express the rat (A7) or Ahb-2 receptor, exhibit a subcellular localization in untreated 
cells that is both cytoplasmic and nuclear, but becomes predominantly nuclear after a 60-
min exposure to TCDD (Figure A-2).  Importantly, exposure of any of these cell lines to 
the CRM-1 nuclear export inhibitor leptomycin B (LMB) for 2 or 4 h results in an 
accumulation of the AHR in the nucleus that is not seen in Hepa-1 cells expressing the 
Ahb-1 (Figure A-2).  LMB-induced nuclear localization of the endogenous AHR was also 
observed in the MCF7 human breast cancer cell line (Wentworth et al., 2004).  Thus, 
these previous findings show an LMB-induced accumulation of nuclear AHR that is 
suggestive of rat and mouse Ahb-2 receptors that are dynamically shuttling between 
through the nucleus with a periodicity of 90–180 min.   
Since these results indicated that the subcellular localization of the AHR and its 
ability to shuttle through the nucleus was dependent on the species and strain of AHR 
examined and since these findings correlated to a reduced level of XAP2 associated with 
the AHR complex, it was again pertinent to assess whether the lack of shuttling seen in 
the Hepa-1 was related to its genetic background or whether these biochemical properties 
were specific to the AHR expressed in the cell.  To evaluate this question, AHWT and 
AHb2 cells were propagated on glass coverslips, exposed to TCDD or LMB, and then  
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fixed and stained for AHR protein.  As was previously shown, the location of the Ahb-1 
receptor in the AHWT cells was predominantly cytoplasmic and became nuclear following 
1 h of TCDD treatment (Figure 2.6).  In addition, as observed in the wild-type Hepa-1 
lines, 4 h of LMB exposure did not influence the location of the Ahb-1 receptor.  In 
contrast, the unliganded Ahb-2 receptor exhibited a subcellular localization that was both 
cytoplasmic and nuclear that became more strongly nuclear in the presence of LMB 
(Figure 2.8, lower panels).  Since the Ahb-2 receptor showed a predominately nuclear 
localization prior to LMB treatment, the change in nuclear fluorescence intensity was 
measured by the average level of fluorescence among a population of nuclei as detailed in 
Chapter Six.  In the experiment shown, the average level of fluorescence in control nuclei 
was 106 ± 10 (across a population of 100 cells), whereas the LMB-treated nuclei 
averaged 165 ± 12 (also across a population of 100 cells).  Thus, these results show that 
nucleocytoplasmic shuttling of an AHR can occur in the Hepa-1 cell line, but that this 
shuttling is dependent on the species of AHR that is expressed.   
Furthermore, this lack of nucleocytoplasmic shuttling in the Hepa-1 line 
expressing the Ahb-1 receptor can be directly correlated to the high level of XAP2 
association seen with this receptor species.  Other studies performed in this laboratory 
have demonstrated that reductions in XAP2 by siRNA treatment in the Hepa-1 line result 
in an AHR that is associated with reduced levels of XAP2 similar to the situation seen in 
cells expressing other AHR species (Figure A-3).  Additionally, while these cells with 
reduced XAP2 show the same cytoplasmic distribution of the AHR as cells transfected 
with control siRNA, there is a marked increase in the nuclear localization of the AHR 
when cells transfected with siXAP2 are treated with LMB for 4 h, which was not  
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Figure 2.6: Subcellular localization of AHR in AHWT and AHb2 cells exposed to 
TCDD or LMB. Cells were grown on glass coverslips exposed to the compounds 
detailed below and then fixed as detailed previously (Holmes and Pollenz, 1997; Pollenz, 
1996; Pollenz et al., 1994). Coverslips were incubated with A-1 IgG (1.0 µg/ml) and 
visualized with GAR-Rhodamine IgG (1:400). A, B, D, and E, AHWT cells exposed to 
Me2SO (0.1%) (A) for 1 h, TCDD (2 nM) for 1 h (B), methanol (0.5%) for 4 h (D), or 
LMB (20 nM) for 4 h (E). F–I, AHb2 cells exposed to Me2SO (0.1%) for 1 h (F), TCDD (2 
nM) for 1 h (G); methanol (0.5%) for 4 h (H), or LMB (20 nM) for 4 h (I). C, the parental 
LA-I cell line stained and photographed under the identical conditions to the AHWT and 
AHb2 cells. All panels were exposed for identical times. Bar (A), 10 µm. 
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observed in LMB-treated cells transfected with siCON (Figure A-4).  Together, these 
results suggest that when endogenous XAP2 is reduced in the Hepa-1 cell line, the 
endogenous AHR exhibits a reduced association with XAP2 that is similar to that seen in 
the rat and Ahb-2 receptor and, importantly, that such a reduction appears to result in a 
receptor capable of undergoing dynamic nucleocytoplasmic shuttling.  Thus, the high 
levels of XAP2 associated with the Ahb-1 appear to prevent shuttling of this AHR species.  
Since dynamic nucleocytoplasmic shuttling has been shown to be important level of 
control for many transcriptional regulators such as members of the E2F family, NFκB, 
and mdm2 (Cartwright and Helin, 2000), transcriptional regulation of some target genes 
may differ between the C57BL/6J mouse and other species.   
 
2.5 Exogenous Expression of XAP2 Does Not Affect the Subcellular Localization of the 
Ahb-1 or the Ahb-2 Receptor 
Previous results from this laboratory further suggest that the entire pool of Ahb-1 
receptor complexes in Hepa-1 cells is associated with XAP2 since exogenous expression 
of XAP2 in the Hepa-1 line results in an equivalent level of association between the Ahb-1 
receptor and XAP2, though there was a large increase in cellular expression of XAP2 
(Figure A-5).  Additionally, when exogenous XAP2 is expressed in the Hepa-1 line, no 
significant alterations were seen in the localization of the Ahb-1 receptor (Figure A-6).  
Likewise, transgenic animals exhibiting a hepatocyte specific increase in XAP2 
expression levels also fail to exhibit increased levels of Ahb-1•XAP2 association 
(Hollingshead et al., 2006).  Since the Ahb-2 receptor and rat AHR appeared to be 
associated with a lesser degree of XAP2, even in the presence of similar cellular levels of 
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XAP2, these receptor complexes are either not all associated with XAP2, unlike the Ahb-1, 
or there is a reduced affinity of XAP2 for the Ahb-2 receptor leading to a weaker 
association of these proteins and possible loss during immunoprecipitation analysis.  
Therefore, studies were also carried out to determine whether increased expression of 
XAP2 in lines expressing the Ahb-2 receptor would increase the level of association 
between the Ahb-2 and XAP2 and/or inhibit nucleocytoplasmic shuttling of the Ahb-2 
receptor.  To establish whether Ahb-2 complexes could be generated with increased XAP2 
association in the presence of exogenous XAP2 expression, AHb2 cells were transfected 
as above, lysed and the AHR immunoprecipitated with A-1A anti-AHR IgG.   The 
samples were then evaluated for AHR and XAP2 protein by Western blotting.  A 
representative experiment is shown in Figure 2.14 and quantified results presented in 
Figure 2.7.  The input samples demonstrate that AHb2 cells transfected with XAP2 
exhibited an increase in the total cellular level of XAP2 compared with cells transfected 
with control vector, and that such an increase in XAP2 resulted in increased association 
of the Ahb-2 receptor with XAP2 (Figures 2.7 and 2.8).   Indeed, when the AHR was 
immunoprecipitated from these samples, the ratio between the level of AHR and the total 
amount of XAP2 associated with the endogenous Ahb-2 complex was similar to that seen 
in the Ahb-1 (Figure 2.8).   
To establish whether these Ahb-2 complexes exhibiting increased XAP2 
association would be exhibit an altered subcellular distribution, cells were transfected 
with control vector or pCI-hXAP2 as detailed in Chapter Six and allowed to recover for 
48 h, and subsequently harvested and analyzed by Western blotting or fixed onto 
coverslips and stained for AHR or XAP2 (Figure 2.9 A).  Western blot analysis of these 
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Figure 2.7: Association of the Ahb-2 receptor with XAP2 in cells expressing increased 
levels of XAP2.  Hepa-1 (WT) or AHb2 stable lines were transfected with pCI-hXAP2 or 
control vector pcDNA3.1 as detailed in Chapter Six. After 24 h, populations of cells were 
harvested, and cytosol was generated for immunoprecipitation experiments.  600 µg of 
cytosol from the indicated samples was precipitated in duplicate with either AHR (AHR-
IgG) or preimmune IgG (Pi-IgG) as detailed in Chapter Six. Each of the precipitated 
samples as well as 15 µg of cytosol (input) was resolved by SDS-PAGE and blotted. 
Blots were stained with either 1.0 µg/ml A-1A IgG or XAP2 mouse IgG1 (1:750), and 
reactivity was visualized by ECL with GAR-HRP or GAM-HRP IgG (1:10,000). mXAP2, 
endogenous mouse XAP2; hXAP2, exogenous human XAP2; and AHR (AHR). The IgG 
bands are presented to show the consistency of the precipitations. C, samples from cells 
transfected with pcDNA3.1; X, samples from cells transfected with pCI-hXAP2.  The 
precipitated IgG band is shown to demonstrate the uniformity of the precipitation across 
all samples.    
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Figure 2.8: Quantification of association of the Ahb-2 receptor with XAP2 in cells 
expressing increased levels of XAP2.  Computer densitometry was used to determine 
the relative level of AHR or XAP2 protein present in the precipitated samples from 
Figure 2.13. Each column represents the relative densitometry units of an individual band 
and can be used to evaluate differences in the ratio of XAP2/AHR in the different 
samples. However, because of the difference in the sensitivity of each antibody for its 
target protein, the ratio does not represent the absolute number of protein molecules. Note 
that the XAP2/AHR ratio is essentially between the WT and WT+XAP2 samples, while 
the relative amount of XAP2 increases in the b2 samples transfected with XAP2 to a 
XAP2/AHR ratio similar to WT levels. end, endogenous expression; ex, exogenous 
expression; tot, total expression levels. 
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Figure 2.9: Localization of Ahb-2 receptor in AHb2 cells expressing hXAP.  AHb2 
populations were transfected with pCI-hXAP2 (XAP2) or control vector pcDNA3.1 
(CON) as detailed in Chapter Six. A, Western blot of AHR and XAP2 expression in total 
cell lysates prepared from transfected cells.  Each of the samples was resolved by SDS-
PAGE and blotted. Blots were stained with either 1.0 µg/ml A-1A anti-AHR IgG, anti-β 
actin IgG (1:1000), or XAP2 mouse IgG (1:750), and reactivity was visualized by ECL 
with GAR-HRP (1:10,000; AHR, Actin) or GAM-HRP IgG (1:10,000; XAP2). B, 
Duplicate populations of transfected cells were fixed and stained for the AHR with 1.0 
µg/ml A-1A AHR IgG or hXAP2 IgG and visualized with GAR-RHO IgG (1:400; AHR) 
or GAM-FITC (1:400; XAP2). Scale bar, 10 µm. 
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samples revealed an increased level of total cellular XAP2 following transfection.  
Unexpectedly, however, immunohistochemical staining of the Ahb-2 receptor in cells 
transiently transfected with XAP2 failed to exhibit any changes in AHR localization from 
control transfected cells (Figure 2.9 B).  However, it is important to note that while the 
total level of XAP2 association is these transfected cells increased relative to endogenous 
Ahb-2•XAP2 association, this level remained lower than that seen with the Ahb-1.  It is 
noteworthy, though, that while 100% of the population of Ahb-1 complexes appeared to 
be associated with XAP2 and Ahb-2 complexes appeared to be endogenously associated 
with less XAP2, Ahb-2 complexes could be “forced” to associate with increased levels of 
XAP2 when the cellular expression of XAP2 was greatly increased.  Since an increased 
association with the Ahb-2 receptor could be achieved, further studies should be 
performed to evaluate the potential affect of this increased association of the Ahb-2 
receptor with XAP2.  Transgenic hepatocyte specific overexpression of XAP2 in the C3H 
mouse expressing the Ahb-2 receptor, as has been performed in the C57BL/6J mouse 
(Hollingshead et al., 2006), may be particularly insightful and may serve as a better 
model for examining the potential impact of XAP2 overexpression in model systems 
where the AHR is endogenously associated with lower levels of XAP2. 
 
2.6 Degradation of the Mouse Ahb-2 Receptor in Hepa-1 Background Varies from the  
Ahb-1 Receptor 
The AHR proteins expressed in the A7 and C2C12 cells also exhibit an increased 
susceptibility to TCDD-induced degradation wherein C2C12 and A7 cells treated with 
TCDD for 0–120 min results in a dramatic reduction of cellular AHR protein by the 120-
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min time point (Figure A-7).   Indeed, in the C2C12 lines, AHR protein was not 
detectable at the 90-min time point, and in A7 cells, the AHR protein decreased by 88% 
of control levels by the 120-min time point.  Additionally, previous reports have shown 
that the AHR was also reduced by greater than 90% following 120 min of TCDD 
exposure in the 10T1/2 cell line (Pollenz et al., 1994; Richter et al., 2001).  In contrast, 
TCDD-induced degradation of the Ahb-1 receptor exhibits a degradation profile of lesser 
magnitude whereby AHR protein in this line is only reduced by 30–40% after 120 min. 
Collectively, these results indicate that the endogenous Ahb-2 and rat receptors are 
degraded to near completion within 2 h of ligand exposure and highlight another striking 
difference in the response of these AHR proteins in comparison to the Ahb-1 receptor.  
Since the AHR expressed in the A7 and C2C12 cells exhibited a different time course 
and magnitude of degradation from the AHR expressed in the Hepa-1 cells, it was 
therefore pertinent to assess the degradation of the AHR in the AHb2 cell line in 
comparison to the AHWT line.  To evaluate the degradation pattern of each receptor, both 
lines were compared in a time course of degradation following ligand binding.  Two 
different time course experiments were completed.  In the first experiment, cells were 
treated with TCDD for 0, 1, 2, 4, or 6 hours and total cell lysates were harvested and 
evaluated by SDS-PAGE and Western blotting for levels of AHR, CYP1A1, and actin.  
Results from a representative experiment are given in Figure 2.10.  In the second 
experiment, cells were treated with TCDD for 0, 30, 60, 90, or 120 minutes and total cell 
lysates were again harvested and evaluated by SDS-PAGE and Western blotting for 
levels of AHR, CYP1A1, and actin.  Results from a representative experiment are given 
in Figure 2.10 B inset. In both time courses evaluated, TCDD-induced degradation in the  
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Figure 2.10: Western blot analysis of AHR in stable cell lines expressing Ahb-1 or 
Ahb-2 receptors exposed to TCDD. A, AHWT and AHb2 cells were treated with Me2SO 
(0.1%) for 6 h or TCDD (2 nM) for the indicated times. Total cell lysates were prepared, 
and equal amounts of protein were resolved by SDS-PAGE, blotted, and stained with A-
1A IgG (1.0 µg/ml) and actin IgG (1:1000). Reactivity was visualized by ECL with 
GAR-HRP (1:10,000), and protein bands were quantified and normalized as detailed 
(Holmes and Pollenz, 1997; Pollenz, 1996; Pollenz et al., 1994). B, the levels of AHR 
protein in the AHWT and AHb2 samples were divided by the corresponding level of actin, 
and the average ± S.E. of the three independent samples was plotted as the percentage of 
time 0 control. The inset shows the time course of degradation over 120 min.   
*, statistically different from the control siRNA; p < 0.001. 
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AHb2 line was more rapid and proceeded to a greater magnitude than that in the AHWT.  
Indeed, the Ahb-2 receptor was reduced by 52% after 2 h and >85% after 6 h of TCDD 
exposure compared with 28 and 74% for the Ahb-1 receptor.  Overall, while the Ahb-2 
receptor expressed in the AHb2 line exhibited a reduced degradation rate than that 
expressed in the C2C12 line, the increased magnitude of degradation seen in the AHb2 
line was more representative of that observed in the C2C12 cell line which endogenously 
expresses the AHRb-2 or the rat A7 cell line than the Hepa-1 (compare Figures 2.10 and 
A-7).    
 
2.7 Time Course of CYP1A1 Induction is Unaltered by Ah Receptor Type 
Since nucleocytoplasmic shuttling and a more rapid degradation profile could be 
impacting target gene induction by the Ahb-2 compared to the Ahb-1 following ligand 
binding, the ability of each receptor to induce CYP1A1 was assessed.  LA-I cells not 
expressing any exogenous AHR were also examined to insure that the levels of CYP1A1 
protein were not influenced by the presence of any endogenous receptor in the LA-I line.  
Figure 2.11 shows that CYP1A1 was detectable within 2 h of TCDD exposure in both 
cells lines and increased proportionally over time.  To determine whether there were any 
quantitative differences in the induction of CYP1A1 protein in the two cell lines, cells 
were treated with TCDD for 16 h, and identical levels of total cell lysates were evaluated 
by quantitative Western blotting.  Interestingly, the level of CYP1A1 protein induced 
after 16 h was not statistically different between the AHWT and AHb2 cell lines although 
the Ahb-2 receptor was associated with less XAP2 and degraded with a more rapid profile 
(Figures A-1, 2.5, A-7, and 2.10).  Thus, in this model system, a reduction in the level of  
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Figure 2.11: Western blot analysis of CYP1A1 protein in stable cell lines expressing  
Ahb-1 or Ahb-2 receptors following exposure to TCDD. A, AHWT and AHb2 cells were 
treated with Me2SO (0.1%) for 6 h or TCDD (2 nM) for the indicated times. Total cell 
lysates were prepared, and equal amounts of protein were resolved by SDS-PAGE, 
blotted, and stained with rat CYP1A1 IgG (1.0 µg/ml) and actin IgG (1:1000). Reactivity 
was visualized by ECL with GAR-HRP (1:10,000). B, LA-I, AHWT, and AHb2 cells were 
treated with Me2SO (0.1%) or TCDD (2 nM) for 16 h. Total cell lysates were prepared, 
and equal amounts of protein were resolved by SDS-PAGE, blotted, and stained with rat 
CYP1A1 IgG (1.0 µg/ml) and actin IgG (1:1000). Reactivity was visualized by ECL with 
GAR-HRP (1:10,000), and protein bands were quantified and normalized as detailed 
(Holmes and Pollenz, 1997; Pollenz, 1996; Pollenz et al., 1994). C, the levels of CYP1A1 
protein in the LA-I, AHWT, and AHb2 samples were divided by the corresponding level of 
actin, and the average ± S.E. of the three independent samples was potted as normalized 
densitometry units. Con, average density of Me2SO-treated cells. 
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Figure 2.12: Analysis of dose-response for CYP1A1 induction in stable cell lines 
expressing Ahb-1 or Ahb-2 receptors.  A, Triplicate plates of AHWT or AHb2 cells were 
dosed with 1, 10, 100, or 1000 pM TCDD for 6 hr at 37° as detailed in Chapter Six.  
Total cell lysates were prepared, and equal amounts of protein were resolved by SDS-
PAGE, blotted, and stained with A-1A IgG (1.0 µg/ml), rat CYP1A1 IgG (1.0 µg/ml), 
and actin IgG (1:1000). Reactivity was visualized by ECL with GAR-HRP (1:10,000), 
and protein bands were quantified and normalized as detailed (Holmes and Pollenz, 1997; 
Pollenz, 1996; Pollenz et al., 1994).  B, the levels of CYP1A1 protein in the AHWT and 
AHb2 samples were divided by the corresponding level of actin, and the average of the 
three independent samples was plotted compared to the time 0 control.  Each data point 
represents the average of the triplicate normalized samples for each TCDD concentration.  
Note that the EC50 for CYP1A1 induction in both AHWT or AHb2 cells is similar an close 
to the expected 30-50 pM range.  
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XAP2 in the core AHR complex did not appear to impact induction of the endogenous 
CYP1A1 gene. To confirm these CYP1A1 induction levels, dose-response studies were 
performed using graded doses of TCDD on cell lines in culture.  Following the 
incubation, cells were harvested and evaluated for CYP1A1 protein and actin expression 
by quantitative Western blotting as detailed previously.  Representative results are shown 
in Figure 2.12.   From these studies, it was determined that the AHWT and AHb2 lines 
exhibited a similar EC50 (~40 pM) for CYP1A1 induction in response to TCDD that was 
within the 30-50 pM published range (Pollenz, 1996).  WT Hepa-1 cells were included as 
a control, and exhibited similar results as those obtained using the AHWT line (data not 
shown).  Together, these data further support the hypothesis that properties of the 
receptor itself rather than other cellular factors are mostly responsible for subcellular 
localization and degradation following ligand binding. 
 
2.8 AHb2 Stable Line Conclusions 
  When considered in the context of the results presented in Figures 2.5-2.19, these 
findings collectively show that the Ahb-2 receptor when in the same C57BL/6J genetic 
background as the Ahb-1 exhibits distinct susceptibility to ligand exposure and 
nucleocytoplasmic shuttling when compared with the Ahb-1 receptor.  Additionally, these 
biochemical properties of the Ahb-2 receptor mimic those of the Ahb-2 endogenously 
expressed in the C2C12 cell line.  Furthermore, these studies indicate that these 
differences are likely related to the receptor-dependent reduced association of the Ahb-2 
receptor with XAP2 rather than cellular context.  Studies focusing on the function of the 
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AHR in the C57BL/6Jmouse or Hepa-1 cells are therefore not universal descriptions of 
AHR function and may not be entirely representative of receptor function in the human. 
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Chapter Three 
Generation and Characterization of Stable Lines Expressing Ah-Receptors Deficient in 
DNA-Binding or ARNT Dimerization 
 
3.1 Rationale for AHR Mutant Lines 
Agonist binding to the AHR results in degradation of the receptor following DNA 
binding, but not of the complex’s components: ARNT, XAP2, p23, or Hsp90 (Cioffi et 
al., 2002; Giannone et al., 1998; Pollenz, 2002; Roman and Peterson, 1998; Roman et al., 
1998).  While it has been well-established that the AHR is targeted for degradation 
following ligand activation, the mechanism of this event remains unclear (Dale and 
Eltom, 2006; Davarinos and Pollenz, 1999; Giannone et al., 1998; Ma, 2007; Ma and 
Baldwin, 2000; Ma et al., 2000; Morales and Perdew, 2007; Ohtake et al., 2007; Poland 
and Glover, 1988; Pollenz, 2002; Pollenz, 2007; Pollenz and Dougherty, 2005; Pollenz et 
al., 2005; Song and Pollenz, 2002; Song and Pollenz, 2003; Wentworth et al., 2004).  
Following TCDD binding, the AHRb-1 is rapidly depleted by 80-95% within 4-6 hours of 
treatment in numerous cell culture models and does not return to basal levels as long as 
ligand is present in the media (Pollenz, 1996; Reick et al., 1994).  This degradation is 
even more rapid with the Ahb-2, human or rat receptors, depleting by 90-100% within 2 
hours of treatment (Pollenz and Dougherty, 2005).  In either case, this degradation has 
been demonstrated to occur via the 26S proteasome complex since pre-treatment with the 
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proteasome inhibitors MG-132 or lactacystin prior to treatment with agonist blocks 
degradation of the receptor, while pre-treatment with inhibitors of calpain, serine, or 
cysteine proteases or lysosomal proteases does not inhibit the degradation response 
(Davarinos and Pollenz, 1999; Ma and Baldwin, 2000; Wentworth et al., 2004).  
Furthermore, ligand-dependant degradation can also be blocked by pre-treatment with the 
transcription inhibitor actinomycin D (AD) or the translation inhibitor cycloheximide 
(CHX) without affecting nuclear localization or DNA binding of the receptor, suggesting 
that both active transcription and translation are necessary for ligand-induced degradation 
of the AHR (Pollenz et al., 2005).  A summary of the potential pathways leading to AHR 
degradation is given in Figure 3.1. 
Thus, it was pertinent to assess whether ligand-induced degradation of the AHR, 
which appears to require active transcription and translation, required active transcription 
of the AHR•ARNT complex itself.  If DNA binding is necessary for degradation of the 
receptor by the agonist-dependent pathway, than mutations or truncations of the DNA 
binding domain should impact the ability of the receptor to be degraded.  Similarly, if a 
region responsible for dimerization with ARNT were mutated, DNA binding would be 
prevented by loss of ARNT heterodimerization and should impact degradation of the 
receptor.   
To formally investigate the impact that DNA binding and ARNT dimerization 
mutations would have on the degradation of the AHR, and whether the differences in 
degradation were due to the receptor itself or other cellular factors, stable lines were 
generated exploiting the LA-I, AHR deficient cells as described in Chapter Six.  The use  
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Figure 3.1: Schematic of the AHR ligand-dependent and ligand-independent 
degradation pathways. In brief, ligands such as halogenated aromatic hydrocarbons 
(HAHs), polychlorinated biphenyls (PCBs), polyaromatic hydrocarbons (PAHs) enter a 
cell, bind to the AHR complex leading to a conformational change of the receptor, which 
then translocates to the nucleus and heterodimerizes with ARNT.  The AHR•ARNT 
complex then associates with xenobiotic response elements with the core sequence 5’-
T(T/A)GCGTG to regulate phase I and phase II metabolizing enzymes, typified by 
CYP1A1.  The AHR is then targeted for degradation via the 26S proteasome in the 
nucleus (Roberts and Whitelaw, 1999), but degradation can also occur following nuclear 
export via CRM-1 (dashed line; Davarinos and Pollenz, 1999).  In ligand-independent 
degradation, hsp90 inhibitors such as geldanamycin and radicicol bind to Hsp90, 
resulting in nuclear accumulation of the AHR and subsequent degradation via the 26S-
proteasome without DNA binding or ARNT dimerization (Chen et al., 1997); however, 
this degradation is independent of nuclear import and can occur in the cytoplasm (dashed 
line; Song and Pollenz, 2002).  Note that while ligand-dependant degradation can be 
blocked by pre-treatment with the transcription inhibitor actinomycin D (AD) or the 
translation inhibitor cycloheximide (CHX), degradation of the AHR via GA cannot be 
blocked by treatment with either AD or CHX (Pollenz et al., 2005). 
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of a genetically identical background to examine the function and degradation rate of the 
mutant receptors in comparison with the wild-type AHRb-1 provided significant insights 
into these questions. 
 
3.2 Generation of LA-I Lines Expressing AHR DNA Binding Mutants and ARNT 
Dimerization Mutants 
The first step in these studies was the evaluation of potential sites for mutation or 
truncation in the AHR that would disrupt DNA binding or ARNT dimerization as desired.  
The AHR basic domain spans amino acid residues 13-39 and appears to make 2 amino 
acid base contacts with DNA using tyrosine 9 and arginine 39 (Bacsi and Hankinson, 
1996; Fukunaga et al., 1995).  Based on this data, a construct was generated in which the 
amino-terminal portion of the AHR was truncated resulting in the loss of the first 40 
amino acids (trAHR).  This construct was generated and stably integrated into the LA-I 
line as described in Chapter Six.  Additionally, a second construct was generated in 
which the AHR arginine 39 residue was mutated to an alanine, which has previously been 
shown to reduce the DNA binding potential of the AHR to approximately 1±1% versus 
wild-type receptor (Bacsi and Hankinson, 1996; Figure 3.2).  For the ARNT dimerization 
mutants, a construct which had previously been evaluated by this laboratory (Pollenz and 
Barbour, 2000) was used, wherein two leucine residues within a portion of the spacer 
region between the PAS-A and PAS-B domains of the AHR, thought to contain a second 
nuclear export site (NES), were mutated to alanines leading to an inability to dimerize 
with ARNT (AHR-L69/71A, referred to as AHR∆NES; Figure 3.2).   
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Figure 3.2: Schematic of AHR mutations for R39A and ∆NES AHR mutant stable 
lines.  AHR protein domain schematic indicating the amino acid positions of the 
mutagenized residues and the locations of the characterized domains.  Thin horizontal 
lines indicate functional domain regions.  NLS, nuclear localization sequence; NES, 
nuclear export sequence; bHLH, basic-helix-loop-helix; PAS, PER/ARNT/SIM 
homology regions; PAC, PAS-associated c-terminal region; TAD, transactivation domain; 
P/S/T-rich, proline, serine and threonine-rich sequence. Numbers underneath represent 
amino acid positions. Note that while the Ahb-1 receptor is shown as an example, the R39 
and the L69/71 are conserved among all characterized murine AHR alleles. 
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Constructs were then tested by transient transfection into the AHR-deficient LA-I Hepa-1 
variant or in PT67 viral packaging cells, then analyzed by SDS-PAGE and evaluated by 
Western blotting (Figure 3.3 A and B).  Western analysis also validated that the 
molecular mass of each protein was correct.  Following transfection of viral packaging 
cells, viral media was collected and used to infect target cells and stable lines surviving a 
two-week selection in neomycin were then analyzed for expression of the target genes by 
SDS-PAGE and Western blotting (Figure 3.3 C and D).   Stable lines expressing the 
trAHR, the R39A, and the ∆NES AHR proteins were then selected and those that 
expressed the receptor to the same physiological level as the AHRb-1 in WT Hepa-1 cells 
were chosen for future study.  Total cell lysates of each stable line revealed no 
differences in total cellular levels of AHR, ARNT or Hsp90 (Figure 3.4).  Note that while 
the cellular content of the trAHR line is not shown, no differences were observed. 
  
3.3 Characterization of AHR Mutants Deficient in DNA Binding and ARNT Dimerization   
Stable cell lines expressing the trAHR were then treated with TCDD for 0, 1, 2, 4, 
or 6 hours and total cell lysates harvested, assayed for total protein content, and evaluated 
by SDS-PAGE and Western blotting for levels of AHR, CYP1A1, and actin.  Results 
from a representative experiment are given in Figure 3.5.  However, there was no 
apparent difference in the rate of degradation between the AHRb-1 and the trAHR 
receptors when expressed in Hepa-1, suggesting that DNA binding of the AHR was not 
relevant to the ability of the liganded receptor to undergo degradation.  However, the 
trAHR, which was localized to the cytoplasm as expected, continued to become 
predominately nuclear in the presence of ligand, even though the NLS was removed in  
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Figure 3.3: Western analysis of AHRtr, R39A, and ∆NES AHR mutants.  Equal 
amounts of total cell lysates from independent samples were resolved by SDS-PAGE, 
blotted, and stained with A-1A rabbit IgG (1.0 µg/ml) and -actin rabbit IgG (1:1000).  
Reactivity was visualized by ECL with GAR-HRP IgG (1:10,000). A, LA-I cells 
transiently expressing the AHRtr compared to WT cells endogenously expressing the 
Ahb-1 receptor.   B, PT67 cells transiently stably expressing the R39A or ∆NES receptor 
compared to several AHR controls.  C, D, Stable line analysis of the AHRtr, R39A, and 
∆NES AHR constructs.  Arrows indicate examples of clones used for subsequent analysis 
based on similar expression levels of the AHR in WT Hepa-1 cells. 
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Figure 3.4: Western analysis of R39A and ∆NES AHR mutant stable lines.  Stable 
cell lines expressing the R39A AHR, the ∆NES AHR, and the wild-type AHR (A3) were 
generated as detailed in Chapter Six.  Equal amounts of total cell lysates from LA-I, 
Hepa-1 (WT), ∆NES, R39A, or A3 cells were resolved by SDS-PAGE, blotted, and 
stained with A-1A rabbit IgG (1.0 µg/ml), -actin rabbit IgG (1:1000), or hsp90 rabbit 
IgG (1:500). Reactivity was visualized by ECL with GAR-HRP IgG (1:10,000). 
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Figure 3.5: Time course of ligand-induced degradation of AHRWT and trAHR.  A, 
The indicated cell lines were treated with 0.5% Me2SO (time 0 control), or TCDD (5nM) 
for the indicated times (hr) at 37°C.  Dosing was staggered so that all cells were 
harvested at the same time.  Equal amounts of total cell lysates were resolved by SDS-
PAGE, blotted and stained with A-1A anti-AHR IgG (1.0μg/ml), anti-P450 (1:750) and 
anti-β actin (1:1000).  Reactivity was visualized by ECL with GAR-HRP (1:10,000). B, 
The level of AHR protein at each time point was divided by the corresponding level of 
actin for normalization purposes and the average ± S.E. of the three independent samples 
plotted as a function of the vehicle control cells (100%).   
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the truncation and this removal confirmed by DNA sequencing analysis (data not shown).  
Thus, the truncated AHR did not appear to be functioning as expected.  However, the  
trAHR did appear to be unable to induce CYP1A1 protein in the presence of ligand 
(Figure 3.5).  Since the truncation of 40 amino acids from the NH-terminus of the AHR  
could be affecting the folding of the AH receptor or the interaction of the AHR with other 
proteins, leading to seemingly confounding data, an alternate approach was taken to 
evaluate the degradation of a full-length AHR deficient in DNA binding.   
For this approach, an AHR construct was generated in which the arginine 39 
residue was mutated into an alanine (R39A) as previously described.  As before, the 
functional ability of the R39A mutant was characterized and the degradation pattern 
assessed.  Since the R39A mutant had already been thoroughly characterized in its 
deficiency to bind DNA when coexpressed with ARNT and treated with TCDD (Bacsi 
and Hankinson, 1996), studies were initiated to confirm the lack of function in vivo by 
evaluating the ability of the R39A stable line to induce CYP1A1 following treatment 
with TCDD.  A representative experiment is given in Figure 3.6.  Similar to the trAHR 
construct, the absence of CYP1A1 induction in Hepa-1 cells stably expressing the R39A 
AHR following 6 or 16 hrs of TCDD treatment indicates the inability of the mutant AHR 
to bind DNA.  Since this study only evaluated the ability of either construct to induce a 
single gene, studies were initiated to further support the hypothesis that neither the R39A 
nor the ∆NES AHR constructs were able to function in target gene induction,.  For these 
studies, stable lines expressing the wild-type AHR, the R39A, or the ∆NES AHR 
constructs were transfected with the XRE controlled GudLuc 1.1 luciferase reporter and 
pSV-β-Galactosidase as detailed in Chapter Six.  A representative experiment is given in  
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Figure 3.6: Overday or overnight ligand-induced degradation of the AHRwt, R39A, 
or ∆NES stable lines.  The indicated cell lines were treated with 0.5% Me2SO (time 0 
control), or TCDD (5nM) for 6 (+) or 16 hours (++) at 37°C.  Dosing was staggered so 
that all cells were harvested at the same time.  A, Equal amounts of total cell lysates were 
resolved by SDS-PAGE, blotted and stained with A-1A anti-AHR IgG (1.0μg/ml), anti-
P450 (1:250; Santa Cruz) and anti- β actin (1:1000).  Reactivity was visualized by ECL 
with GAR-HRP (1:10,000). B, Computer densitometry was used to determine the relative 
level of AHR protein present in the Me2SO or TCDD samples presented on the blot in A 
for the AHRWT and R39A stable lines.  The level of AHR present was normalized to the 
level of actin and each column represents the relative densitometry units of an individual 
band and shows that the degradation of the R39A AHR is minimal compared to wild-type 
AHR. 
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Figure 3.7.  While stable lines expressing the wild-type AHR were capable of inducing 
very high levels of luciferase activity following TCDD treatment, neither the R39A nor 
the ∆NES lines were capable of driving luciferase expression above that of the AHR-
deficient LA-I parental line.  Indeed, these lines exhibited TCDD-dependent luciferase 
activity that was >40-fold lower than that of the lines expressing wild-type AHR. 
However, unlike the trAHR, the R39A AHR remained predominately cytoplasmic and 
exhibited nuclear accumulation only following 1 hr of TCDD treatment (Figure 3.8).   
Since the R39A AHR should be capable of dimerizing with ARNT, it is expected that 
such a nuclear accumulation should occur in the presence of TCDD.  Interestingly, the 
∆NES lines appeared to express a receptor that was predominately nuclear even in the 
absence of TCDD (Figure 3.8 middle panels).  However, since association of the AHR 
with XAP2 appears to require the PAS B/ligand binding domain of the AHR (Meyer and 
Perdew, 1999), which partly overlaps with the sequence removed in the ∆NES construct, 
it is possible that the ∆NES AHR would exhibit a reduced association with XAP2, and 
would therefore be capable of shuttling through the nucleus as seen with the Ahb-2 
receptor in Chapter Two.  However, this hypothesis has not yet been tested. 
To confirm that the R39A AHR remained capable of dimerizing with ARNT and 
to further confirm that the ∆NES AHR could not, cytosol was prepared from R39A or  
∆NES cell lines treated with 0.5% Me2SO or 10μM TCDD and subjected to 
immunoprecipitation analysis using anti-AHR antibodies as detailed in Chapter Six 
(Figure 3.9).  In these studies, ARNT was specifically immunoprecipitated in the TCDD 
treated R39A cell lines and failed to precipitate with AHR antibodies in the Me2SO 
treated samples or when pre-immune antibodies were used.  Furthermore, cytosol 
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Figure 3.7: Analysis of TCDD-induced luciferase activity in LA-I, AHWT, R39A, and 
∆NES stable lines.  The indicated cell lines were transfected with pSV- β -Galactosidase 
along with GudLuc 1.1 and treated with Me2SO (0.5%) or TCDD (5nM) for 6 hours.  
Luciferase activity and β-Galactosidase activity were measured as previously described in 
Chapter Six and (Zeruth and Pollenz, 2007).  All luciferase values were normalized to β -
Galactosidase. 
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Figure 3.8: Subcellular localization of the ∆NES and R39A AHR.  Cells were grown 
on glass coverslips, exposed to Me2SO (0.5%) or TCDD (5nm) for 1 hr and then fixed as 
detailed in Chapter Six. Coverslips were incubated with anti-AHR A-1 IgG (2.8μg/ml) 
and visualized with GAR-RHO IgG (1:400).  The top row shows control LA-I, ∆NES, or 
the R39A stable lines exposed to Me2SO.  The bottom row shows those cells exposed to 
TCDD (5nM) for 1 hour (+).  Each set of panels was exposed for identical times.   
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Figure 3.9: Immunoprecipitation analysis of ARNT association in ∆NES and R39A 
stable lines.  Cytosol was prepared from ∆NES and R39A lines treated with 0.5% 
Me2SO (-) or 10uM TCDD (+) as detailed in Chapter Six.  800μg of cytosol was 
precipitated with either high affinity anti-AHR A-1A IgG (5μg; A) or affinity pure pre-
immune rabbit IgG (5μg; Pi) along with protein A-G agarose (25ul) for 2.5 hours at 4°C 
with rocking.  Pellets were washed 3 times for 5 minutes each with TTBS supplemented 
with sodium molybdate (20mM) and then boiled in 30ul SDS sample buffer.  15μg 
cytosol (input) or 15ul of the eluted protein were resolved by SDS-PAGE, blotted, and 
stained for ARNT (R1 IgG at 1μg/ml). Reactivity was measured by ECL with GAR-HRP 
(1:10,000). A, precipitated with ARNT; Pi, precipitated with pre-immune IgG.  Note the 
precipitation of ARNT in the treated R39A samples that is absent in the ∆NES samples.  
The precipitated IgG band is shown to demonstrate the uniformity of the precipitation 
across all samples.    
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prepared from 0.5% Me2SO or 10μM TCDD ∆NES stable lines confirmed the lack of 
ARNT dimerization in this mutant since ARNT was not co-precipitated with the AHR in 
any sample type (Figure 3.9).  Thus, while the R39A AHR remained capable of 
associating with ARNT, the mutant receptor failed to function in CYP1A1 induction, 
while the ∆NES AHR was neither capable of dimerizing with ARNT or binding DNA. 
 Additionally, cytosolic and nuclear extracts prepared from the wild-type, R39A or 
∆NES stable lines treated with 0.5% Me2SO or 10nM TCDD revealed that while the 
AHR and ARNT co-accumulated in nuclear extracts of cell lines expressing the wild-type 
AHR, in cells expressing AHR proteins deficient in DNA binding or ARNT dimerization, 
ARNT failed to accumulate in nuclear extracts following TCDD treatment (Figure 3.10).  
While ARNT is a nuclear protein, in its latent state, ARNT is not tightly associated with 
nuclear structures and therefore has a tendency to “leak” from nuclear extracts into the 
cytosolic compartment (Pollenz et al., 1994).  Thus, this lack of nuclear accumulation is a 
result of the failure of ARNT to be recruited to bind DNA rather than being indicative of 
nuclear ARNT.  Taken together, the collective results shown in Figures 3.4-3.8 reveal 
that the R39A and ∆NES stable lines express Ah receptor that is deficient in either DNA 
binding (R39A) or ARNT dimerization (∆NES), but in each case remains otherwise 
functional.  Thus the ability of the AHR receptor to be degraded under these conditions 
can now be examined. 
 
3.4 Ligand-Dependent Degradation of the AHR Requires DNA Binding  
To initially examine the degradation profile of these constructs, stable cell lines 
expressing the R39A or ∆NES mutation were treated for 6 or 16 hours with TCDD and  
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Figure 3.10: Analysis of accumulation of AHR and ARNT in cytosolic and nuclear 
extracts from AHWT, R39A, and ∆NES stable lines.  The indicated stable cell lines 
were treated with Me2SO (0.5%; -) or TCDD (10nM; +) for 1 h at 37°C.  Cytosolic (C) 
and nuclear extracts (N) were prepared as detailed in Chapter Six.  Equal amounts of the 
indicated cytosolic and nuclear extracts were combined with 2X gel sample buffer and 
resolved by SDS-PAGE, blotted and stained with anti-AHR A-1A IgG (1.0μg/ml) or anti-
ARNT R1 IgG (1.0 μg/ml).  Reactivity was visualized by ECL with GAR-HRP 
(1:10,000).  The bold arrow on the bottom indicates the accumulation of both AHR and 
ARNT in the nuclear extracts from TCDD treated AHRWT cells. 
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the resulting protein levels analyzed by SDS-PAGE and Western blotting and compared 
to those seen in the AHWT line (Figure 3.11).  Interestingly, neither line exhibited >30% 
degradation of the AHR at either 6 or 16 hours.  To confirm this lack of degradation, 4 
and 5 hour time points of TCDD treatment were also examined with neither point 
exhibiting >30% reduction in AHR (data not shown).   Taken together, this suggests that 
the DNA-binding event is itself necessary for ligand-induced degradation of the AHR and 
by preventing DNA binding either directly or by inhibiting dimerization with ARNT, the 
ability of the AHR to degrade is limited. 
Since a modest level of degradation of the AHR was seen in both the R39A and 
∆NES lines in the presence of TCDD, it was also pertinent to assess the mechanism of 
this degradation and whether this small level of degradation was occurring in a ligand-
dependent manner similar to loss of the wild-type AHR; albeit to a lesser magnitude.  To 
determine if this small loss of mutant receptor was occurring via the ligand-dependant or 
ligand-independent pathway, further studies were performed using actinomycin D (AD), 
a known blocker of ligand-induced degradation of the AHR (Pollenz et al., 2005).  
Interestingly, the 30% loss of the mutant AHR proteins exhibited in the presence of 
TCDD was unable to be blocked by pretreatment of cells with AD prior to dosing with 
TCDD in either the ∆NES or R39A line (results for R39A not shown), though neither 
was it able to fully block degradation in the AHWT line, which still exhibited a >15% loss 
of receptor (Figure 3.11).  Thus, while the minimal loss of the receptor in the ∆NES and 
R39A occurred in a ligand-dependent manner, it did not appear to be occurring via the 
same ligand-induced mechanism seen in the AHWT line.  However, this assessment is 
difficult since pretreatment with AD did not completely inhibit degradation of the AHR  
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Figure 3.11: Impact of actinomycin D on TCDD-induced degradation of AHRwt and 
∆NES stable lines.  Indicated cell lines (AHRwt, top; or AHR ∆NES, bottom) were 
treated normally with 0.5% Me2SO (CON) or TCDD (5nM) for 4 hours (TCDD), with 
the AD (0.3uM) inhibitor for 5 hours (AD), or pre-treated with AD for 1 hour followed 
by treatment with TCDD (5nM) for an additional 4 hours (AD/TCDD).  A, Equal 
amounts of total cell lysates were resolved by SDS-PAGE, blotted and stained with A-1A 
anti-AHR IgG (1.0μg/ml) and anti-β actin (1:1000).  Reactivity was visualized by ECL 
with GAR-HRP (1:10,000).  B, Computer densitometry was used to determine the 
relative level of AHR protein present in the each sample treatment type presented on the 
blot in A for the AHRWT and ∆NES stable lines.  All AHR levels were normalized to 
actin controls. 
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in the AHWT line, and, therefore, the low level of degradation seen in the AHWT line may 
be occurring by the same mechanism of that of the AHR in the ∆NES and R39A lines. 
 
3.5 Ligand-Independent Degradation of the AHR Does Not Require DNA Binding 
Ligand-independent degradation of the AHR is typified by treatment with 
geldanamycin (GA), a benzoquinone ansamycin capable of binding to the ATP-binding 
pocket of Hsp90 and thereby likely altering the conformation of the Hsp90 associated 
AHR to allow for nuclear translocation of the receptor and its subsequent degradation 
without disruption of the AHR complex itself and, importantly, without DNA binding or 
subsequent gene induction (Chen et al., 1997; Meyer et al., 2003b; Song and Pollenz, 
2002).  This pathway is characterized by a rapid and robust degradation profile (>80% 
within 1 hour) that also appears to occur via the 26S proteasome and can be blocked by 
MG-132 or lactacystin (Song and Pollenz, 2002).  Additionally, degradation of the AHR 
via GA cannot be blocked by treatment with either AD or CHX, suggesting that multiple 
mechanisms exist for the degradation of the receptor, though both terminate at the 26S 
proteasome (Pollenz et al., 2005). 
Since ligand-independent degradation of the AHR induced by GA results in 
degradation of the AHR without DNA binding, it was expected that AHR protein 
deficient in DNA binding or ARNT dimerization would continue to exhibit the same time 
course and magnitude of GA-induced degradation as wild-type receptor.  Thus, AHWT, 
R39A, and ∆NES stable lines were treated with 200uM GA for 0, 60, or 120 min and the 
level of AHR protein assessed and compared to that of Hepa-1 lines endogenously 
expressing the Ahb-1.  Results from a typical experiment are presented in Figure 3.12.  In  
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Figure 3.12: Geldanamycin-induced degradation of wild-type Hepa-1 cells, AHWT, 
R39A, or ∆NES stable lines.  The indicated cell lines were treated with 0.5% Me2SO 
(time 0 control), or Geldanamycin (200nM) for 60 or 120 min at 37°C.  Dosing was 
staggered so that all cells were harvested at the same time.  A, Equal amounts of total cell 
lysates were resolved by SDS-PAGE, blotted and stained with A-1A anti-AHR IgG 
(1.0μg/ml) and anti-β actin (1:1000).  Reactivity was visualized by ECL with GAR-HRP 
(1:10,000). B, Computer densitometry was used to determine the relative level of AHR 
protein present in the each sample treatment type presented on the blot in A for the Hepa-
1, AHRWT, R39A and ∆NES stable lines.  All AHR levels were normalized to actin 
controls.  Hepa-1, grey diamonds; AHRWT, open circles; ∆NES, black triangles R39A, 
white squares. 
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contrast to the minimal degradation of the R39A or ∆NES AHR in the presence of 
TCDD, in the presence of GA, the R39A and ∆NES AHR proteins exhibited a similar 
time course and magnitude of degradation over 120 minutes in a ligand-independent 
manner.  As expected, total AHR levels in all cell types were reduced by >70% within 60 
min and by nearly 100% within 120 min (Figure 3.12).  The similarity of both the time 
course and magnitude of this degradation in the absence of TCDD suggests that the 
ligand-independent mechanism of AHR degradation induced by GA remains intact 
regardless of the ability of the receptor to function as a transcription factor.  Therefore, 
GA-induced degradation of the AHR does not appear to require DNA binding of the 
AHR.  Furthermore, these studies indicate that the lack of degradation of the AHR in the 
R39A and ∆NES is not a result of an inability of the mutant AHR to be degraded. 
 
3.6 Impact of NH-Terminal Tags on AHR Degradation 
During the creation of stable lines expressing amino-terminally tagged AHR 
proteins to be used in another set of studies, it became apparent that the presence of these 
tags was altering the degradation rate of the AHR following ligand binding.  Figure 3.13 
and 3.14 illustrates the schematic of the tagged AHR proteins as well as their expression 
levels in several cell lines stably expressing the untagged AHR (AHWT), His Max tagged 
AHR (HMAHR; a Hexahistidine tag with Xpress epitope), or GFP-tagged AHR (GFPAHR; 
green fluorescent protein), which were generated as detailed in Chapter Six.  After dosing 
these lines, or other independent stable lines expressing either tagged AHR, with TCDD 
for 0, 2, 4, 6, 8 or 16 hours, the amino-terminally tagged AHR proteins exhibited a 
marked reduction in the overall level of degradation when compared to stable lines 
 111
 
 
Figure 3.13: Invitrogen plasmid maps for generating constructs with NH-terminal 
tags.  Target genes are expressed from the cytomegalovirus immediate early (CMV IE) 
promoter and the plasmids contain both neomycin (G418) and ampicillin resistance used 
for antibiotic selection in eukaryotic and prokaryotic cells respectively.  Top: Constructs 
were generated with NH-terminal EYFP tags by cloning products in frame with the 
EYFP sequence present on the EYFP fusion vector.  Bottom:  Constructs were generated 
with NH-terminal HisMax tags by TOPO cloning products in frame with the 
6xHis/Xpress sequence present on the pcDNA 4/HisMax vector.  Vectors were obtained 
from the manufacturer (Invitrogen; Carlsbad, California). 
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expressing the untagged AHR (Figure 3.15).  Indeed, while the AHWT exhibited an 
approximately 70-80% reduction in total AHR levels following 6 hours of TCDD TCDD 
treatment, which appeared to recover to nearly time 0 levels by 16 hours, indicating a 
lesser magnitude of degradation for these receptor types.  Interestingly, while the overall 
magnitude of degradation in the HMAHR and GFPAHR lines was reduced compared to 
untagged AHR, these receptors exhibited a greater level of degradation following TCDD 
treatment than the non-functional AHR mutants (R39A and ∆NES), and maintained the 
ability to induce CYP1A1 to nearly the same level as wild-type AHR (Figure 3.16).  
Thus, the magnitude of ligand-induced degradation of the AHR can be affected without 
creating non-functional AHR types and functional ability of the receptor is not the sole 
determinant for AHR degradation.  
 Furthermore, treatment with GA revealed no difference in the time course or 
magnitude of the degradation of the AHR in lines expressing the untagged AHR, the 
HMAHR, or the GFPAHR with all three lines exhibiting a >80% reduction in total AHR 
levels after 120 min of GA-treatment, similar to the results obtained in the previously 
detailed studies (Figure 3.17).   These results again indicate a different mechanism for the 
ligand-induced and ligand-independent degradation of the AHR and further suggest that 
the mechanism for ligand-independent degradation may have little to do with the AHR 
itself, since numerous AHR constructs differing in size and in functional ability all 
exhibit similar magnitudes of GA-induced degradation. 
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Figure 3.14: Characterization of HM- and GFP-tagged AHR stable lines. A, 
Schematic showing location and size of the HisMax and GFP tags.  B, Equal amounts of 
total cell lysates from independent clones were resolved by SDS-PAGE, blotted, and 
stained with A-1A anti-AHR rabbit IgG (1.0 µg/ml) and anti- -actin rabbit IgG (1:1000).  
Reactivity was visualized by ECL with GAR-HRP IgG (1:10,000). LA-I, mutant Hepa-1 
cells deficient in AHR expression; WT, wild-type Hepa-1 cells; AHWT, LA-I clones 
stably expressing the Ahb-1 receptor; HMAH, LA-I clones stably expressing the HisMax 
tagged AHR; GFPAH, LA-I clones stably expressing the GFP tagged AHR.  Note that 
each lane represents an independent clone.   
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Figure 3.15: Ligand-induced AHR degradation in HM- and GFP-tagged AHR stable 
lines. A, Stable cell lines expressing the untagged AHR, the HisMax tagged AHR, or the 
GFP-tagged AHR were dosed with Me2SO (0.5%, time 0 control) or 10 nM TCDD for 2, 
4, 6, 8 or 16 hours.  Equal amounts of total cell lysates from independent samples were 
resolved by SDS-PAGE, blotted, and stained with A-1A anti-AHR rabbit IgG (1.0 µg/ml) 
and anti- -actin rabbit IgG (1:1000).  Reactivity was visualized by ECL with GAR-HRP 
IgG (1:10,000).  B, The amount of AHR protein at each time point was analyzed by 
computer densitometry of the blots shown in A as detailed in Chapter Six.  Results were 
normalized to the level of actin and are expressed as the percentage of protein seen at 
time 0 ± SEM. AHWT, LA-I clones stably expressing the Ahb-1 receptor; HMAH, LA-I 
clones stably expressing the HisMax tagged AHR; GFPAH, LA-I clones stably expressing 
the GFP tagged AHR.  Note that each lane represents an independent clone.   
treatment, both the HMAHR and GFPAHR exhibited a nadir of 42% AHR after 4 hours of 
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Figure 3.16: Ligand-induced CYP1A1 induction in HM- and GFP-tagged AHR 
stable lines. A, Stable cell lines expressing the untagged AHR (A), the HisMax tagged 
AHR (H), or the GFP-tagged AHR (G) were dosed with Me2SO (0.5%, time 0 control) or 
10 nM TCDD for 2, 4, 8 or 16 hours (+).  Equal amounts of total cell lysates from 
independent samples were resolved by SDS-PAGE, blotted, and stained with A-1A anti-
AHR rabbit IgG (1.0 µg/ml), anti-CYP1A1 IgG (1:750) and anti- -actin rabbit IgG 
(1:1000).  Reactivity was visualized by ECL with GAR-HRP IgG (1:10,000).  B, The 
amount of CYP1A1 protein after TCDD treatment was analyzed by computer 
densitometry of the blots shown in A as detailed in Chapter Six.  Results were normalized 
to the level of actin and are expressed as the percentage of protein compared to the 
untagged AHR control.  
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Figure 3.17: Geldanamycin-induced degradation of the HM- and GFP-tagged AHR.  
The indicated cell lines were treated with 0.5% Me2SO (time 0 control), or Geldanamycin 
(200nM) for 30, 60, 90 or 120 min at 37°C.  Dosing was staggered so that all cells were 
harvested at the same time.  A, Equal amounts of total cell lysates were resolved by SDS-
PAGE, blotted and stained with A-1A anti-AHR IgG (1.0μg/ml) and anti-β actin (1:1000).  
Reactivity was visualized by ECL with GAR-HRP (1:10,000). B, Computer densitometry 
was used to determine the relative level of AHR protein present in the each sample 
treatment type presented on the blot in A.  All AHR levels were normalized to actin 
controls.   
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Chapter Four 
Functional Analysis of ARNT2 in AHR-mediated Signal Transduction 
 
4.1 Rationale for Evaluating ARNT2 Function 
 ARNT is a member of the basic-helix loop-helix PER/ARNT/SIM (bHLH/PAS) 
protein family that is involved in mediating numerous developmental and response 
pathways (Crews, 1998; Furness et al., 2007; Kewley et al., 2004).  Several isoforms of 
ARNT have been identified in mammalian and aquatic species and are termed: ARNT 
(HIF-1B), ARNT2, ARNT3 (BMAL1, ARNTL1, MOP3, JAP3), and ARNT4 (BMAL2, 
ARNTL2, MOP9).  ARNT and ARNT2 possess a 95% amino acid identity within the 
bHLH and >80% amino acid identity PAS A and B domains that are known to be 
involved in DNA binding and heterodimerization (Pongratz et al., 1998; Reisz-Porszasz 
et al., 1994).  ARNT appears to be ubiquitously expressed in nearly all cell types in 
various species (Abbott, 1995; Aitola and Pelto-Huikko, 2003; Hirose et al., 1996; 
Holmes and Pollenz, 1997; Kozak et al., 1997; Sojka et al., 2000), while ARNT2 was 
initially classified a being expressed primarily in the brain and kidney (Hirose et al., 
1996).  However, while ARNT is known to have a more ubiquitous expression pattern 
than ARNT2, mRNA for the two genes is co-expressed to some degree during mouse 
development and in most adult tissues (Aitola and Pelto-Huikko, 2003).  It is interesting, 
therefore, that gene knock-out of either ARNT or ARNT2 in mice, results in embryonic 
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or perinatal lethality that is characterized by distinct phenotypes (Keith et al., 2001; 
Kozak et al., 1997; Maltepe et al., 1997).  These findings have led to the hypothesis that 
the ARNT and ARNT2 proteins have distinct functions in the presence of various 
dimerization partners and are not fully capable of complementing each other, despite the 
high level of amino acid identity.  But while much is known about the expression of 
ARNT at the protein level and its ability to dimerize with various bHLH/PAS partners, 
the level of ARNT2 protein expression in cells and tissues and well as its interactions 
with other proteins are less defined (Crews, 1998; Furness et al., 2007; Kewley et al., 
2004; Reisz-Porszasz et al., 1994) (See Chapter One).   
 Unfortunately, the limited number of studies that have evaluated biochemical and 
molecular differences in ARNT and ARNT2 function and whether they compete for 
dimerization partners report conflicting results (Hirose et al., 1996; Sekine et al., 2006).  
In addition, there are no studies that have evaluated the co-expression of ARNT and 
ARNT2 protein in cell lines or tissues.  In an effort to address these questions, studies 
were initiated to investigate the ability of defined concentrations of ARNT and ARNT2 
to interact with the AHR and bind DNA in vivo and in vitro, and to isolate model systems 
in which both proteins were expressed physiologically.   
 
4.2 ARNT2 Does Not Function to the Same Level as ARNT in AHR-Mediated Signaling 
 It has been reported that in comparison with ARNT, the ARNT2 isoform exhibits a 
reduced ability to complement AHR signaling in the induction of XRE driven luciferase 
reporter activity in response to treatment with 3-Methylcholanthrene (3-MC) (Sekine et 
al., 2006).  To directly compare the ability of ARNT2 to substitute for ARNT in AHR-
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mediated signaling of an endogenous gene (CYP1A1), several ARNT/ARNT2 constructs 
were prepared.  Initially, ARNT and ARNT2 full length cDNAs were cloned into either 
pcDNA 3.0(-) with or without a V5 epitope tag at the NH-terminal of the full length 
ARNT or ARNT2 protein (Figure 4.1).  Since antibodies raised against ARNT and 
ARNT2 are differently specific, the presence of a common NH-terminal tag allowed each 
ARNT to be detected with the same specificity by the same antibody.  These constructs 
were then transiently transfected into the LA-II ARNT deficient cell line and their ability 
to complement the defect in these cells was analyzed.  To determine whether or not each 
ARNT was able to form a DNA binding species with AHR capable of transactivation of 
XRE controlled genes, luciferase reporter studies were completed using these constructs.  
In this case, the ARNT or ARNT2 lines were transfected with an XRE controlled 
luciferase reporter construct along with β-galactosidase, a transfection efficiency control.  
Results from a typical experiment are shown in Figure 4.2.  In these experiments, LA-II 
cells transfected with naked vector were unable to complement AHR-mediated signaling 
in response to TCDD as expected.  Additionally, when the LA-II cells were transfected 
with ARNT alone, high basal levels of luciferase activity were seen that became even 
greater in the presence of TCDD.  However, when mARNT2 was transfected into the 
LA-II cells, both the basal levels as well as the levels of luciferase activity in response to 
TCDD were significantly reduced to <17% of those levels seen with ARNT alone.  These 
data indicate that ARNT2 is not as well able to complement the defect in the ARNT-
deficient line. 
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Figure 4.1: Protein schematic of V5-ARNT and V5-ARNT2 constructs.  The 14 
amino acid V5 epitope (GKPIPNPLLGLDST) was cloned directly 5' to the ARNT 
sequence onto each of the ARNT proteins into pcDNA 3.1 (-) downstream of a T7 
promoter along with a consensus Kozak sequence.  The original ARNT start codon was 
removed to prevent possible transcription of a clam ARNT lacking the V5 tag.   
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Figure 4.2: Analysis of TCDD-induced luciferase activity in LA-II cells transfected 
with ARNT or ARNT2.  LA-II cells were transfected with identical amounts of ARNT 
or ARNT2 vector and with pSV- β -Galactosidase along with GudLuc 1.1 and treated 
with Me2SO (0.5%) or TCDD (5nM) for 6 hours.  Luciferase activity and β-
Galactosidase activity were measured as previously described in Chapter Six and (Zeruth 
and Pollenz, 2007).  All luciferase values were normalized to β -Galactosidase.  LA-II = 
parental cells transfected with naked vector; ARNT = LA-II cells expressing V5-ARNT; 
ARNT2 = LA-II cells expressing V5-ARNT2.   
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 To assess this data on a more physiological scale, it was pertinent to determine 
whether or not each ARNT was able to form a DNA binding species with AHR capable 
of transactivation of the endogenous CYP1A1 protein induction in response to treatment 
with TCDD as well as to assess the relative levels of ARNT and ARNT2 in each sample 
type.  Therefore, ARNT and ARNT2 constructs possessing a common NH-terminal V5 
epitope tag were separately transfected into LA-II cells, treated with TCDD and the 
resulting cell lysates analyzed by SDS-PAGE and Western blotting for target protein 
expression.  Representative results are given in Figure 4.3.  As expected, the LA-II cells 
were unable to induce CYP1A1 protein in response to TCDD; however, they were able to 
do so when ARNT was reintroduced by transfection as has been previously shown 
(Hoffman et al., 1991; Whitlock and Galeazzi, 1984).  In contrast, ARNT2 appeared to be 
unable to functionally substitute for ARNT during AHR-mediated induction of CYP1A1 
protein in response to TCDD even though ARNT and ARNT2 were expressed to similar 
levels as assessed by computer densitometry quantification of V5 staining.   This 
inefficiency in complementing loss of ARNT was also mimicked when untagged ARNT 
proteins were used, when ARNT2 was expressed at a greater level than ARNT, and when 
other AHR ligands were used (EJD, unpublished observations). 
 To confirm that the inability of ARNT2 to substitute for ARNT was not a result of 
poor transfection efficiency resulting in subpopulations of LA-II cells expressing high 
levels of ARNT2 while others expressed little or no ARNT2, yielding an apparent overall 
similar level of ARNT2 with less apparent CYP1A1 induction, immunohistochemistry 
was performed on samples similar to those used in Figure 4.3 A.  Resultant microscopy 
images are given in Figure 4.3 B.  In these studies, it is apparent that while ARNT and 
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Figure 4.3: Induction of CYP1A1 protein in cells expressing ARNT or ARNT2. A, 
LA-II cells were transfected with the indicated constructs as detailed in Chapter Six and 
treated with Me2SO (0.5%) or TCDD (2nM) for 6 hours at 37°C.  Equal amounts of total 
cell lysates from triplicate plates were resolved by SDS-PAGE, blotted and stained with 
A-1A IgG (1.0μg/ml), anti-V5 IgG (1:500), anti-CYP1A1 (1:200) as well as anti-β-actin 
(1:1000).  Reactivity was visualized by ECL with GAR-HRP (1:10,000) or GAM-HRP 
(1:10,000).  LA-II = parental cells transfected with naked vector; V5-ARNT = LA-II cells 
expressing V5-ARNT; V5-ARNT2 = LA-II cells expressing V5-ARNT2.  B, LA-II cells 
were propagated on glass coverslips and transfected and treated as detailed in A.  Fixed 
slips were stained with anti-ARNT IgG (0.5μg/ml), anti-ARNT2 IgG (0.5μg/ml), or anti-
CYP1A1 (1:100) and reactivity was visualized using GAR-RHO (1:400).  All panels that 
were stained with the same antibodies were photographed for identical times.   ARNT) 
LA-II cells transfected with ARNT and stained for ARNT. ARNT+TC CYP) LA-II cells 
transfected with ARNT, treated with TCDD or Me2SO  (CON) and stained for CYP1A1.  
Arrowheads indicate cells expressing cytoplasmic CYP1A1.  ARNT2) LA-II cells 
transfected with ARNT2 and stained for ARNT2.  ARNT+TC CYP) LA-II cells 
transfected with ARNT2, treated with TCDD or Me2SO (CON) and stained for CYP1A1.    
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ARNT2 were not transfected with 100% efficiency, a similar percentage of cells were 
transfected with ARNT2 as was seen with ARNT; however, while the ability of ARNT 
transfected cells to induce CYP1A1 in response to TCDD was robust, no induction of 
CYP1A1 was seen in any cell in the population transfected with ARNT2.  LA-II cells 
transfected with naked vector showed no apparent staining for ARNT, ARNT2, or 
CYP1A1 in the presence or absence of TCDD (data not shown).  These data further 
suggest that in cell culture, ARNT2 is not able to substitute for ARNT in the TCDD-
dependent induction of CYP1A1. 
 To further assess this question independently from transiently transfected cell lines, 
stable cell lines expressing ARNT or ARNT2 were generated using the ARNT deficient 
LA-II line as detailed in Chapter Six.  The creation of these lines allowed for populations 
of cells clonally expressing either ARNT or ARNT2, allowing for a comparison of the 
ability of either protein in function in the AHR mediated induction of CYP1A1 following 
TCDD treatment.  Thus, each cell line was plated onto triplicate 35mm cell culture plates, 
dosed with 0.5% Me2SO or 10nM TCDD for 2, 4, or 6 hrs, harvested, and assessed for 
total protein content.  Identical amounts of total cellular protein were then assessed by 
SDS-PAGE and Western blotting for target protein expression relative to wild-type 
Hepa-1 cells.  Results from an experiment are shown in Figure 4.4.  In these studies, the 
Hepa-1 cells endogenously expressing ARNT show a robust induction of CYP1A1 
protein at 2, 4 and 6 hrs of TCDD treatment.  Similarly, LA-II stable lines expressing 
ARNT were capable of inducing CYP1A1 protein in response to TCDD treatment at all 
examined time points.  While the level of induction in this cell lines was lower than that  
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Figure 4.4: Induction of CYP1A1 protein in ARNT or ARNT2 stable lines. Equal 
amounts of total cell lysates from the indicated cell lines treated with 0.5% Me2SO or 
10nM TCDD for 2, 4, or 6 hrs were resolved by SDS-PAGE, blotted and stained with A-
1A IgG (1.0μg/ml), anti-V5 IgG (1:500), anti-CYP1A1 (1:200) as well as anti-β-actin 
(1:1000).  Reactivity was visualized by ECL with GAR-HRP (1:10,000) or GAM-HRP 
(1:10,000).  ARNT, LA-II line stably expressing ARNT; ARNT2, LA-II line stably 
expressing ARNT2. 
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seen in the Hepa-1 cells, the level of ARNT was also lower.  This is expected since a 
reduction in ARNT can lead to a reduction in CYP1A1 induction (RSP, unpublished 
observations).  In contrast, cell lines stably expressing ARNT2 remained incapable of 
inducing CYP1A1 at any of the examined time points, confirming that ARNT2 cannot 
functionally substitute for ARNT in this situation. 
 
4.3 Inability of ARNT2 to Function in the Regulation of CYP1A1 is Not a Result of 
Proline 352  
 Within the PAS B motif of all characterized ARNT2 proteins, there is a proline 
residue in a position where all characterized vertebrate ARNT proteins contain a histidine. 
A recent report has suggested that ARNT2 does not function in AHR signaling in vivo 
due to the presence of this proline at amino acid 352 within the PAS B domain of the 
murine ARNT2 protein (Sekine et al., 2006).  This assessment was based on the 
observation that mutant ARNT containing the homologous proline showed a reduced 
ability to function in the induction of CYP1A1, similar to the results obtained for ARNT2.  
However, this hypothesis was not examined directly since an ARNT2 construct 
possessing a histidine substitution was not evaluated for a gain-of-function study.  
Furthermore, homology modeling places this residue outside of the central β-sheet that is 
the characterized functional region for the PAS B domain and also suggests that the 
three-dimensional structure of the ARNT and ARNT2 PAS domains are similar (Figure 
4.5 A).  Therefore, to directly address whether this residue is responsible for loss of 
function in ARNT2, mutagenesis was utilized to change the proline at amino acid 352 to 
a histidine in the V5-tagged ARNT2 cDNA (ARNT2-H).  Studies were designed to  
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Figure 4.5: Induction of CYP1A1 protein in cells expressing ARNT, ARNT2, or 
ARNT2-H.  A, Homology modeling of ARNT and ARNT2 PAS domains showing the 
position of the swapped histidine and proline residues within the PAS B domain of 
ARNT and ARNT2 prepared by Pandini et al. (2007).  B, LA-II cells were transfected 
with the indicated expression constructs as detailed in Chapter Six and treated with 
DMSO (0.5%) or TCDD (2nM) for 6 hours at 37°C.  Equal amounts of total cell lysates 
from triplicate plates were resolved by SDS-PAGE, blotted and stained with anti-V5 IgG 
(1:500), anti-CYP1A1 (1:200) as well as anti-β-actin (1:1000).  Reactivity was visualized 
by ECL using GAR-HRP (1:10,000) or GAM-HRP (1:10,000).  Each lane represents an 
independent sample.  LA-II, parental cells transfected with naked vector.  
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assess the ability of ARNT2-H to restore AHR-mediated induction of the endogenous 
CYP1A1 gene in the LA-II cell line as detailed for ARNT2 above.  The results in Figure 
4.5 B show that ARNT, ARNT2 and ARNT2-H were expressed to similar levels in the 
LA-II cells, but as before, only cells expressing ARNT were capable of inducing 
endogenous CYP1A1.  In addition, immunofluorescence microscopy confirmed that all 
proteins were expressed in the nucleus and only cells expressing ARNT expressed 
CYP1A1 protein (data not shown).  Thus, these studies show that ARNT2 does not 
appear to function to the same level of ARNT in the induction of the endogenous 
CYP1A1 gene in cell culture and the lack of function is not due to the presence of a 
proline at amino acid 352. 
 
4.4 In Vitro Synthesized ARNT and ARNT2 Appear to Exhibit Equivalent Ability to 
Dimerize with the AHR and Bind DNA  
 To determine whether the reduced ability of ARNT2 to complement AHR signaling 
was occurring at the level of DNA binding, electrophoretic mobility shift assays (EMSA) 
were performed using either in vitro translated ARNT or ARNT2 along with mouse AHR 
(Ahb-1).  Equal amounts of ARNT and ARNT2 protein as determined by quantified 
computer densitometry analysis of Western blotting against the common NH-terminal V5 
epitope were mixed with AHR and the samples incubated in the presence of TCDD or 
Me2SO for 2 h.  Antibodies against ARNT, ARNT2, AHR or pre-immune antibodies 
were then added to aliquots of the original TCDD-activated samples to supershift specific 
proteins (Figure 4.6).  This technique prevents proteins specific to the antibody being 
used from entering the gel matrix as a result of the increased size of the antibody-bound  
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Figure 4.6: Schematic for evaluation of DNA binding potential of ARNT and 
ARNT2 using in vitro synthesized and activated samples.  In vitro synthesized V5-
ARNT, V5-ARNT2, and AHR were produced as detailed in Chapter Six and a portion of 
each sample was denatured and evaluated for ARNT, ARNT2, or AHR protein by 
Western analysis using either anti-V5 IgG (1:500) or A-1A anti-AHR IgG (1ug/ml) and 
visualized by ECL with GAM-HRP IgG (1:10,000; V5) or GAR-HRP IG (1:10,000; 
AHR).  The intensity of the resultant bands from the Western analysis were quantified by 
computer densitometry as detailed in Chapter Six and equal amounts of either ARNT 
protein were combined with unprogrammed reticulocyte and AHR protein and incubated 
in the presence of DMSO (0.5%, vehicle) or TCDD (100 nM, ligand) for 2 h at 30°C.  
Following activation, aliquots of each sample were combined with EMSA sample buffer 
and antibodies as described in Chapter Six and in figure legends.  These aliquots were 
then subjected to both EMSA and further Western analysis. 
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protein complex.  The formation of AHR•ARNT•XRE and AHR•ARNT2•XRE 
complexes were then evaluated by EMSA by probing the samples with a 32-P labeled 
XRE from the murine CYP1A1 promoter (Figure 4.7).  In both cases (AHR and ARNT 
or AHR and ARNT2), mixtures of both proteins formed a TCDD-dependent DNA 
binding shift that was not visible in samples activated with the Me2SO vehicle suggesting 
that the evident shift was a result of activation of the AHR (Figure 4.7, compare lanes 1-2 
and 7-8).  Furthermore, this study demonstrated that the TCDD-dependent DNA binding 
shift depended on the presence of both the AHR as well as an ARNT protein (either 
ARNT or ARNT2) and the DNA binding shifts corresponded to the relative molecular 
mass of AHR•ARNT and AHR•ARNT2 complexes.  In the TCDD-activated samples 
containing AHR and ARNT, addition of antibodies against either AHR or ARNT resulted 
in a supershifting of complexes containing these proteins, essentially ablating DNA 
binding.   In contrast, antibodies against ARNT2 in the AHR/ARNT samples or pre-
immune antibodies have no effect on the shift, demonstrating that the shift depends on 
the presence of both the ARNT and AHR proteins.  Similarly, in the TCDD-activated 
samples containing AHR and ARNT2, addition of antibodies against either AHR or 
ARNT2 resulted in a supershifting of complexes containing these proteins, essentially 
ablating DNA binding.   In contrast, antibodies against ARNT in the AHR/ARNT2 
samples or pre-immune antibodies have no effect on the shift, demonstrating that this 
shift depends on the presence of both the ARNT2 and AHR proteins.  Thus, these studies 
show that both ARNT and ARNT2 were capable of forming TCDD-dependent DNA 
binding shifts that depended on the presence of AHR protein.  Furthermore, the intensity 
of the DNA binding shift was similar when equal amounts of either ARNT protein was  
 131
 
Figure 4.7: DNA binding of AHR•ARNT and AHR•ARNT2 heterodimers.  In vitro 
expressed AHR was combined with either ARNT or ARNT2 into a stock sample and then 
aliquoted and incubated in the presence of DMSO (0.5%) or TCDD (100 nM) for 2 h at 
30°C.  A, Aliquots from the stock samples were mixed with 32P-labeled XRE 
oligonucleotides and protein•DNA complexes resolved as detailed in Chapter Six.  In 
some samples, 50ng of IgG specific to ARNT (A1), ARNT2 (A2), AHR (Ah) or 
preimmune IgG (IG) were included in the binding reaction prior to loading on the gel.  
The location of the specific AHR•ARNT•XRE and AHR•ARNT2•XRE complex and free 
XRE are indicated. B, Aliquots of the activation reactions utilized in the EMSA were 
denatured and evaluated for ARNT, ARNT2 or AHR protein by Western analysis using 
either anti-V5 IgG (1:500) or anti-AHR IgG (1ug/ml) and visualized by ECL with GAM-
HRP IgG (1:10,000; V5) or GAR-HRP IG (1:10,000; AHR).  Note that the concentration 
of both V5-ARNT and V5-ARNT2 in each sample is similar. C, control samples; T, 
samples activated with TCDD. 
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co-expressed with the AHR, suggesting that ARNT and ARNT2 have an equal ability to 
associate with the AHR and bind DNA when expressed in vitro (Figure 4.7, B). 
 To examine whether this would hold true when both ARNT and ARNT2 were co-
expressed along with the AHR in equal ratios, another EMSA was performed using a 
mixture of ARNT and ARNT2 proteins along with in vitro synthesized AHR (Figure 4.8). 
In this experiment, a mixture of both ARNT proteins with the AHR again resulted in the 
formation of a DNA binding shift that was TCDD-dependent (Figure 4.9 A).  
Furthermore, this shift resulted from equal expression of both ARNT proteins and 
appeared to require both proteins as well as the AHR.  Interestingly, the addition of 
antibodies against ARNT in the mixed sample, resulted in a DNA binding shift that was 
approximately 51% of the intensity of  the duplicate sample with TCDD alone when 
quantified by computer densitometry, suggesting that ARNT containing complexes 
account for approximately 49% of the total DNA binding shift (Figure 4.9 A, lane 3, C).  
Similarly, the addition of antibodies against ARNT2 yielded a shift that was 50% of the 
intensity of the control, suggesting that ARNT2 containing complexes also account for 
approximately 50% of the total shift (Figure 4.9 A, lane 4, C).  In contrast, addition of 
antibodies against the AHR ablated all evidence of DNA binding, further suggesting that 
the DNA binding shift seen in each lane is indeed representative of ARNT or 
ARNT2•AHR heterodimers, while addition of pre-immune IgG had no effect on DNA 
binding.  Furthermore, these differences in DNA binding were not attributable to the 
amount of protein in each sample as revealed by quantitative Western blotting performed 
on a portion of the exact samples used for the EMSA since each EMSA sample contained 
approximately equal amounts of both ARNT and ARNT2 as determined by V5 staining  
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Figure 4.8: Schematic for evaluation of DNA binding potential of a mixture of 
ARNT and ARNT2 using in vitro synthesized and activated samples.  In vitro 
synthesized V5-ARNT, V5-ARNT2, and AHR were produced as detailed in Chapter Six 
and a portion of each sample was denatured and evaluated for ARNT, ARNT2, or AHR 
protein by Western analysis using either anti-V5 IgG (1:500) or A-1A anti-AHR IgG 
(1ug/ml) and visualized by ECL with GAM-HRP IgG (1:10,000; V5) or GAR-HRP IG 
(1:10,000; AHR).  The intensity of the resultant bands from the Western analysis were 
quantified by computer densitometry as detailed in Chapter Six and equal amounts of 
both ARNT and ARNT2 proteins were combined with unprogrammed reticulocyte and 
AHR protein and incubated in the presence of DMSO (0.5%, vehicle) or TCDD (100 nM, 
ligand) for 2 h at 30°C.  Following activation, aliquots of each sample were combined 
with EMSA sample buffer and antibodies as described in Chapter Six and in figure 
legends.  These aliquots were then subjected to both EMSA, further Western analysis, 
and immunoprecipitation analyses. 
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Figure 4.9: DNA binding of AHR•ARNT and AHR•ARNT2 heterodimers in the 
presence of both ARNT and ARNT2.  In vitro expressed AHR was combined with 
equal amounts of both ARNT and ARNT2 into a stock sample and then aliquoted and 
incubated in the presence of DMSO (0.5%) or TCDD (100 nM) for 2 h at 30°C.  A, 
Aliquots from the stock samples were mixed with 32P-labeled XRE oligonucleotides and 
protein•DNA complexes resolved as detailed in Chapter Six.  In some samples, 50ng of 
IgG specific to ARNT (A1), ARNT2 (A2), AHR (Ah) or preimmune IgG (IG) were 
included in the binding reaction prior to loading on the gel.  B, Aliquots of the activation 
reactions utilized in C were denatured and evaluated for ARNT expressing using anti-V5 
IgG (1:500) and visualized by ECL with GAM-HRP IgG (1:10,000; V5).  Note that the 
level of ARNT and ARNT2 was similar.  C) The intensity of the shifted bands from 
several different EMSA experiments were quantified by computer densitometry as 
detailed in Chapter Six.  Results are plotted as the mean +/- SE of each shifted band with 
the samples containing preimmune IgG set to 100%.  IG, samples incubated with 
preimmune IgG; A1, samples incubated with anti-ARNT IgG; A2, samples incubated 
with anti-ARNT2.  Numbers on the bottom indicate the relative intensity compared to 
samples containing preimmune IgG. *, Statistically different from samples incubated 
with IgG; p<0  
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(Figure 4.9 B).  Additionally, each sample also contained approximately equal amounts 
of AHR (data not shown).  Taken together, this suggests that both ARNT and ARNT2 are 
approximately equally able to heterodimerize with the AHR and bind XREs when 
synthesized in vitro and expressed at identical levels. 
While ARNT and ARNT2 appeared to exhibit an equal ability to contribute to a 
DNA binding shift that required AHR, it had not yet been demonstrated directly that this 
shift was occurring through dimerization of the ARNT or ARNT2 proteins with the AHR.  
Instead, the EMSA analyses identified that the DNA binding shift depended upon ligand-
activated AHR as well as the presence of an ARNT protein. Therefore, it was pertinent to 
assess the direct interaction of these proteins through alternate methods.   To establish 
that activated AHR complexes could be generated that were associated with either ARNT 
or ARNT2, in vitro expressed AHR and equal amounts of ARNT and ARNT2 were co-
incubated and activated as detailed previously, and immunoprecipitation studies carried 
out using anti-AHR IgG.  A representative experiment is shown in Figure 4.10.  The input 
samples demonstrate that the in vitro expressed proteins exhibited equal amounts of AHR 
protein and also expressed equal amounts of both ARNT and ARNT2 as assessed by 
quantitative Western blotting against the V5 epitope.   As expected, when the AHR was 
immunoprecipitated from these samples in the absence of TCDD, the AHR precipitated 
efficiently, but neither ARNT protein was co-precipitated with the AHR (Figure 4.10 lane 
3).  In the TCDD activated samples, the AHR was precipitated to the same level as before; 
however, in this sample both ARNT and ARNT2 were brought down using anti-AHR 
IgG (Figure 4.10 compare lanes 3 and 5).  Furthermore, the level of ARNT that was co-
precipitated with the AHR was equal to that of the ARNT2 that was precipitated,  
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Figure 4.10:  Association of ARNT and ARNT2 with AHR.  In vitro expressed AHR, 
ARNT, and ARNT2 were combined into a stock sample and then equally split and 
incubated in the presence of DMSO (0.5%) or TCDD (100 nM) for 2 h at 30°C.  Equal 
amounts of each sample were then incubated with 1 μg anti-AHR IgG (Ah) or pre-
immune IgG (Pi) for 1 hr at 4oC.  The samples were then precipitated with protein A/G 
agarose beads, washed with TTBS and the boiled in the presence of 1x gel sample buffer.  
Equal amounts of sample were resolved by SDS-PAGE, blotted and stained with either 
anti-V5 IgG (1:500) or anti-AHR IgG (1ug/ml) and visualized by ECL with GAM-HRP 
IgG (1:10,000; V5) or GAR-HRP IG (1:10,000; AH).  The precipitated IgG band (lanes 
3-6) is shown to demonstrate the uniformity of the precipitation across all samples.    
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demonstrating that in the presence of both ARNT and ARNT2, the AHR was equally able 
to dimerize with either protein in a ligand-dependent manner.  This held true in non-
mixed ARNT samples as well, when ARNT or ARNT2 protein co-precipitated with the 
AHR individually (data not shown).  Thus, these studies demonstrate that both ARNT 
isoforms can form TCDD-dependent AHR heterodimers when expressed in vitro.  
Additionally, these studies support the ability of these dimers to bind DNA, since 
portions of the samples used for immunoprecipitation analyses were also used in EMSA 
experiments that mimicked the data previously shown (data not shown).  
 
4.5 ARNT2 Can Out-Compete ARNT for Association with the Liganded AHR 
 Since in vitro synthesized ARNT2 appeared to be equally able to heterodimerize 
with the AHR and bind DNA, the effect of increasing amounts of ARNT2 on the ability 
of ARNT to heterodimerize with the AHR was also evaluated.  In vitro synthesized 
ARNT was mixed with AHR and ARNT2 was added in a 1:1, 1:3, or 1:11 ratio versus 
ARNT, in each case keeping the total level of ARNT proteins constant.  The resulting 
samples were then incubated in the presence of TCDD or Me2SO for 2 h.  Again, 
antibodies against ARNT, ARNT2, AHR or pre-immune antibodies were then added to 
duplicate portions of the 1:11 protein mix in the presence of TCDD to prevent target 
proteins from entering the gel matrix.  The formation of AHR•ARNT•XRE and 
AHR•ARNT2•XRE complexes were then evaluated by EMSA.  Representative results 
shown in Figure 4.11 indicate that as previously shown, ARNT•AHR heterodimers 
formed a TCDD-dependent DNA binding shift and that addition of ARNT2 to this 
mixture increased the intensity of the DNA binding shift, reaching saturation by the 1:11  
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Figure 4.11:  Effect of ARNT2 concentration on the formation of AHR•ARNT 
complexes.  In vitro expressed AHR was combined with the indicated ratios of ARNT 
and ARNT2, the samples equally split and incubated in the presence of DMSO (0.5%) or 
TCDD (100 nM) for 2 h at 30°C.  A) Aliquots of the activated reactions were denatured 
and evaluated for ARNT, ARNT2 or AHR protein by Western analysis using either anti-
V5 IgG (1:500) or A-1A (1ug/ml) and visualized by ECL with GAM-HRP IgG (1:10,000; 
V5) or GAR-HRP IG (1:10,000; AHR).  B) The exact samples visualized in A were 
mixed with 32P-labeled XRE oligonucleotides and protein•DNA complexes resolved as 
detailed in Chapter Six.  In some samples, 50ng of IgG specific to ARNT (A1), ARNT2 
(A2), or preimmune IgG (IG) were included in the binding reaction prior to loading on 
the gel (lanes 11-14).  The location of the specific AHR•ARNT•XRE and 
AHR•ARNT2•XRE complex and free XRE are indicated.  Numbers indicate the relative 
level of ARNT or ARNT2 that were used in the activation reaction.   
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sample.  Western blotting of the EMSA samples confirmed the relative ratios of both 
ARNT proteins as determined by computer densitometry analysis of V5 staining.  In the 
1:3 and 1:11 ratio sample containing increased levels of ARNT2, the majority of 
heterodimers appeared to be ARNT2•AHR dimers, though ARNT remained in this 
sample, as evidenced by the addition of antibodies against each protein.  While addition 
of ARNT antibodies to the 1:11 ratio sample had no apparent effect on the overall 
intensity of the DNA binding shift, addition of antibodies against ARNT2 or AHR 
instead ablated all DNA binding.  These results suggest that ARNT2 is indeed able to 
associate with the AHR and furthermore can out-compete ARNT for AHR dimerization. 
 
4.6 The Ability of ARNT2 to Associate with the AHR and Bind DNA is Not Dependent on 
AHR Concentration or ARNT Protein Concentration 
 Since studies examining the ability of either ARNT protein to associate with the 
AHR have shown conflicting results (Dougherty and Pollenz 2007; Hirose et al., 1996; 
Sekine et al., 2006), it was important to assess possible reasons for the discrepancies 
between these studies and in those contained in this report.  If ARNT and ARNT2 truly 
differed in their ability to associate with the AHR and bind DNA in vitro in contrast to 
the results presented in Figures 4.7-4.11, what conditions being used in our studies might 
lead to the apparent equal ability of these proteins to function in DNA binding?   
 One such condition that could alter the apparent ability of these proteins to function 
during the EMSA assay is if the level of AHR or ARNT being used in the studies.  Since 
these studies used in vitro synthesized proteins, it is possible that high levels of 
expression of the ARNT proteins or the AHR led to an association of these proteins that 
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would not seen if the proteins were expressed at more physiological levels.  This idea was 
the basis for the explanation of the discrepancies between the ability of ARNT2 to 
associate with the AHR that was seen by Hirose et al. (1996), versus the apparent 
inability of these proteins to associate in the studies performed by Sekine et al. (2006).  
However, while this claim was made by Sekine et al. (2006), it remained untested.  Thus, 
it was important to assess whether the concentration of either the AHR or the ARNT 
proteins played a role in the ability/inability of these proteins to associate in vitro.   
 To begin to evaluate this question, limiting amounts of in vitro expressed AHR 
were combined with equal ratios of either ARNT or ARNT2 into stock samples and then 
aliquoted and incubated in the presence of DMSO (0.5%) or TCDD (100 nM) for 2 h at 
30°C and tested for target protein expression by Western blotting (Figure 4.12 A).  In 
these studies, the level of AHR was altered while the level of ARNT and ARNT2 was 
held constant.  Aliquots from the stock samples were then mixed with 32P-labeled XRE 
oligonucleotides and protein•DNA complexes resolved as detailed in Chapter Six.  
Representative results are given in Figure 4.12 B.  As the level of AHR increased in the 
EMSA samples, so did the intensity of the ligand-dependent DNA binding shift, 
suggesting that the level of AHR being used in these studies was a limiting factor for 
ARNT or ARNT2.  Since the level of DNA binding increased in the presence of 
increased AHR, and since the intensity of the DNA binding shift was similar between 
ARNT and ARNT2 when co-expressed with similar levels of AHR, overexpression of the 
AHR could be ruled out as a factor influencing the association of these proteins. 
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Figure 4.12: DNA binding of AHR•ARNT and AHR•ARNT2 heterodimers in the 
presence of limiting AHR.  Limiting amounts of in vitro expressed AHR were combined 
with either ARNT and ARNT2 in equal ratios into stock samples and then aliquoted and 
incubated in the presence of DMSO (0.5%) or TCDD (100 nM) for 2 h at 30°C.  A, 
Aliquots of the activation reactions utilized in B were denatured and evaluated for ARNT 
and AHR expression using anti-V5 IgG (1:500) or A-1A anti-AHR IgG (1μg/ml) and 
visualized by ECL with GAR-HRP IgG (1:10,000; AHR) or GAM-HRP IgG (1:10,000; 
V5).  Note that the level of ARNT and ARNT2 was similar, while the level of AHR was 
altered. B, Aliquots from the stock samples were mixed with 32P-labeled XRE 
oligonucleotides and protein•DNA complexes resolved as detailed in Chapter Six.   
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 Since the ability of ARNT2 to associate with the AHR and bind DNA could also be 
related to possible overexpression of ARNT2 relative to the AHR yielding artifactual 
results, it was important to assess whether dilution of each of the ARNT proteins relative 
to each other would alter the results obtained in the assay.  Therefore, another EMSA was 
performed to directly compare the ability of each ARNT to associate with the AHR and 
bind DNA at reduced levels.  To analyze this, increasing amounts of either in vitro 
synthesized ARNT or ARNT2 were incubated with identical amounts of AHR in the 
presence of TCDD or Me2SO for 2 h and the formation of AHR•ARNT•XRE and 
AHR•ARNT2•XRE complexes evaluated by EMSA as previously described.  
Comparable dilutions were then examined for DNA binding relative to the amount of 
ARNT or ARNT2.  In each dilution set, both ARNTs were able to heterodimerize with 
the AHR and bind DNA in a TCDD-dependent fashion (Figure 4.13 A).  Furthermore, 
quantification of the DNA binding shift by densitometry revealed that the intensity of the 
DNA binding shift was similar between comparable ARNT2 dilution and ARNT dilution 
sets exhibiting 78% binding in the lowest ARNT2 dilution, 106% binding in the middle 
set, and 114% binding at the highest concentration of ARNT2 in comparison with the 
ARNT dilutions (Figure 4.13 B).  Likewise, at each dilution, the relative amounts of 
ARNT and ARNT2 were similar in range as determined by quantified Western blotting 
of the EMSA samples stained against the V5 epitope, though there was 1.9, 1.3, and 1.3 
times more ARNT2 than ARNT respectively (Figure 4.13 B).  No significant differences 
in the levels of AHR between samples were noted (Figure 4.13 A).  Since the lowest 
dilution set showed 90% more ARNT2 than ARNT, yet exhibited only 78% binding 
relative to the ARNT sample, there may have been a slight difference in affinity of  
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Figure 4.13: Effect of target protein concentration on the formation of AHR•ARNT 
and AHR•ARNT2 heterodimers.  In vitro expressed AHR was mixed with increasing 
concentrations of ARNT or ARNT2, the samples equally split and incubated in the 
presence of DMSO (0.5%) or TCDD (100 nM) for 2 h at 30°C.  A) A portion of the 
activated samples were denatured and evaluated for ARNT and ARNT2 or AHR 
expression by Western analysis using anti-V5 IgG (1:500) or anti-AHR IgG (1ug/ml), 
respectively.  Reactive bands were visualized using GAM-HRP IgG (1:10,000) and ECL.  
The remaining samples were mixed with 32P-labeled XRE oligonucleotides and 
protein•DNA complexes resolved as detailed in Chapter Six.  The location of the specific 
AHR•ARNT•XRE and AHR•ARNT2•XRE complex and free XRE are indicated.  B) The 
relative level of ARNT and ARNT2 protein (left) and DNA binding (right) was 
determined using computer densitometry of the bands shown in the Western blot of A.  
The relative intensity of the shifted bands from the EMSA in A was determined using 
computer densitometry.   
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ARNT2 for the AHR in comparison with ARNT at low levels of ARNT proteins.  
However, throughout the evaluated points, the expression of the ARNT proteins and the 
relative level of DNA binding was essentially equal, and under no conditions was 
ARNT2 unable to associate with the AHR and bind XREs.  Therefore, in contrast to the 
statement posed by Sekine et al. (2006), high expression levels of these proteins do not 
appear to play a role in their association.  
 
4.7 The Ability of ARNT2 to Associate with the AHR and Bind DNA May be XRE-Specific 
 The murine CYP1A1 promoter has been demonstrated to possess five functional 
putative XREs ranging from -489 to -1218 nucleotides upstream of the transcriptional 
start site and have been designated as XRE A, B, D, E, and F (Lusska et al., 1993). In 
those studies, each of these XREs was shown to exhibit varying levels of CAT activity 
when used to drive reporter constructs while XRE C appeared to be non-responsive 
(Figure 4.14 A). Since the previous studies described herein (Figures 4.7-4.13) had used 
only XRE D as a probe for DNA binding, it was possible that the ability of each ARNT 
to bind DNA was related to the XRE being used and would not be mimicked with other 
CYP1A1 XREs.  To evaluate this possibility, each XRE as described by Lusska et al. 
(1993) was labeled with 32P, quantified by spectrophotometry and scintillation counting, 
normalized to the number of counts/minute and used as a probe against aliquots  of single 
samples containing in vitro activated AHR•ARNT or AHR•ARNT2 dimers as previously 
described.   Typical results are shown in Figure 4.14 B.  Each XRE showed an 
approximately equal ability to associate with AHR•ARNT or AHR•ARNT2 dimers with 
the exception of XRE A, which appeared to show a greater affinity for AHR•ARNT than  
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Figure 4.14: Analysis of XRE sequence on the DNA binding ability of AHR•ARNT 
or AHR•ARNT2 heterodimers.  A, Schematic representing the mouse CYP1A1 
promoter XRE locations and relative activity levels as described by Lusska et al. (1993).  
Position numbers are nucleotide positions relative to the transcriptional start site. B, AHR 
and ARNT or ARNT2 were expressed in vitro and mixed together, incubated in the 
presence of Me2SO (-; 0.5%) or TCDD (170 nM) for 2 h at 30°C and a portion of each 
sample analyzed by EMSA, as detailed in Chapter Six.  The location of the specific 
AHR•ARNT•XRE and AHR•ARNT2•XRE complex are indicated.  C, Equal volumes of 
2x gel sample buffer were added to the remaining portion of each EMSA sample and the 
samples used for Western blotting.  Duplicate Western blots were stained with anti-V5 
IgG (1:500) and visualized by ECL with GAM-HRP IgG (1:10,000). 
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AHR•ARNT2 dimers.  It is important to note, however, that in the studies by Lusska et al. 
(1993), XRE A appeared to contribute the least amount of functional activity towards the 
induction of CAT activity driven by this XRE alone in comparison with other functional 
CYP1A1 XREs.  Additionally, in repeated experiments, this discrepancy appeared to be 
less extreme than represented by this individual EMSA.  In the event that AHR•ARNT/2 
dimers had a preference for the non-responsive XRE C, the ability of this XRE to bind 
either ARNT or AHR•ARNT2 dimers was also examined and no discrepancy found 
between binding (data not shown).  Again, these differences were not attributable to 
variations in the levels of ARNT vs. ARNT2 and no significant differences in the levels 
of AHR between samples were noted (Figure 4.14 C, data not shown).  Thus, while the 
ability of AHR•ARNT/2 heterodimers to bind DNA may be XRE specific, it is unlikely 
that increased affinity or a lack thereof of either dimer for individual XREs of the 
CYP1A1 promoter plays a role in the inefficiency of ARNT2 in substituting for ARNT in 
AHR-mediated regulation of CYP1A1 since XREs B, C, D, E, and F that contribute 
>90% of the functional regulation of CYP1A1 all show an essentially equivalent ability 
to be bound by either heterodimer.   
 
4.8 DNA Binding Ability of AHR•ARNT2 Heterodimers Appears to be Ligand Dependent 
 Since previous studies had examined the ability of ARNT2 to associate with the 
AHR using 3-methylcholanthrene (3-MC) rather than TCDD and seen disparities 
between ARNT and ARNT2•AHR dimerization, and since little is known in regard to the 
structure of the liganded AHR, it was pertinent to assess whether these disparities were 
related to the ligand being used (Hirose et al., 1996; Sekine et al., 2006).  To examine this 
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possibility, identical pools of AHR and ARNT or AHR and ARNT2 were activated using 
either TCDD, 3-MC, or benzo[a]pyrene (BAP) and the formation of AHR•ARNT•XRE 
and AHR•ARNT2•XRE complexes evaluated by EMSA as previously described.  In the 
first set of experiments, ARNT or ARNT2 were co-expressed individually with the AHR, 
activated in the presence of Me2SO, TCDD, or 3-MC, and analyzed by EMSA (Figure 
4.15).   As previously seen, activation of the EMSA samples with TCDD yielded a DNA 
binding complex in both the AHR•ARNT and AHR•ARNT2 samples that exhibited a 
similar intensity (Figure 4.15 B).  Interestingly, activation of the EMSA samples with 3-
MC resulted in a DNA binding shift that was similar in intensity to the AHR•ARNT 
TCDD activated sample, but was significantly (p<0.05) reduced in the AHR•ARNT2 
sample over the course of three experiments, though the levels of ARNT and AHR 
proteins remained constant (Figure 4.15 B, data not shown). 
 In a mixture experiment similar to Figure 4.9, samples containing equal levels of 
both ARNT and ARNT2 activated with either TCDD, 3-MC, or BAP exhibited similar 
discrepancies (Figure 4.16).  As previously seen, in a sample containing equal levels of 
both ARNT and ARNT2, activation with TCDD yielded a DNA binding complex that 
consisted of approximately 46% ARNT•AHR dimers and 44-54% ARNT2•AHR dimers 
(Figure 4.16 A, B).  In contrast, though ARNT and ARNT2 were equally expressed, 
activation by either 3-MC or BAP yielded a DNA binding complex that exhibited 24-
36% binding when antibodies against ARNT were included following activation and 61-
64% binding when antibodies against ARNT2 were included, suggesting that in the case 
of 3-MC, 64% of the DNA binding shift was attributable to ARNT•AHR dimers and, in 
the case of BAP 76% were likewise attributed to ARNT•AHR dimers (Figure 4.16 B, D).   
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Figure 4.15: Effect of 3-MC on the DNA binding of AHR•ARNT and AHR•ARNT2 
complexes.  A, In vitro expressed AHR was combined with either ARNT or ARNT2 into 
a stock sample and then aliquoted and incubated in the presence of DMSO (0.5%), 
TCDD (100 nM) or 3-MC (54µM) for 2 h at 30°C.  Aliquots from the stock samples were 
mixed with 32P-labeled XRE oligonucleotides and protein•DNA complexes resolved as 
detailed in Chapter Six.  The location of the specific AHR•ARNT•XRE and 
AHR•ARNT2•XRE complexes are indicated.  Free XRE was run off the bottom of the 
gel so that the difference in migration of the complexes could be observed.  B, Aliquots 
of the activation reactions utilized in A were denatured and evaluated for ARNT and 
ARNT2 protein by Western analysis using anti-V5 IgG (1:500) and visualized by ECL 
with GAM-HRP IgG (1:10,000).  Note that the concentration of both V5-ARNT and V5-
ARNT2 in each sample is similar.  T, samples activated with TCDD; M, samples 
activated with 3-MC. The intensity of the shifted bands from several different EMSA 
experiments were quantified by computer densitometry as detailed in Chapter Six.  
Results are plotted as the mean +/- SE of the 3-MC or TCDD activated samples. *, 
statistically different from the ARNT sample activated with 3-MC; p<0.05. 
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Figure 4.16. Effect of different ligands on the DNA binding of AHR•ARNT and 
AHR•ARNT2 complexes.  In vitro expressed AHR, ARNT, and ARNT2 were combined 
into a stock sample and then equally split and incubated in the presence of the specific 
ligands for 2 h at 30°C as detailed below.  A, Samples were incubated with DMSO 
(0.5%), TCDD (100nM) or 3-MC (54µM) and then mixed with 32P-labeled XRE 
oligonucleotides and protein•DNA complexes resolved as detailed in Chapter Six.  In 
some samples, 50ng of IgG specific to ARNT (A1), ARNT2 (A2), AHR (AH) or 
preimmune IgG were included in the binding reaction prior to loading on the gel.  The 
location of the specific AHR•ARNT•XRE and AHR•ARNT2•XRE complex and free 
XRE are indicated.  B, Aliquots of the stock activation mixture utilized in A were 
denatured and evaluated for ARNT and ARNT2 expression by Western analysis.  The 
Western blot was stained with anti-V5 IgG (1:500) and visualized by ECL with GAM-
HRP IgG (1:10,000).  The intensity of the shifted bands from the EMSA in A was 
quantified by computer densitometry as detailed in Chapter Six.  Results are plotted with 
the samples containing preimmune IgG set to 100%.  IG = samples incubated with 
preimmune IgG; A1 = samples incubated with anti-ARNT IgG; A2 = samples incubated 
with anti-ARNT2.  Numbers on the bottom indicate the relative intensity compared to 
samples containing preimmune IgG.  C, Samples were incubated with DMSO (0.5%), 
TCDD (100nM) or BAP (17µM) and EMSA performed as detailed in A.  D, Aliquots of 
the stock activation mixture utilized in C were denatured and evaluated for ARNT and 
ARNT2 expression by Western analysis as indicated in B. The intensity of the shifted 
bands from the EMSA in C was quantified by computer densitometry as detailed in 
Chapter Six.  Results are plotted with the samples containing preimmune IgG set to 100%.  
IG, samples incubated with preimmune IgG; A1, samples incubated with anti-ARNT IgG; 
A2, samples incubated with anti-ARNT2.  Numbers on the bottom indicate the relative 
intensity compared to samples containing preimmune IgG. 
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Since treatment with saturating levels of 3-MC or BAP resulted in a greater proportion of 
ARNT•AHR dimers than ARNT2•AHR dimers, ARNT may have a greater affinity for 3-
MC or BAP liganded AHR than ARNT2 suggesting that the activating AHR ligand may 
confer the specificity of the AHR for its heterodimeric partner (likely through receptor 
conformational differences) or may confer the specificity of DNA binding by the 
AHR•ARNT/2 dimer using this model system.  
 To evaluate whether the AHR ligand was altering the specificity of the AHR for 
either the ARNT proteins or altering the specificity of the liganded AHR•ARNT2 dimer, 
it was necessary to establish that AHR complexes activated with TCDD or BAP could be 
generated that were associated with either ARNT or ARNT2.  Therefore, in vitro 
expressed AHR and equal amounts of ARNT and ARNT2 were co-incubated and 
activated as detailed previously, and immunoprecipitation studies carried out using anti-
AHR IgG, anti-ARNT IgG, or anti-ARNT2 IgG.  A representative experiment is shown 
in Figure 4.17.  The input sample (lane 9) demonstrates equal amounts of both ARNT 
and ARNT2 were co-expressed with the AHR.   As expected, when the AHR was 
immunoprecipitated from these samples in the presence of TCDD, the AHR precipitated 
efficiently, and both ARNT proteins were co-precipitated to equivalent levels (Figure 
4.17 lane 5).  Additionally, IgG against ARNT or ARNT2 specifically precipitated each 
ARNT protein and also co-precipitated the AHR.  Interestingly, in the BAP activated 
samples, the AHR was precipitated to the same level as before; however, in this sample 
both ARNT and ARNT2 were also brought down using anti-AHR IgG to the same levels 
as before (Figure 4.17 compare lanes 1 and 5).  Furthermore, when portions of the same 
mixture used for immunoprecipitation were subjected to EMSA analysis, DNA binding  
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Figure 4.17:  Association of ARNT and ARNT2 with BAP or TCDD activated AHR.  
In vitro expressed AHR, ARNT, and ARNT2 were combined into a stock sample and 
then equally split and incubated in the presence of DMSO (0.5%, -), BAP (17 μM, B) or 
TCDD (100 nM, T) for 2 h at 30°C.  A, Equal amounts of each sample were then 
incubated with 1 μg anti-AHR IgG (A),  1 μg anti-ARNT IgG (1), 1 μg anti-ARNT2 IgG 
(2), or pre-immune IgG (Pi) for 1 hr at 4oC or saved for analysis of input (Inp).  The 
samples were then precipitated with protein A/G agarose beads, washed with TTBS and 
the boiled in the presence of 1x gel sample buffer.  Equal amounts of sample were 
resolved by SDS-PAGE, blotted and stained with either anti-V5 IgG (for ARNT and 
ARNT2, 1:500) or anti-AHR IgG (1ug/ml) and visualized by ECL with GAM-HRP IgG 
(1:10,000; V5) or GAR-HRP IG (1:10,000; AH).  The precipitated IgG band is shown to 
demonstrate the uniformity of the precipitation across all samples.   B, Portions of the 
immunoprecipitation reactions used in A were mixed with 32P-labeled XRE 
oligonucleotides and protein•DNA complexes resolved as detailed in Chapter Six.   
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shifts were seen as before.  Taken together, this suggests that the ligand activating the 
AHR alters the ability of the AHR•ARNT2 dimer to bind DNA, but not the ability of 
these complexes to form in this model system. 
 
4.9 The Ability of ARNT or ARNT2 to Dimerize with the AHR in Vitro May be Receptor 
Species Dependent 
 The Ahb-1 receptor found in the C57, C58, and the MA/My strains is known to 
exhibit several distinct characteristics from other Ah murine alleles as well as Ah 
receptors from other species (see Chapter Two).  While the Ahb-1 receptor exists as a 
~95kDa (805 amino acid) cytosolic receptor, which does not appear to be shuttling 
through the nucleus endogenously, the Ahb-2 receptor found in the murine BALB/cBy, A, 
and C3H strains as well as the rat and human AHR exist as a ~104kDa (848 amino acid) 
receptor that is primarily nuclear and exhibits dynamic nucleocytoplasmic shuttling 
(Poland et al., 1994; Pollenz and Dougherty, 2005).  Furthermore, the Ahb-1 is truncated 
when compared with Ah receptors found in other mammalian species, containing a point 
mutation that prematurely truncates the receptor at 805 amino acids, while the Ahb-2, rat, 
and human AHR all contain an additional 42-45 amino acids at their carboxy-terminus 
that have 70% identity.  As this additional carboxy-terminal sequence is present in the 
other AHR alleles as well as across species and is reasonable conserved in sequence, it is 
reasonable to assume that this sequence may be functionally relevant.  Therefore, it was 
relevant to assess the ability of ARNT or ARNT2 to heterodimerize with other Ah 
receptor species.  This was investigated by incubating equal amounts of in vitro 
synthesized ARNT or ARNT2 with equal amounts of Ahb-1, Ahb-2 or rat AHR, activating 
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the receptors with TCDD or BAP and examining the DNA binding ability of each 
AHR•ARNT or AHR•ARNT2 dimer by EMSA (Figure 4.18).  As expected, both ARNT 
and ARNT2 were able to form a TCDD- or BAP-dependant DNA binding shift with each 
Ah receptor species (Figure 4.18 A).  Additionally, the formation of AHR•ARNT and 
AHR•ARNT2 heterodimers was essentially equal in the presence of the Ahb-1 receptor 
activated with TCDD (Figure 4.18 A, compare lanes 2 and 5), while ARNT2 showed a 
reduced affinity for BAP liganded AHR as seen previously (Figure 4.18 A, compare 
lanes 3 and 6).  In contrast, however, ARNT2 appeared to exhibit a greater affinity for rat 
AHR in the presence of TCDD or BAP than ARNT as computer densitometry analysis of 
the intensity of the DNA binding shift revealed a band that was 33-75% greater in 
intensity in the Ahb-2•ARNT2 and Rat AHR•ARNT2 samples than in identical samples 
containing ARNT (Figure 4.18 A, B).  Importantly, this was not due to different levels of 
ARNT2 in these samples, since the levels of ARNT, ARNT2, and AHR remained 
constant across the sample types (Figure 4.18 C).  Additionally, while ARNT previously 
showed a greater affinity for BAP-liganded AHR than ARNT2, this did not appear to be 
maintained when other Ah receptor species were used (Figures 4.16, 4.18).  Instead, 
while ARNT and ARNT2 exhibited similar magnitudes of binding when activated by 
TCDD, but not when activated with BAP, in the presence of Ahb-1 receptor as expected, 
ARNT exhibited a lesser magnitude of binding in comparison with ARNT2 in the 
presence of Ahb-2 receptor or rat AHR irrespective of ligand.  Similarly, both Ahb-2 
receptor and rat AHR exhibited a lesser degree of binding when activated with BAP in  
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Figure 4.18: Analysis of AHR species on the formation of TCDD or BAP dependent 
AHR•ARNT or AHR•ARNT2 heterodimers.  A, Ahb-1, Ahb-2, rat AHR, ARNT and 
ARNT2 were mixed and incubated in the presence of Me2SO (-; 0.5%), TCDD (100 nM), 
or BAP (17 μM) for 2 h at 30°C and a portion of each sample analyzed by EMSA, as 
detailed in Chapter Six.  The location of the specific AHR•ARNT•XRE and 
AHR•ARNT2•XRE complex and free XRE are indicated.  Non-specific binding is also 
noted by the asterisk.  B, Equal volumes of 2x gel sample buffer were added to the 
remaining portion of each EMSA sample and the samples used for Western blotting.  
Duplicate Western blots were stained with either anti-V5 IgG (1:500) or with A-1A AHR 
IgG (1.0μg/ml) and visualized by ECL with GAM-HRP IgG (1:10,000) or GAR-HRP 
(1:10,000). C, The DNA binding shift from each EMSA TCDD or BAP treated lane 
resulting from combination of Ahb-1, Ahb-2, or rat AHR with ARNT or ARNT2 was 
quantified by densitometry and normalized against background.  Results are plotted as 
the relative densitometry units for each sample. 
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the presence of either ARNT or ARNT2 in comparison to activation with TCDD, 
suggesting that BAP is a weaker ligand for these Ah receptor species, but not for the  
Ahb-1 receptor.  Together, these results suggest that ARNT2 can dimerize with several Ah 
receptor species and the Ahb-2 and rat AHR, which more closely resemble the human 
AHR, may have a greater affinity for ARNT2 than ARNT.  Thus, the ability of ARNT2 
to function in other genetic backgrounds from the Hepa-1 expressing Ahb-1 should be 
addressed. 
 
4.10 The Ability of ARNT or ARNT2 to Dimerize with the AHR in Vitro Does Not Appear 
to Differ When Expressed in Vivo 
 Since ARNT, ARNT2, or the AHR may have post-translational modifications that 
could potentially influence their ability to heterodimerize, it was important to assess 
whether the previously described relationships between ARNT and ARNT2•AHR dimer 
formation would be mimicked in vivo.  Therefore, V5-ARNT and V5-ARNT2 were 
transfected into LA-II cells, and following a 24 hr recovery period, total cell lysates were 
generated, activated by TCDD or BAP, analyzed by EMSA and the resulting binding 
ability assessed by EMSA. Representative results are given in Figure 4.19.  As seen in the 
in vitro synthesized protein experiments, ARNT2 remained able to associate with the 
AHR and bind XREs when expressed in vivo, suggesting that no post-translational 
modifications are occurring in LA-II cytosol that would alter the affinity of the ARNT2 
for the AHR (Figure 4.19 A).  Additionally, since ARNT2 remained able to dimerize 
with the AHR when LA-II cytosol was incubated with ARNT2, this also suggests that the  
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Figure 4.19: DNA binding of ARNT and ARNT2 expressed in cell culture.  
Expression vectors for ARNT and ARNT2 were transfected in LA-II cells and cytosol 
produced as detailed in Chapter Six.  A, Stock mixtures containing equal levels of ARNT 
and ARNT2 protein were incubated with DMSO (0.5%), TCDD (100nM) or BAP (17µM) 
for 2 h at 30°C.  Samples were aliquoted and mixed with 32P-labeled XRE 
oligonucleotides and protein•DNA complexes resolved as detailed in Chapter Six.  In 
some samples, 50ng of IgG specific to ARNT (A1), ARNT2 (A2), AHR (AH) or 
preimmune IgG were included in the binding reaction prior to loading on the gel.  The 
location of the specific AHR•ARNT•XRE and AHR•ARNT2•XRE complex and free 
XRE are indicated.  B, An aliquot of the stock activation mixture utilized in A were 
denatured and evaluated for ARNT and ARNT2 expression by Western analysis.  The 
Western blot was stained with anti-V5 IgG (1:500) and visualized by ECL with GAM-
HRP IgG (1:10,000).  The intensity of the shifted bands from the EMSA in A was 
quantified by computer densitometry as detailed in Chapter Six.  Results are plotted with 
the samples containing preimmune IgG set to 100%.  IG, samples incubated with 
preimmune IgG; A1, samples incubated with anti-ARNT IgG; A2, samples incubated 
with anti-ARNT2.  Numbers on the bottom indicate the relative intensity compared to 
samples containing preimmune IgG. 
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Ahb-1 does not exhibit any post-translational modifications that would alter its ability to 
recognize ARNT2.   
 As expected, ARNT also retained an apparent higher affinity for BAP liganded Ahb-
1 receptor in comparison with ARNT2 (Figure 4.19 A, B).   When antibodies were 
included in the EMSA reaction using ARNT or ARNT2 expressing cytosol to ablate 
either ARNT or ARNT2 containing complexes, as previously detailed, ARNT and 
ARNT2 again showed an apparently equal ability to bind DNA in the presence of TCDD, 
but not BAP.   
 Furthermore, when similar studies were performed to directly compare the binding 
ability of samples generated from in vitro synthesis of ARNT or ARNT2 against those 
generated from transfected LA-II cytosol, the intensity of DNA binding was equal when 
similar levels of ARNT proteins were compared either in vitro or in vivo (data not shown).  
Importantly, these results collectively indicate that the previous results based on in vitro 
synthesized ARNT, ARNT2, and AHR (Figures 4.7-4.18) do not differ from similar 
studies based on in vivo expressed proteins and therefore, there are no significant post-
translational modifications that appear to alter the ability of either ARNT protein or AHR 
to heterodimerize or bind XREs in this model system. 
 
4.11 Inhibition of ARNT by ARNT2 in AHR-Mediated Signaling 
 Since ARNT2 appeared to be able to bind DNA in response to TCDD, yet exhibited 
a decreased ability to complement loss of ARNT in LA-II cells, it became of interest to 
determine if its co-expression with ARNT would impede the ability of ARNT to 
complement AHR-mediated signaling, possibly through squelching of the AHR.  LA-II 
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cells were therefore transfected with either: naked vector, ARNT, or ARNT with 
increasing amounts of ARNT2, along with pSV-β-Galactosidase and GudLuc 1.1 
plasmids and treated with Me2SO (0.5%) or TCDD (5nM) for 6 hours.   Luciferase 
studies were then performed as previously described.  LA-II cells transfected with naked 
vector were unable to complement AHR-mediated signaling in response to TCDD as 
expected (Figure 4.20).  Additionally, when the LA-II cells were transfected with ARNT 
alone, high basal levels of luciferase activity were seen that became even greater in the 
presence of TCDD.  However, when ARNT2 was co-expressed with ARNT in either a 
2:1 or 1:1 ratio of plasmid DNA, the levels of luciferase activity in response to TCDD 
were significantly reduced in comparison with ARNT alone.  Importantly, the overall 
level of ARNT expression remained constant as the level of ARNT2 was changed.  Thus, 
this suggests that ARNT2 when co-expressed with ARNT may exhibit some degree of 
dominant negative activity.   
 To confirm whether or not this result would be mimicked in vivo, WT Hepa-1 cells 
endogenously expressing ARNT were transfected with ARNT2 and correspondingly 
evaluated by SDS-PAGE and Western blotting.  After 6 hrs of TCDD treatment, the WT 
cells transfected with ARNT2 exhibited an approximately 30% reduction in the level of 
CYP1A1 protein in comparison to the untransfected WT cells as determined by 
quantitative Western blotting (Figure 4.21 A).  Similarly, in a second experiment where 
other time points were evaluated, the WT cells transfected with mARNT2 exhibited an 
approximately 20% reduction in the level of CYP1A1 protein in comparison to the 
untransfected WT cells as determined by quantitative Western blotting at 2 and 4 hrs of 
TCDD treatment (data not shown).   At both 4 hours and 6 hours, this reduction was  
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Figure 4.20: Impact of ARNT2 expression on AHR-mediated signaling.  LA-II cells 
were transfected with equal total amounts of naked vector, ARNT alone, or ARNT with 
increasing amounts of ARNT2 as indicated as well as with equal amounts of both pSV-β-
Galactosidase and GudLuc 1.1 plasmids as described in Chapter Six.  Following 24 h 
recovery, cells were then treated with Me2SO (0.05%) or TCDD (5nM) for 6 hours.  
Equal amounts of total cell lysates were resolved by SDS-PAGE, blotted and stained with 
mouse ARNT IgG (A1; 1 μg/ μl) or mouse ARNT2 IgG (1:500).  Reactivity was 
visualized by ECL with GAR-HRP (1:10,000). All luciferase values were normalized to 
β -Galactosidase. 
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Figure 4.21: Impact of ARNT2 expression on AHR-mediated signaling in cell 
culture. A, Hepa-1 cells were transfected with naked vector or ARNT2 expression 
vectors and treated with DMSO (0.5%) or TCDD (2nM) for 6 h at 37°C.  Equal amounts 
of total cell lysates were resolved by SDS-PAGE, blotted and stained with either anti 
AHR IgG (1µg/ml), anti-ARNT2 IgG (1µg/ml), anti-CYP1A1 IgG (1:200), or anti-β-
actin IgG (1:1000).  Reactivity was visualized by ECL with GAR-HRP (1:10,000).  Each 
lane represents and independent sample.  CYP1A1 protein expression was quantified by 
computer densitometry and normalized to β -actin controls.  Results represent the mean 
+/- SE of three independent samples. *, Statistically different from TCDD treated cells 
that were not transfected with ARNT2; p<0.05.  B, Hepa-1 cells were propagated on 
glass coverslips and transfected and treated as detailed in A.  Fixed slips were stained 
with anti-ARNT IgG (0.5μg/ml; A1), anti-ARNT2 IgG (0.5μg/ml; A2), or anti-CYP1A1 
(1:100) and reactivity was visualized using GAR-RHO (1:400).  All panels that were 
stained with the same antibodies were photographed for identical times.  WT, cells 
transfected with naked vector.  WT + A2, cells transfected with ARNT2 vector.   
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statistically significant (P<0.05) and similar reductions were not seen when WT cells 
were transfected with excess ARNT (data not shown).  Therefore, again, the co-
expression of ARNT2 with ARNT appeared to be hindering the ability of ARNT to 
function in AHR-mediated signaling, albeit through an unknown mechanism. 
 
4.12 ARNT2 Does Not Function to the Same Level as ARNT in Endogenous AHR-
Mediated Signaling 
 The previous studies suggest that ARNT2 has the potential to affect AHR-mediated 
signaling in a negative manner when expressed in cell culture.  However, it is not known 
whether the conditions utilized for the various studies represent a truly physiological 
condition.  For example, the ability of ARNT2 to impact AHR-mediated signaling and 
affect the function of AHR•ARNT2 complexes in vivo will be dependent on the co-
expression of ARNT and ARNT2 in the same cells.  Also, since transient transfections 
typically lead to >60% overexpression of the target protein, the inhibition of ARNT 
functionality in AHR-mediated signaling by ARNT2 may be artifactual based on non-
physiologic expression of ARNT2.  This stresses the importance of examining protein 
function using endogenous protein levels.  Thus, to examine the possible role of ARNT2 
in AHR-mediated signaling, it is necessary to also examine cells endogenously 
expressing ARNT2.  However, it has generally been hypothesized that ARNT and 
ARNT2 are not expressed in the same cells at the protein level due to the limited tissue 
distribution of ARNT2 (Hirose et al., 1996).  Importantly, a more recent study, has 
described mRNA for both ARNT and ARNT2 as being co-localized in many murine 
peripheral organs and neuronally derived tissue, suggesting that distribution of ARNT2 
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may not be as restricted as previously described (Aitola and Pelto-Huikko, 2003).  In 
addition, studies of ARNT2 expression have generally examined mRNA for ARNT2 with 
no analysis of endogenous protein expression.   
 In order to investigate possible interactions between ARNT and ARNT2 in a 
physiological setting, studies were carried out to determine the expression of ARNT and 
ARNT2 protein in various murine tissues and cell culture lines.  In the first set of studies, 
whole tissue lysates from the brain, eye, heart, kidney, liver, lung, muscle, skin, spleen, 
and thymus were prepared as described in Chapter Six and analyzed for AHR, ARNT, 
and ARNT2 protein by Western blotting.  Figure 4.22 shows that while ARNT protein 
was detected in all the tissues evaluated as has previously been described, expression of 
ARNT2 protein was detected in the brain, eye, and kidney, and was also detected at lower 
expression levels in the heart, spleen and thymus (Figure 4.22 A).  From these studies, it 
is evident that ARNT2 expression is not limited only to the brain and kidneys, though 
these tissues do exhibit the highest relative levels.  Since these results do not confirm that 
the ARNT and ARNT2 protein are localized to the same cells, several continuous cell 
lines were purchased from ATCC and the level of ARNT and ARNT2 protein evaluated 
by Western blotting.  Figure 4.22 B shows that ARNT and ARNT2 protein were co 
expressed in human pigmented retinal epithelial cells (ARPE-19), rat central nervous 
system cells (B35), and human, mouse and rat kidney cells (A498, TCMK, NRK, 
respectively).  To gain insight into the ratio of ARNT and ARNT2 protein in these lines, 
ARNT and ARNT2 TNT reactions containing equal amounts of ARNT and ARNT2 
protein (Figure 4.22 C), were included in the experiment so that the staining with the 
specific ARNT and ARNT2 antibodies could be normalized against staining of the in  
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Figure 4.22: ARNT and ARNT2 protein expression in tissues and cells.  A, Total cell 
lysates were generated from a variety of adult C57BL/6Jmouse tissues, resolved by SDS-
PAGE, blotted and stained with anti-ARNT R1 IgG (1.0μg/ml) or anti-ARNT2 IgG 
(1:500).  Antibodies were titered to react to the TNT samples with the same sensitivity.  
Reactivity was visualized by ECL with GAR-HRP (1:10,000).  Tissues expressing both 
ARNT and ARNT2 proteins are noted by the asterisk.  B, The indicated cell lines were 
purchased from ATCC, and cultured as detailed in Chapter Six.  Total cell lysates 
evaluated for expression of both ARNT and ARNT2 using RI and ARNT2 IgG that were 
titered to give the same level of reactivity to the TNT samples.  ARPE-19 normal rat 
kidney; TCMK-1, mouse kidney; A498; human kidney adenocarcinoma; Hepa-1, mouse 
hepatoma; TNT, in vitro synthesized ARNT or ARNT2.  C, The same level of TNT 
samples loaded in B was stained with anti-V5 IgG (1:500).  Reactivity was visualized by 
ECL with GAM-HRP (1:10,000).  D, ARNT and ARNT2 levels were determined by 
computer densitometry from the blots presented in B.  Results are presented as relative 
densitometry units.   
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vitro synthesized proteins with anti-V5 IgG.  The quantified results are presented in 
Figure 4.22 D.  The ratio of ARNT:ARNT2 protein was variable among the different 
cells with the NRK-49F rat kidney cells showing a near equal ratio (1.3:1), and the A498 
cells showing the lowest (7.2:1).  Thus, these studies confirm that ARNT and ARNT2 
can be co-expressed in the same cell and provide novel models for the future analysis of 
the physiological interactions of these proteins in AHR as well as other bHLH/PAS 
signaling pathways.    
 
4.13 Analysis of ARNT2 Function When Endogenously Expressed 
 Since the hRPE lines appeared to co-express both ARNT and ARNT2 
endogenously as determined by SDS-PAGE and Western blotting, it was pertinent to 
assess the function of ARNT2 in these lines.  Importantly, these lines also express AHR 
protein and CYP1A1 protein was induced in these cells in response to treatment with 
TCDD (Figure 4.23, lanes 3, 4).  Using short-interfering RNA (siRNA) against ARNT or 
ARNT2, levels of either ARNT or ARNT2 were decreased by >80% or by >50% 
respectively.  Interestingly, reduction of ARNT led to complete ablation of CYP1A1 
activity in response to TCDD, even though endogenous levels of ARNT2 continued to be 
expressed (Figure 4.23, lanes 5-8).  While this agreed with previous data that suggested 
that ARNT2 was not capable of substituting for ARNT in the induction of CYP1A1 in 
cell culture (Figures 4.2-4.4), it is in contrast to unpublished studies from this laboratory 
that suggest that low levels of ARNT are sufficient for CYP1A1 induction (RSP).   
 Reduction of ARNT2, however, showed no alteration of the ability to induce 
CYP1A1 in response to TCDD (Figure 4.23, lanes 9-12).  This result was intriguing in  
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Figure 4.23: Reduction of endogenous ARNT or ARNT2 by siRNA knockdown in 
hRPE cells. A, hRPE cells were transfected with siRNA specific to ARNT (siA) or 
ARNT2 (siA2) or control siRNA (siCON) as detailed in Chapter Six. Forty-eight hours 
later, cells were dosed with Me2SO (0.5%) or TCDD (5nM) for 6 h at 37°C, and equal 
amounts of total cell lysates were resolved by SDS-PAGE, blotted and stained with either 
anti-AHR IgG (1µg/ml), anti-ARNT IgG (1µg/ml ), anti-ARNT2 IgG (1:500), anti-
CYP1A1 IgG (1:200), or anti-β-actin IgG (1:1000).  Reactivity was visualized by ECL 
with GAR-HRP (1:10,000).  Each lane represents and independent sample.  B, computer 
densitometry was used to determine the relative level of ARNT or ARNT2 protein 
present in the samples presented on the blot in A. Each column represents the relative 
densitometry units of an individual band and shows the level of reduction of each protein 
following siRNA treatment. 
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light of the results presented in Figures 4.20-4.21 that suggested that ARNT2 could 
inhibit induction of CYP1A1 in Hepa-1 cells.  Interestingly, reduction of ARNT2 by 
siRNA did not appear to increase induction of CYP1A1 protein induction following 
treatment with TCDD suggesting that co-expression of ARNT2 with ARNT in the hRPE 
lines does not appear to have an inhibitory effect on the induction of CYP1A1 in 
response to TCDD.  However, previous studies in this laboratory have demonstrated that 
ARNT when reduced to 10-15% of its endogenous concentration in Hepa-1 cells 
maintains its ability to function in AHR-mediated signaling with visible induction of 
CYP1A1 protein via Western blotting as a result of its endogenous expression level being 
10-fold greater than that of the AHR protein (Holmes and Pollenz, 1997).  In the case of 
this experiment, reduction of ARNT to 10% its normal concentration led to an inability to 
complement AHR-mediated signaling.  Therefore, it is possible that ARNT2 has an 
inhibitory effect on ARNT only when expressed to a greater level than ARNT as seen in 
both the transient transfections in WT cells and following siRNA against ARNT.  Thus, 
the ratio of ARNT to ARNT2 may be important to AHR-signaling in cells co-expressing 
both ARNT proteins.  Co-siRNA treatment against both ARNT and ARNT2 may assist in 
demonstrating this possibility, whereby if the above hypothesis were correct, it would be 
expected that in hRPE cells reduced in both ARNT and ARNT2, the 10% of ARNT 
remaining would then remain able to complement AHR-mediated signaling as a result of 
loss of the repressive ARNT2 expression.  This is also particularly intriguing given that 
NRK cells, which express higher levels of ARNT2 than the hRPE cells, appear to be 
unable to induce CYP1A1 in the presence of TCDD, although the ARNT and AHR 
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proteins are expressed.  As such, reduction of ARNT2 in these lines may restore CYP1A1 
induction if ARNT2 is truly inhibiting this signaling pathway. 
 
4.14 ARNT2 from Nuclear Extracts Fails to Bind XREs 
 To confirm previous findings that ARNT and ARNT2 are equally capable of 
heterodimerizing and binding DNA when expressed in cell culture, nuclear extracts were 
prepared as detailed in Chapter Six from hRPE and NRK lines treated with Me2SO or 
TCDD for 1 hr.  The resultant nuclear extracts were then evaluated for target protein 
expression by Western blotting and DNA binding assessed by EMSA analysis.  
Representative results are shown in Figure 4.24.  In striking contrast to the results 
presented in Figures 4.7-4.19, these EMSA assays revealed no evidence of XRE binding 
requiring ARNT2.  Instead, while the typical TCDD-dependent DNA binding shift was 
evident in both the NRK and hRPE lines, inclusion of IgG against either ARNT or AHR 
ablated all evidence of DNA binding, while inclusion of ARNT2 IgG had no effect.  This 
suggests that ARNT2 was not contributing to the level of DNA binding seen following 
TCDD treatment in these lines, though ARNT2 could be detected in the nuclear extracts 
of both lines (Figure 4.24 C, data not shown for RPE).   
 Since these lines exhibit a reduced level of ARNT2 in comparison to ARNT, it is 
possible that the reduced level of ARNT2 was leading to an inability to visualize 
AHR•ARNT2 DNA binding.  To assess whether the lack of apparent ARNT2 binding 
was a sensitivity issue or was specific to nuclear extracts, cytosolic extracts were also 
prepared from NRK cells and in vitro activated with Me2SO or TCDD as previously 
described since cytosolic extracts of Hepa-1 cells exogenously expressing ARNT2 were  
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Figure 4.24: DNA binding of NRK and hRPE nuclear extracts.  Nuclear extracts from 
NRK and hRPE cells treated with Me2SO (0.5%, C) or TCDD (100nM, TC) for 1 hr at 
37°C were produced as detailed in Chapter Six.  A, B,  30µg/well of nuclear extracts 
from NRK (A) or RPE (B) cells were aliquoted and mixed with 32P-labeled XRE 
oligonucleotides and protein•DNA complexes resolved as detailed in Chapter Six.  In 
some samples, 50ng of IgG specific to ARNT (A1), ARNT2 (A2), AHR (AH) or 
preimmune IgG were included in the binding reaction prior to loading on the gel.  The 
location of the specific AHR•ARNT•XRE and AHR•ARNT2•XRE complex and free 
XRE are indicated.  C, An aliquot of the nuclear extract mixtures utilized in A were 
denatured and evaluated for AHR, ARNT, and ARNT2 expression by Western analysis.  
The Western blot was stained with anti-AHR IgG (1µg/µl), anti-ARNT IgG (1µg/µl), or 
anti-ARNT2 IgG (1:250) and visualized by ECL with GAR-HRP IgG (1:10,000).   
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capable of exhibiting ARNT2-dependent DNA binding in the EMSA assay.  Therefore, 
NRK cytosolic extracts were evaluated for DNA binding potential by EMSA assay 
analysis and representative results are shown in Figure 4.25.  Interestingly, in contrast to 
the results obtained for in vitro activated cytosol of Hepa-1 cells co-expressing ARNT 
and ARNT2, the NRK lines did not exhibit any evidence of the formation of DNA-bound 
complexes containing ARNT2 (Figure 4.25 A, lanes 3 and 4).  However, when additional 
ARNT2 was added to the DNA-binding reaction, the cytosolic extracts exhibited very 
strong TCDD-dependent DNA binding shifts that could be supershifted with IgG against 
ARNT2, but not with pre-immune IgG (Figure 4.25 B).  Therefore, these studies 
demonstrate that ARNT2 remains capable of forming XRE-bound complexes with the 
AHR in the NRK genetic background, suggesting that protein(s) in the NRK lines is not 
inhibiting the ability of ARNT2 to function in these assays.  Thus, the lack of visible 
ARNT2 association with DNA in Figure 4.24 and 4.25 A may be a sensitivity issue rather 
than a biochemical one. 
 To further evaluate this, nuclear extracts were also prepared from wild-type Hepa-1 
cells and wild-type Hepa-1 cells transfected with ARNT2 (WT+ARNT2), expressing 
high levels of ARNT2 in comparison to the low levels seen in NRK or hRPE lines.  
Western blot analysis of these nuclear extracts revealed a TCDD-dependent nuclear 
accumulation of both the AHR and ARNT, and revealed that ARNT2 appeared to be 
constitutively associated with nuclear structures (Figure 4.26 A), similar to results seen in 
the NRK line (Figure 4.24 C).  EMSA analysis of the nuclear extracts also revealed 
strikingly similar results to those obtained in the NRK and hRPE lines, wherein the 
typical TCDD-dependent DNA binding shift was evident in both the WT and  
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Figure 4.25: DNA binding of NRK cytosolic extracts.  Cytosolic extracts from NRK 
cells treated with Me2SO (0.5%, C) or TCDD (100nM, TC) for 1 hr at 30°C were 
produced as detailed in Chapter Six.  A, 60µg/well of cytosolic extracts from NRK cells 
were mixed with 32P-labeled XRE oligonucleotides and protein•DNA complexes resolved 
as detailed in Chapter Six.  In some samples, 50ng of IgG specific to ARNT (A1), 
ARNT2 (A2), AHR (AH) or preimmune IgG were included in the binding reaction prior 
to loading on the gel.  The location of the specific AHR•ARNT•XRE and free XRE are 
indicated.  A, 15µg/well of cytosolic extracts from NRK cells were mixed with 32P-
labeled XRE oligonucleotides and protein•DNA complexes resolved as detailed in 
Chapter Six.  In some samples, in vitro synthesized ARNT2 (A2) was included in the 
binding reaction prior to loading on the gel.  The location of the specific 
AHR•ARNT•XRE, AHR•ARNT2•XRE, and free XRE are indicated.  In some samples, 
50ng of IgG specific to ARNT (A1), ARNT2 (A2), AHR (AH) or preimmune IgG were 
included in the binding reaction prior to loading on the gel.  The location of the specific 
AHR•ARNT•XRE is indicated.   
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WT+ARNT2 lines, but inclusion of ARNT2 IgG had no effect, while inclusion of IgG 
against either ARNT or AHR ablated all evidence of DNA binding.  These data again 
suggested that ARNT2 was not contributing to the level of DNA binding seen following 
TCDD treatment in the WT+ARNT2 lines (Figure 4.26 B).  This was particularly 
intriguing since in vitro activated cytosolic extracts of Hepa-1 cells expressing both 
ARNT and ARNT2 showed disparate results wherein XRE-bound complexes could be 
supershifted with ARNT2 IgG (Figure 4.19).  However, since ARNT2 appeared to be 
constitutively associated with nuclear structures even in the absence of TCDD and did 
not show a large increase in nuclear extract protein levels following TCDD treatment, 
unlike the ARNT or AHR protein, it is possible that ARNT2 is inaccessible to the AHR 
during the transformation of the AHR complex into an AHR•ARNT/2 heterodimer.  If 
this were true, it may be pertinent to assess whether the addition of ARNT2 to nuclear 
extracts from NRK cells would generate AHR•ARNT2 dimers as seen with cytosolic 
extracts in Figure 4.25.  If excess ARNT2 led to the formation of AHR•ARNT2 dimers, 
this would further suggest that AHR remains capable of dimerizing with ARNT2 and 
binding DNA in cell culture and that ARNT2 may have an endogenous function that 
impairs its ability to freely associate with the ligand activated AHR in the nucleus.  Thus, 
further studies should be performed to assess the ability of ARNT2 isolated from nuclear 
extracts to function during AHR signaling and to further identify possible reasons for the 
difference between in vitro activated cytosolic ARNT2 to dimerize with the AHR versus 
ARNT2 from nuclear extracts. 
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Figure 4.26: DNA binding of Hepa-1 nuclear extracts.  Nuclear extracts were 
generated from wild-type Hepa-1 cells transfected with naked vector (WT) and wild-type 
Hepa-1 cells transfected with ARNT2 (WT+A2) dosed with Me2SO (0.5%, -) or TCDD 
(100nM, +) for 1 hr at 37°C were produced as detailed in Chapter Six.  A, An aliquot of 
the nuclear extract mixtures utilized in B were denatured and evaluated for AHR, ARNT, 
and ARNT2 expression by Western analysis.  The Western blot was stained with anti-
AHR IgG (1µg/µl), anti-ARNT IgG (1µg/µl), or anti-ARNT2 IgG (1:250) and visualized 
by ECL with GAR-HRP IgG (1:10,000).  B, 30µg/well of nuclear extracts from WT or 
WT+A2 cells were mixed with 32P-labeled XRE oligonucleotides and protein•DNA 
complexes resolved as detailed in Chapter Six.  In some samples, 50ng of IgG specific to 
ARNT (A1), ARNT2 (A2), AHR (AH) or preimmune IgG were included in the binding 
reaction prior to loading on the gel.  The location of the specific AHR•ARNT•XRE is 
indicated.   
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 Conversely, another possibility for the apparent lack of DNA binding in nuclear 
extracts from lines expressing ARNT and ARNT2 is that AHR•ARNT2 dimers are 
forming in these extracts, but are unable to bind DNA.  If this were the case, then 
immunoprecipitation analysis of nuclear extracts should reveal the presence of such 
dimers.  To test this hypothesis, nuclear extracts were prepared from NRK cells and wild-
type Hepa-1 cells transfected with ARNT2 (WT+A2), and subjected to 
immunoprecipitation analysis using anti-AHR IgG.  Additionally, these samples were 
compared to cytosolic extracts generated from both lines, since cytosolic extracts from 
WT+A2 did exhibit AHR•ARNT2 dimerization and therefore, should act as a positive 
control for the nuclear extracts.  Representative results are presented in Figure 4.27.  
Immunoprecipitation of the NRK extracts revealed that precipitation of the AHR 
specifically co-precipitated ARNT in nuclear extracts of TCDD treated cells (Figure 4.27 
A).  In contrast, ARNT2 did not appear to co-precipitate with the AHR in any of the 
NRK samples.  However, since the proportion of AHR or ARNT2 precipitated in the 
nuclear extracts was less than 15% of the amount seen in the input, it was again possible 
that sensitivity of the ARNT2 antibodies was an issue in this assay since 15% of the 
already low levels of ARNT2 expressed in the NRK line would be undetectable.  Future 
studies employing a more sensitive ECL such as SuperSignal® West Femto Maximum 
Sensitivity Substrate ECL kit (Pierce, Rockford, IL) or precipitation of larger amounts of 
nuclear extract could help to resolve this issue. 
 In contrast to the studies shown in Figure 4.27 A, immunoprecipitation of the 
WT+A2 extracts revealed that precipitation of the AHR specifically co-precipitated 
ARNT in nuclear extracts of TCDD treated cells, but co-precipitated ARNT2 in all of the 
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Figure 4.27: Immunoprecipitation analysis of NRK and WT Hepa-1 cells expressing 
ARNT2.  Cytosolic extracts (CY) from NRK cells (A) or wild-type cells transfected with 
ARNT2 (B) were treated with Me2SO (0.5%, C) or TCDD (100nM, TC) for 1 hr at 30°C 
and were produced as detailed in Chapter Six.  Nuclear extracts (NE) from these lines 
were generated from lines treated with Me2SO (0.5%, C) or TCDD (10nM, T) for 1 hr at 
37°C and were produced as detailed in Chapter Six.  800ug of cytosolic extracts or 300ug 
of nuclear extracts were then incubated with 1 μg monoclonal anti-AHR IgG (IP) or pre-
immune IgG (Pi) for 1 hr at 4oC or saved for analysis of input (Input).  The samples were 
then precipitated with protein A/G agarose beads, washed with TTBS and the boiled in 
the presence of 1x gel sample buffer.  Equal amounts of sample were resolved by SDS-
PAGE, blotted and stained with A-1A anti-AHR IgG (1ug/ml), anti-ARNT IgG (1ug/ml), 
or anti-ARNT2 (1:500) and visualized by ECL with GAR-HRP IG (1:10,000).  The 
precipitated IgG band is shown to demonstrate the uniformity of the precipitation across 
all samples.    
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samples evaluated with the greatest levels of AHR associated ARNT2 present in the 
nuclear extracts from TCDD treated cells; however, these nuclear extracts could not bind 
DNA in the EMSA assay (Figure 4.27 B, Figure 4.26).  Numerous studies were 
performed to examine the specificity of the AHR antibody that provide evidence that the 
monoclonal AHR antibody used for these analyses would not non-specifically precipitate 
the ARNT2 protein (data not shown).  However, due to the very high levels of ARNT2 
expression resulting from the transient transfection of the wild-type cells, it was also 
possible that the interaction itself was non-specific, particularly since ARNT2 co-
precipitated with the AHR even in Me2SO treated cells.  Therefore, this hypothesis is yet 
unclear and future studies should continue to assess whether AHR•ARNT2 dimers are 
forming that are unable to bind DNA. 
 
4.15 Function of ARNT Versus ARNT2 in Hypoxic Signaling 
 To confirm that ARNT2 is functional in other signaling pathways that are believed 
to involve ARNT2 and where its involvement has been supported by the previously 
described knockout studies as detailed in Chapter One, the ability of ARNT2 to 
complement loss of ARNT in hypoxia-mediated signaling was evaluated.  To evaluate 
the potential role of ARNT2 during hypoxia, various ARNT constructs were transfected 
into LA-II cells along with an HRE controlled luciferase reporter and were then subjected 
to physiological hypoxia for 14 hours.  Representative results are given in Figure 4.28 A.  
These results demonstrate a functional role for ARNT2 in hypoxia-mediated signaling 
and functional activity for our ARNT2 construct.  In LA-II cells transfected with either 
murine ARNT2 or zebrafish ARNT2, high levels of HRE controlled luciferase activity 
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were seen following 16 hours of hypoxia that were similar to those seen in LA-II cells 
transfected with murine ARNT.  To correlate these data to results obtained in cell culture, 
NRK cells endogenously expressing ARNT and ARNT2 were cultured under normal 
conditions or in the presence of TCDD as controls or cultured in the presence of Cobalt 
chloride (CoCl2) or desferrioxamine (DFO), known chemical inducers of hypoxia (Cain, 
1975; Myers et al., 1985; Nielsen et al., 1987; Wang and Semenza, 1993).  As previously 
shown, following 1 hr treatment with TCDD, ARNT but not ARNT2, accumulated in 
nuclear extracts prepared from NRK cells (Figure 4.28 B).  In contrast, both ARNT and 
ARNT2 protein increased in nuclear extracts in response to the hypoxic inducers CoCl2 
or DFO, suggesting a functional DNA binding response for both ARNT proteins during 
the hypoxic response.  Further analysis to examine specific gene regulation requiring the 
ARNT proteins as well as their ability to interact with HIF and bind HREs should be 
performed in the future, but, importantly, these initial results indicate that the ARNT2 
used in the previously described studies is capable of functioning in the hypoxic response 
and therefore a lack of response during AHR signaling is not an artifact of a non-
functional ARNT2 construct.   
 
4.16 Evaluation of Potential ARNT and ARNT2 Homodimers 
 ARNT has also been implicated in serving as a transcriptional regulator in a 
homodimeric form, based on early studies in which it was demonstrated that during size 
exclusion HPLC of Sf9 whole cell lysates, ARNT was eluted as a single peak with a 
molecular mass of 205 kDa (Sogawa et al., 1995).  These studies also demonstrated that 
ARNT could form homodimers via the HLH/PAS domains, had affinity for the core  
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Figure 4.28: Analysis of the role of ARNT2 in hypoxia.  LA-II cells were transfected 
with identical amounts of ARNT or ARNT2 vector and with pSV- β -Galactosidase along 
with an HRE-controlled luciferase reporter and cultured in 5% O2 for 14 hrs.  Hypoxia 
responsive luciferase activity and β-Galactosidase activity were measured as previously 
described in Chapter Six and (Zeruth and Pollenz, 2007).  All luciferase values were 
normalized to β -Galactosidase.  LA-II = parental cells transfected with naked vector; 
ARNT = LA-II cells expressing ARNT; ARNT2 = LA-II cells expressing ARNT2, 
zfARNT2 = LA-II cells expressing ARNT2 from the zebrafish, Danio rerio. B,  
Cytosolic (CYTO) and nuclear extracts (NE) from wild-type Hepa-1 cells transfected 
with ARNT2 were cultured untreated (C), or in the presence of TCDD (2 nM, T), Cobalt 
Chloride (100 μM, Co), or Desferrioxamine (100 μM, D) for 1 hr at 37°C were produced 
as detailed in Chapter Six.  Arrows below indicate accumulation of ARNT and ARNT2, 
but not AHR in response to hypoxia induced by Cobalt Chloride or Desferrioxamine.   
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sequence of the adenovirus major late promoter (MLP) containing the canonical E-box 
(5’CACGTG) sequence, and could drive expression of E-box controlled reporters when 
produced in vitro similar to the activities of other E-box binding proteins MyoD, Max, 
and USF.  Further studies showed similar results, again suggesting that ARNT 
homodimerize, could associate with the E-box sequence and could competitively displace 
the c-Myc/Max heterodimer from binding to the E-box, though the ability of ARNT to 
homodimerize may be dependent upon ARNT phosphorylation status (Antonsson et al., 
1995; Huffman et al., 2001; Levine and Perdew, 2001; Levine and Perdew, 2002; 
Swanson et al., 1995; Swanson and Yang, 1999).  However, no studies have attempted to 
examine ARNT homodimerization using full-length proteins expressed in cell culture.  
Additionally, ARNT2 homodimerization has not been evaluated except by means of 
yeast-two hybrid interactions using truncated ARNT2 proteins.  Furthermore, the idea of 
ARNT•ARNT2 interactions have not yet been proposed since it was believed that these 
proteins are not co-expressed.  Therefore, the ability of ARNT or ARNT2 to serve a 
homodimeric role was analyzed as was the potential for ARNT•ARNT2 interactions. 
 To begin to analyze whether or not these interactions were occurring, constructs for 
each ARNT were generated that possessed a HisMax (HM) or V5 epitope tag as detailed 
previously and in Chapter Six.  In each case, in vitro synthesized HM-ARNT was mixed 
with V5-ARNT, HM-ARNT with V5-ARNT2, V5-ARNT and HM-ARNT2, or untagged 
ARNT and ARNT2.  Alternatively, sets of ARNT and ARNT2 were transfected into the 
ARNT deficient LA-II cells.   In either case, immunoprecipitation analyses were 
performed using antibodies against HM, V5, ARNT, or ARNT2 to assess the potential 
interactions of each protein.   For example, LA-II cells were transfected with either 
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HisMax (HM) tagged ARNT (or HM-ARNT2) and V5 tagged ARNT (or V5-ARNT2) or 
both ARNT and ARNT2.  For the HM-ARNT•V5-ARNT and HM-ARNT2•V5-ARNT2 
homodimerization studies, either ARNT or ARNT2 was immunoprecipitated using HM 
or V5 antibodies and Western blot analysis of each sample stained with the opposing 
antibody.  For the ARNT•ARNT2 dimerization study, either ARNT or ARNT2 was 
immunoprecipitated with ARNT or ARNT2 antibodies and Western blots stained for the 
presumed partner.  Interestingly, ARNT and ARNT2 showed little ability to 
homodimerize or heterodimerize with each other (data not shown).  However, it is 
recognized that even in the event that such interactions were occurring, 
immunoprecipitation analyses would be able to resolve only a portion of these.  In a 
mixture of HM-ARNT and V5-ARNT, where ARNT was capable of homodimerizing, it 
is possible that HM-ARNT•HM-ARNT, V5-ARNT•V5-ARNT, or HM-ARNT•V5-
ARNT interactions would occur as would a portion of non-dimerized ARNT proteins in 
all likelihood.  Thus, the pool of HM-ARNT•V5-ARNT would likely only represent at 
most ~1/3 of total ARNT complexes and therefore, detection of these dimerized species 
may be limited by the sensitivity of the assay.   
 In a further attempt to analyze the potential formation of ARNT or ARNT2 
homodimers, EMSA analyses using an E-box probe from the adenovirus major late 
promoter (MLP) were performed using cytosolic or nuclear extracts from cells 
endogenously expressing both ARNT proteins (RPE, NRK), wild-type Hepa-1 cells 
expressing ARNT, or Hepa-1 cells transfected with ARNT2 as detailed in Chapter Six.  
In these analyses, a specific shift was observed that was not seen in the presence of a 
labeled mutant E-box probe, but this shift could not be supershifted with antibodies 
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against ARNT or ARNT2, suggesting the involvement of other E-box binding proteins 
(data not shown).  A similar lack of ARNT or ARNT2 E-box binging was also obtained 
using in vitro synthesized ARNT proteins or unprogrammed reticulocytes (data not 
shown).  Again, however, it remains possible that such dimers exist yet do not associate 
with the adenovirus E-box as flanking nucleotides may also play a role in transcription 
factor DNA binding.  Thus, while these studies failed to identify in vivo ARNT or 
ARNT2 dimerization or the presence of ARNT•ARNT2 dimers, they emphasize the need 
to identify in vivo ARNT or ARNT2 homodimers as well as the inherent difficulty of 
performing such studies.  While ARNT homodimers have been implicated in the partial 
regulation of CYP2A5 (Arpiainen et al., 2007), these studies focused on the regulation of 
CYP2A5 in the presence or absence of ARNT, which may be impacting more than 
ARNT alone. 
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Chapter Five 
Implications and Future Directions 
 
5.1 Implications of AHRb-2 Studies 
The AHRb-1 allele carried by the C57BL/6J murine strain contains a point 
mutation that prematurely truncates the receptor at 805 amino acids, while the AHR 
found in other murine strains as well as in the rat and human all contain an additional 42-
45 amino acids at their carboxy-terminus that have 70% identity (Figure 1.3, Table 1.3).  
Thus, as detailed throughout Chapters One and Two, the current model system used for 
the evaluation of the physiological role of the AHR, which focuses on using the C57BL 
mouse and hepatoma cells isolated from this murine strain to assess AHR function, may 
not be the most accurate model.  Furthermore, the results of this report detail a possible 
functional role of this extended carboxy-terminal sequence, either through an altered 
AHR conformation resulting from the presence of this extended sequence or through a 
direct function of this region in the association of the AHR with XAP2.  Collectively, the 
results presented in Chapter Two also describe the impact of this extended region on 
AHR subcellular localization and degradation, which differ between Ah receptor species.  
Furthermore, the use of a genetically identical background to examine the function and 
degradation rate of the AHRb-2 in comparison with the AHRb-1 was ideal and provided 
significant insights into the biological properties of the AHR contributed by this 
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functional region, which, importantly, were mimicked in alternate cell lines 
endogenously expressing the AHRb-2.   
Similarly, studies of XAP2 function in AHR-mediated signal transduction have 
focused on the interactions of XAP2 with the Ahb-1 receptor and have also been based 
primarily on the analysis of XAP2 in transient transfection systems using AHR-deficient 
COS-7 cells.   Collectively, these studies suggested that XAP2 may influence the stability, 
subcellular localization, and overall expression of the AHR (Bell and Poland, 2000; Berg 
and Pongratz, 2002; Carver and Bradfield, 1997; Kazlauskas et al., 2002; LaPres et al., 
2000; Lees et al., 2003; Ma and Whitlock, 1997; Meyer and Perdew, 1999; Meyer et al., 
2000; Meyer et al., 1998; Petrulis et al., 2003; Ramadoss and Perdew, 2005).  However, 
there has been minimal information on the function of endogenous XAP2 as it relates to 
interactions with endogenous AHR proteins from species other than the murine C57BL/6J 
strain since there has been a general assumption that the functions ascribed to XAP2 for 
the Ahb-1 receptor complex are universal for all other Ah receptor species as is the 
function of the AHR itself.  The key findings of the current report challenge this view by 
showing that (i) the level of endogenous XAP2 that associates with the AHR is receptor 
species specific, wherein the AHRb-1 associates with a level of XAP2 that is much greater 
then other mammalian AHR proteins characterized in this report independently of its 
genetic background, (ii) the level of XAP2 associating with the AHR may partially alter 
the subcellular location of the AHR, wherein a high level of XAP2 association with the 
Ahb-1 receptor leads to cytoplasmic retention of the latent AHR complex, while AHR 
proteins exhibiting reduced association with XAP2 appear to dynamically shuttle through 
the nucleus, (iii) increased XAP2 association with the AHR may decrease the rate of 
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ligand-induced degradation of the AHR, and (iv) association of XAP2 with the Ahb-1 
receptor may stabilize a portion of the AHR population in that ~30% of the total cellular 
levels of AHR remain even in the presence of TCDD for 6 hours, whereas >90% loss of 
endogenous Ahb-2 receptor is achieved under the same conditions.  Since these 
associations are maintained even when each receptor species is expressed in the same 
genetic background (ie: in the presence of the same total levels of XAP2 and AHR), these 
results collectively imply that XAP2 may only impact AHR-mediated signaling in the 
context of the Ahb-1 receptor and suggest that the analysis of the AHR-mediated signaling 
via rat and mouse Ahb-2 receptors may better represent the physiology of this signal 
transduction pathway across species and in the human.    
Since these studies revealed biochemical differences between the Ahb-1 receptor 
and AHR proteins from other mammalian species, it will be important to assess the 
functional relevance of these differences, particularly in terms of gene regulation.  Since 
genetic variation will always complicate such studies if different cell lines or organismal 
models are used, the model system of expressing each receptor to the same level in the 
same genetic background using the same promoter will prove useful for such studies.  
Additionally, non-mammalian Ah receptors could be placed in the same genetic context 
as the Ahb-1, though it is possible that non-murine Ah receptors would exhibit differences 
from the Ahb-1 or from their endogenous physiology as a result of not having their 
specific species AHR pathway components.  However, since such studies can always be 
compared to lines endogenously expressed alternate AHR species, such studies could be 
performed if care is taken to ensure that the results obtained are indeed related to AHR 
function. 
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High levels of XAP2 association with the AHR have also been linked to 
displacement of p23 from hsp90 (Hollingshead et al., 2004).  However, these studies 
focused on overexpression of cellular XAP2 in COS cells transfected with Ahb-1 receptor 
and an increase in XAP2 association with the AHR was minimal (Hollingshead et al., 
2004).  Since the studies shown in this report suggest that 100% of the Ahb-1 receptor 
pool is associated with XAP2 (Figure A-5), it is not surprising that no increase in XAP2 
association was seen when XAP2 was overexpressed.  Thus, such studies should be 
repeated in the context of other AHR species that exhibit reduced XAP2 association and, 
preferably, in cells stably expressing the AHR to reduce population differences resulting 
from transfection efficiency.  Importantly, p23 appears to be involved with stabilization 
of the latent AHR complex with Hsp90 and the subsequent ability of the AHR complex 
to heterodimerize with ARNT, and is also involved in the modulation of function for 
many intracellular receptors such as the glucocorticoid receptor and members of the 
intracellular receptor family (Dittmar et al., 1997; Freeman et al., 2000; Shetty et al., 
2003; Wochnik et al., 2004).  
In light of these studies, it could be suggested that increased XAP2 association 
with the AHR would lead to displacement of p23 and subsequent destabilization of the 
latent AHR complex; however, the opposite of this effect was observed.  In the studies 
described in Chapter Two, the Ahb-1 exhibits high XAP2 association and, yet, exhibits 
increased stabilization, though the studies by Hollingshead et al. (2004) would imply that 
high levels of XAP2 association with the AHR would result in the displacement of p23 
and subsequent destabilization the AHR complex.  Thus, it would be pertinent to reassess 
the studies performed by Hollingshead et al. (2004).  To evaluate this, the Ahb-1 and the 
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non-Ahb-1 receptors examined in this report, which exhibited differential association with 
XAP2, should be evaluated for p23 association in the latent AHR complexes.  Such 
studies could easily be performed using the same techniques as those shown for 
AHR•XAP2 analysis.  If non-Ahb-1 receptor species exhibit increased p23 association, 
these data would be supportive of XAP2’s role in displacement of p23, yet would then 
appear to be contradictory of the reported role of p23 in stabilization of the AHR since 
these receptor species undergo a more rapid degradation following ligand-activation.  
Likewise, unless non-Ahb-1 receptor species exhibited decreased p23 association, which 
would not be supportive of XAP2’s role in displacement of p23, there would be no 
apparent correlation between AHR•hsp90•p23 association and the role of p23 in 
stabilization of the AHR.  However, since Ahb-2 complexes can be generated that 
associate with increased levels of XAP2 (Figures 2.7 and 2.8) compared to endogenous 
Ahb-2 when XAP2 is transfected into AHb2 stable lines, these lines will be an ideal model 
for directly analyzing the relationship between the association of AHR•XAP2 and that of 
hsp90•p23 since the effect of increasing XAP2 association with the AHR can be 
evaluated in the context of a receptor capable of exhibiting such an increase. 
XAP2 knockout studies have also recently been performed in the C57BL/6J 
mouse (Lin et al., 2007).  In these studies, knockout of XAP2 was embryonically lethal 
with most homozygous null mice dying by embryonic day 15-17 as a result of severe 
vascular and cardiac abnormalities including the presence of a double outlet right 
ventricle (DORV) and reduced blood flow to the extremities, suggesting a role for XAP2 
in cardiac development.  The authors of this study suggest that these data indicate a role 
for XAP2 outside of AHR and PPARα function.  It is striking, however, that AHR 
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signaling has also been implicated in cardiac development by other studies in that i) AHR 
null mice have been demonstrated to exhibit cardiac hypertrophy resulting from 
thickened ventricular walls and increased cellular proliferation in the heart and ii) TCDD-
treated mice have been shown to also exhibit cardiac hypertrophy, edema, and an 
increased formation of ventricular septal defects (VSDs), which are highly associated 
with DORV (Thackaberry et al., 2003; Walker et al., 1997).   Since loss of XAP2 in the 
C57BL/6J mouse Hepa-1 cell line results in increased nucleocytoplasmic shuttling of the 
AHR and a more rapid degradation profile, loss of XAP2 in the C57BL/6J mouse may 
lead to altered regulation of AHR target genes or complete depletion of the AHR in the 
presence of ligand and in either case, may be contributing to the formation of DORV.  
Furthermore, since it appears that XAP2 may stabilize a portion of the AHR in the 
C57BL/6J mouse, cardiac abnormalities seen with loss of XAP2 could correlate with 
results obtained through loss of the AHR in knockout or TCDD-treated mice; however, 
C2C12 mice do not constitutively develop cardiac conditions though the Ahb-2 is 
endogenously associated with reduced levels of XAP2.  Therefore, it remains possible 
that loss of XAP2 contributes to formation of DORV through disruption of AHR 
signaling by destabilization of the receptor in the presence of ligand.  However, since the 
authors chose to evaluate loss of XAP2 in the C57BL/6J mouse, which expresses the 
Ahb-1 receptor that associates with high levels of XAP2, it would be pertinent to assess 
loss of XAP2 in the BALB/cBy or C3H mouse as well, which express the Ahb-2 receptor 
that associates with reduced levels of XAP2.  Care should also be taken that the animal 
foods being used contain no AHR agonists as the presence of AHR ligands would lead to 
loss of AHR and could contribute to cardiac abnormalities.  Such studies may further 
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support evidence that the effects of loss of XAP2 could be mediated through AHR 
signaling if different physiological abnormalities are seen in different murine strains.   
FKBP12 (human FKBP51) is structurally similar to XAP2 and both proteins 
contain FK (FK506-binding), TPR (tetratricopeptide), and peptidylprolyl isomerase (PPI) 
domains, and both proteins associate with Hsp90 through the TPR domain, yet XAP2 
lacks the ability to bind immunosuppressive drugs through its FK domain and also 
appears to lack PPI activity in which PPI interacts with dynein to regulate receptor 
localization (Carver et al., 1998; Galigniana et al., 2002; Galigniana et al., 2001).  Instead, 
XAP2 interacts with the AHR through its FK domain (Meyer et al., 1998; Peattie et al., 
1992).  It is also striking, however, that loss of the immunophilin FKBP12, which 
functions in the release of Ca2+ from the sarcoplasmic reticulum in skeletal muscle, in 
knockout mice is also embryonic lethal, leading to death between embryonic day 14.5 
and birth, resulting from cardiac hypertrophy and VSDs (Shou et al., 1998).  Furthermore, 
these effects are seen only in male FKBP12 null mice, while null-females exhibit cardiac 
hypertrophy only in the presence of estrogen receptor antagonists, though both sexes 
exhibit deficiencies in Ca2+ release.  Thus, these results suggest a role for estrogen in 
protection from loss of FKBP12 induced cardiac hypertrophy.  It may also then be 
pertinent to assess whether female XAP2 null mice exhibit a similar lack of cardiac 
hypertrophy as seen in males.   
Mutations in the FK domain of XAP2 (R304X), which contains an AHR binding 
region, have also been implicated in predisposition for pituitary adenomas (Georgitsi et 
al., 2007; Vierimaa et al., 2006).  Since little is known regarding the function of XAP2 
outside of its interaction with the AHR, future studies should also therefore be aimed at 
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further analyzing the potential physiological role(s) of XAP2, focusing on its apparent 
role in cardiac development and whether XAP2 also serves a role in Ca2+ regulation since 
knockout of FKBP12 resembles that of XAP2.  Such studies could involve yeast two-
hybrid screens to identify XAP2 interacting proteins, conditional knockouts of XAP2 in 
the heart, and Northern or microarray analysis of cardiac tissues in XAP2 and XAP2-/- 
animals, followed by molecular evaluation of potential gene targets. 
   
5.2 Implications of AHR Degradation Studies 
  Importantly, association with XAP2 may also affect AHR degradation.  Following 
TCDD binding, the AHRb-1 is rapidly depleted by 80-95% within 4-6 hours of treatment 
in numerous cell culture models and does not return to basal levels as long as ligand is 
present in the media (Pollenz, 1996; Reick et al., 1994).  As detailed in Chapters Two and 
Three, this degradation is even more rapid with the Ahb-2, human or rat receptors, which 
deplete by 90-100% within 2 hours of treatment.  The importance of this loss is 
underscored by the variety of physiological defects seen in AHR-/- mice (Andreola et al., 
1997; Fernandez-Salguero et al., 1995; Gonzalez et al., 1995; McDonnell et al., 1996) 
and the evidence that a single oral dose of TCDD can lead to sustained depletion of AHR 
proteins in the liver, spleen, thymus, and lung in vivo and that such a depletion correlates 
with reduction in TCDD-mediated reporter gene expression in mammalian culture cells 
following a second dose of TCDD (Pollenz et al., 1998).   It is important to note that 
many of the phenotypes seen in TCDD-treated mice are similar to those reported for 
AHR-/- mice that have not been exposed to TCDD.  Thus, this loss of AHR may 
contribute to some of the biological effects of xenobiotics.  Degradation of the AHR, 
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therefore, which may be used as a means of attenuating the transcriptional response, can 
have significant repercussions on the future signaling ability of the AHR pool as well as 
biological implications.  Thus, a more rapid degradation profile in animals expressing 
alternate Ah receptor species would likely impact the toxic effects that result from loss of 
receptor, particularly since the AHRb-1 does not appear to exhibit >80% reduction in cell 
culture, while the AHRb-2 and rat AHR appear to be nearly 100% degraded in response to 
TCDD.  Thus, in the presence of sufficient TCDD or other PAHs or HAHs, animals 
expressing non Ahb-1 receptors may exhibit increased susceptibility to these toxins as a 
result of total loss of receptor, particularly if the AHR has other endogenous functions 
that may not be disrupted with >20% AHR remaining.  
Conversely, blockage of degradation by the translation inhibitor CHX in the 
context of a functional AHR appears to result in potentiation of gene induction 
(superinduction), whereby genes regulated by the AHR are induced to a higher level and 
for a longer period of time (Ma and Baldwin, 2000; Pollenz and Barbour, 2000).  
However, in stable lines expressing amino-terminally tagged AHR proteins that exhibit a 
reduced magnitude of degradation, but are capable of inducing CYP1A1 (Figures 3.14 
and 3.15), superinduction at the protein level is not readily apparent.  In fact, the GFP-
AHR exhibits both a reduced magnitude of degradation as well as a reduced level of 
CYP1A1 induction (Figure 3.15).  This suggests that blockage of AHR degradation is not 
sufficient for superinduction of CYP1A1, although evaluation of CYP1A1 at the mRNA 
level should also be performed since the studies describing superinduction using CHX 
could not evaluate CYP1A1 protein. 
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From the results presented in this report, it appears that the AHR can be degraded 
through several distinct mechanisms: (i) ligand-dependant degradation that can be 
blocked by pre-treatment with the transcription inhibitor AD or the translation inhibitor 
CHX without affecting nuclear localization or DNA binding ability of the receptor 
(Pollenz et al., 2005) that requires DNA binding by AHR•ARNT, which suggests that 
both active transcription and translation by AHR•ARNT are necessary for ligand-induced 
degradation of the AHR, (ii) ligand-dependent degradation in which carboxy-terminal 
truncated Ah receptors (Pollenz et al., 2005) as well as those defective in DNA binding or 
ARNT dimerization (Chapter Three) similarly exhibit a very low level of degradation 
following treatment with TCDD; however, this degradation does not require DNA 
binding and cannot be blocked by either AD or CHX, suggesting that this loss is not 
representative of the typical degradation seen following ligand binding with the wild-type 
receptor, (iii) ligand-independent degradation typified by treatment with geldanamycin 
(GA) that leads to nuclear translocation of the receptor and its subsequent degradation, 
but cannot be blocked by treatment with either AD or CHX and occurs without disruption 
of the AHR complex itself and, importantly, without DNA binding or subsequent gene 
induction (Chen et al., 1997; Meyer et al., 2003b; Song and Pollenz, 2002), and (iv) 
endogenous turnover of the AHR about which little is known.  
Thus, the precise mechanisms involved with regulating the degradation of the 
AHR are still not resolved.  It is intriguing to consider that several studies have shown 
that the degradation of some nuclear receptors is correlated to transactivation, DNA 
binding, and the recruitment of co-activators to the promoter/enhancer region of 
responsive genes (Reid et al., 2003; Salghetti et al., 2001; Verma et al., 2004), which 
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appears to be the case with ligand-induced degradation of the AHR. The strong 
association of XAP2 with the Ahb-1 receptor complex (as compared with rat and Ahb-2 
receptors), may slow down the transformation process and prevent a population of AHRs 
from interacting with ARNT, binding DNA, and being degraded as may the presence of 
amino-terminal tags on the AHR, though these characteristics have not been directly 
assessed.   To assess this, it would be possible to examine the intensity of DNA binding of 
in vitro expressed Ahb-1 receptor and ARNT in rabbit reticulocytes.  Unprogrammed 
reticulocytes can be assessed for XAP2 expression by Western blotting to determine 
whether or not they express XAP2 endogenously.  If so, rabbit reticulocytes could be 
used from which XAP2 had been removed.  This could be achieved using a Millipore 
centricon filtration device followed by immunodepletion of the ~37 kDa fraction using 
XAP2 IgG and protein A/G beads in a manner similar to that outlined by Shetty et al. 
(2004).  In either case, in vitro produced XAP2 could be added along with AHR and 
ARNT in activation reactions in increasing amounts and portions of each activation 
reaction removed every 15 min for 2 hours and run on an EMSA as previously described 
to examine AHR•ARNT DNA binding.  A portion of each sample could also be 
immunoprecipitated to examine the association of XAP2 with the AHR complex.  In the 
presence of increasing XAP2 up to saturation of the AHR, it would be expected that the 
presence of XAP2 would stabilize the AHR complex and slow the AHR•ARNT 
transformation process as evidenced by a decreased intensity of DNA binding in XAP2 
containing activation reactions at earlier time points of analysis.  A significantly reduced 
effect on the transformation ability and AHR saturation point would be expected in the 
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context of non-Ahb-1 receptors since these receptor species exhibit reduced association 
with XAP2. 
Interestingly, recent studies also suggest that the Ahb-1 receptor remains associated 
at the CYP1A1 promoter during ligand stimulation in Hepa-1 cells, whereas the human 
AHR shows periods of association and dissociation at the CYP1A1 promoter in MCF-7 
cells (Hestermann and Brown, 2003; Wang et al., 2004).  Thus, it would be important to 
assess whether the human AHR in the Hepa-1 background continues to cycle on/off the 
CYP1A1 promoter to determine whether these associations occur as a result of the AHR 
itself, another cellular factor, or the genome.  These results would be especially important 
in light of a recent report that suggest that oscillation of a transcription factor at a 
promoter is linked to accessibility of binding sites and not an oscillatory recruitment of 
the transcription factor itself (Karpova et al., 2008).  Similar studies could also be 
performed using chromatin immunoprecipitation (ChIP) time course analysis of TCDD 
treated AHb2 cells as well as C2C12 cells to determine whether the Ahb-2 receptor also 
cycles on/off the CYP1A1 promoter endogenously or when expressed in the Hepa-1 
background.  If these receptors also exhibit promoter association cycling, this would 
correlate these results with the rapid degradation profile of these receptors.   
In either case, both ligand-dependent and ligand-independent degradation of the AHR 
have been demonstrated to occur via the 26S proteasome complex since pre-treatment 
with the proteasome inhibitors MG-132 or lactacystin prior to treatment with agonist 
blocks degradation of the receptor, while pre-treatment with inhibitors of calpain, serine 
or cysteine proteases nor lysosomal proteases cannot (Davarinos and Pollenz, 1999; Ma 
and Baldwin, 2000; Wentworth et al., 2004).  As such, several studies have suggested 
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that the AHR is ubiquitinated, though none have demonstrated definitive evidence of 
such events and at this time no specific E3 ligase has been demonstrated to be involved in 
the degradation of the AHR nor has any lysine residue been implicated as a ubiquitination 
site (Ciechanover, 2005; Kazlauskas, 2000; Ma and Baldwin, 2000).   Additionally, in 
studies performed in this laboratory, no accumulation of ubiquitinated AHR is seen under 
the presence of AD or MG-132 (RSP, unpublished observations). 
Recently, AHR ligand dependent, but not estradiol dependent, degradation  of the 
estrogen receptor (ERα) has been shown to occur via ubiquitination by a cullin 4b (cul4) 
E3 ligase multiprotein complex containing the DNA damage binding protein 1 (ddb1), 
and the ubiquitin conjugating enzyme ring finger protein RBX1/ROC1 (Ohtake et al., 
2007).  Surprisingly, in the presence of AHR ligand, atypical cul4 multiprotein 
complexes are formed that also appear to contain the AHR (Ohtake et al., 2007).  These 
cul4bAHR complexes then appear to be involved with AHR ligand-mediated degradation 
of ERα since reduction of any cul4bAHR complex component reduces the degradation of 
ERα.  However, in contrast to these studies, ligand-dependent degradation of the AHR is 
unaffected by reduction of cul4b or cul4b associated proteins such as ddb1 (RSP, 
unpublished results).  Thus, cul4 complexes do not appear to mediate the ubiquitination 
of the AHR. 
 It has also been proposed that the carboxyl terminus of hsc70-interacting protein 
(CHIP), an E3 ligase which contains a TRP domain for interaction with Hsp proteins and 
a U-box domain for recruitment of ubiquitin conjugating enzymes, may play a role in 
AHR degradation.  This hypothesis stems from data suggesting that CHIP interacts with 
Hsp70/Hsc70 or Hsp90 to promote the degradation of Hsp client proteins including the 
 196
glucocorticoid receptor and tau (Ballinger et al., 1999; Dickey et al., 2006; Lees et al., 
2003; Morales and Perdew, 2007).  In these studies, CHIP appeared to be capable of 
interacting with both Hsp90 and the AHR when endogenously expressed, expression of 
CHIP resulted in a dramatic loss of AHR in COS-1 cells, and an in vitro degradation 
assay resulted in ubiquitination of the AHR in the presence of CHIP (Morales and 
Perdew, 2007).  Interestingly, the studies of Morales et al. (2007) also suggested that 
XAP2 can partially protect in vitro expressed Ahb-1 receptor from CHIP mediated 
ubiquitination, but did not protect mutant AHR (Y408A) unable to bind XAP2.  As 
previously discussed, these results again correlate the reduced degradation profile of the 
Ahb-1 receptor, which associates with high levels of XAP2, and the rapid degradation 
profile of the Ahb-2 receptor, which associates with low levels of XAP2.  However, in 
these studies, expression of CHIP∆U-box in COS-1 cells also resulted in loss of AHR, 
suggesting this ubiquitin conjugating domain was not essential for AHR turnover.  
Additionally, loss of CHIP via siRNA in Hepa-1 cells or using CHIP knockout cell lines 
did not impact the degradation of the AHR (Morales and Perdew, 2007; Pollenz and 
Dougherty, 2005).  Thus, CHIP is either not involved in the degradation of the AHR in 
the context of Hepa-1 cells or a compensatory mechanism is at play wherein other E3 
ligases can substitute for loss of CHIP.   
In support of a compensatory mechanism, during CHIP knockout studies, only 
50% of CHIP-/- mice died by postnatal day 30-35, while the remaining animals were 
viable (Dickey et al., 2006).  Since CHIP has been implicated as an E3 ligase responsible 
for modulating the degradation of essential proteins, survival of CHIP knockout animals 
suggests that either a compensatory mechanism(s) exist for degradation of Hsp client 
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proteins, that CHIP alone is not essential for degradation of these proteins, or that 
degradation of these proteins is not strictly necessary for survival.    
Thus, studies must be continued to identify the E3 ligase or AHR lysine residue 
necessary for degradation of the AHR.  While it is possible to mutate each lysine residue 
in the AHR singly to attempt to identify a mutation that would prevent ubiquitination, 
there are 33 lysine residues in the Ahb-1 receptor and mutation of each individually would 
be expensive.  Additionally, any disruption of AHR function would prevent ligand-
dependent degradation of the receptor without necessarily identifying a key 
ubiquitination site.  Furthermore, more than one lysine residue could be a target for 
ubiquitination, which would likely result in failure of this scanning mutagenesis to 
identify a key residue.  Thus, techniques scanning for protein-protein interactions may 
serve better to identify an E3 ligase.  As such, studies are currently underway in this 
laboratory to identify a ligase using yeast expression systems in Saccharomyces 
cerevisiae and gene knockout libraries.   However, while many of the ligases involved 
with ubiquitination are highly conserved, yeast may lack the specific E3 ligase involved 
with targeting the AHR for degradation, particularly since yeast lack AHR and ARNT 
homologs.  Yeast strain may also be important; for example, Saccharomyces cerevisiae 
lack cul4 while Saccharomyces pombe do not (Higa and Zhang, 2007).   In a second 
approach, a bacterial two-hybrid screen will be employed to attempt to identify proteins 
interacting with the carboxy-terminal region of the AHR, where it is believed that any 
ubiquitination would occur.  Potential gene targets from either the yeast or bacterial 
screen will be validated in mammalian cell culture. 
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5.3 Implications of ARNT2 Studies 
 AHR-mediated signal transduction may also be impacted by other cellular factors, 
such as the presence/level of various cofactors or the presence/level of other potential 
heterodimeric partners (ARNT proteins).  The ARNT and ARNT2 proteins share > 95% 
amino acid identity in the bHLH domain and exhibit >80% amino acid identity in the 
PAS A and PAS B domains (Hirose et al., 1996).  These domains are known to specify 
both protein-protein interaction and DNA binding of the various bHLH/PAS proteins 
(Pongratz et al., 1998; Reisz-Porszasz et al., 1994).  Because of this high level of identity 
in these regions, it is striking that the knockout of either ARNT and ARNT2 in the mouse 
produces different phenotypes (Hosoya et al., 2001; Keith et al., 2001; Kozak et al., 1997; 
Maltepe et al., 1997), because it would appear that both proteins have the same potential 
to dimerize with common bHLH/PAS partners.  However, while many of the potential 
partners for ARNT have been evaluated both in vivo and in vitro, the ability of ARNT2 to 
associate with these heterodimeric partners is less well established.  Thus, because there 
is limited functional analysis of the ARNT2 protein in mammalian model systems, the 
goal of the studies outlined in Chapter Four was to investigate whether ARNT and 
ARNT2 could interact with a common dimerization partner in vitro and in cell culture.  
Since different phenotypes could also result from differential tissue/cellular expression of 
ARNT proteins or discrepancies in the level of ARNT proteins in these tissues/cells, it 
was also pertinent to determine the endogenous protein expression of these proteins in the 
mouse.   
 Therefore, experiments were performed to assess the ability of ARNT or ARNT2 
to associate with the AHR.  The analysis of this interaction was chosen since the 
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interaction of ARNT with the AHR can be easily assessed in vitro where the 
stoichiometry of the expressed proteins can be precisely controlled and because there 
have been discrepancies in the literature as to whether or not this interaction is capable of 
occurring (Hirose et al., 1996; Sekine et al., 2006).  Early studies of ARNT2•AHR 
interaction suggested that ARNT2 could dimerize with the AHR, could bind XREs, and 
could induce XRE controlled luciferase reporter activity when coexpressed with the AHR 
in the presence of ligand (Hirose et al., 1996).  In more recent studies, results from the 
same laboratory suggested that the ARNT2 did not dimerize with the AHR (Sekine et al., 
2006).  The results presented in Chapter Four challenge this second view, in that they i) 
clearly show that both ARNT and ARNT2 can specifically interact with the AHR in a 
TCDD-dependant manner in vitro, ii) that both proteins compete with each other equally 
to form dimers with the TCDD-bound AHR, and iii) that ARNT2 was able to out-
compete ARNT for binding to the AHR when expressed in excess of ARNT.   
However, the studies designed in Chapter Four also sought to determine the 
reason for any inequity between the previous studies and our own.  A major finding of 
these studies was that the ability of ARNT2 to associate with the AHR appeared to 
decrease (in comparison to ARNT) when the AHR was activated by ligands other than 
TCDD.  Indeed, when the low affinity non-halogenated polyaromatic hydrocarbons BAP 
or 3-MC were used to activate the AHR in the in vitro assay in the presence of equal 
concentrations of ARNT and ARNT2, approximately two-thirds of the DNA bound 
complexes formed were AHR•ARNT.  These findings were also observed when the in 
vitro assays were carried out with ARNT or ARNT2 protein expressed in cell culture 
lines that lacked either ARNT protein.  This is an intriguing finding that suggests the 
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AHR may have a slightly different conformation when bound with different ligands.  
This implies that dimerization potential may be influenced by type of ligand and this may 
partially explain why recent studies suggest that ARNT2 does not interact with the AHR 
(Sekine et al., 2006).  However, there is little known about how the ligand binding 
domain impacts the structure of the HLH or PAS regions at the molecular level.  
Homology modeling is currently being used to gain insight into this important question 
(Pandini et al., 2007).   
In contrast to the in vitro studies, a physiological model of expression of ARNT2 
using the ARNT-deficient LA-II variant of the Hepa-1 cell line showed that ARNT2 was 
unable to support TCDD-mediated induction of the endogenous CYP1A1 gene.  
Furthermore, not only was ARNT2 unable to support TCDD-mediated induction of the 
endogenous CYP1A1 gene, expression of ARNT2 in the context of the Hepa-1 line 
actually appeared to partially inhibit the positive function of ARNT in AHR-mediated 
signaling by an unknown mechanism.  The ability of ARNT isoforms to function as 
dominant negative regulators of AHR-mediated signaling has previously been reported 
for the ARNTa splice variant expressed in rainbow trout and zebrafish (Necela and 
Pollenz, 1999; Necela and Pollenz, 2001; Pollenz et al., 1996).  In the case of the 
rtARNTa, negative function is manifested by dimerization with the AHR but lack of 
binding to XRE enhancers, resulting in squelching of the AHR.   
A similar mechanism may explain the current results with ARNT2, as Western 
blotting and EMSA studies failed to detect AHR•ARNT2 complexes in nuclear extracts 
of Hepa-1 cells expressing ARNT2 protein, but immunoprecipitation analyses of these 
lines revealed a possible association between ARNT2 and the AHR.  Unfortunately, 
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endogenous association of AHR and ARNT2 could not be detected in cell lines 
expressing both ARNT isoforms.  As previously discussed, this may have arisen from a 
lack of sensitivity in the probing of the resultant precipitations.  Future studies in this area 
should therefore seek to repeat these studies using greater amounts of cytosolic and 
nuclear extracts and/or more sensitive ECL techniques, such as the SuperSignal® West 
Femto Maximum Sensitivity Substrate ECL kit (Pierce, Rockford, IL) that allows 
detection of as little as 1 fg of HRP conjugated protein—approximately 5000x more 
sensitive than the ECL kit (Amersham, Piscataway, NJ) used to analyze the Western blots 
shown in Chapter Four.  These techniques may allow for the detection of dimers that 
were previously undetectable.  Additionally, to reveal whether the negative impact of 
ARNT2 expression on AHR signaling stems from ARNT2•AHR dimerization, it would 
be pertinent to dose Hepa-1 cells expressing ARNT2 with ligands other than TCDD, such 
as BAP or 3-MC.  Since these low-affinity ligands appear to preferentially result in the 
formation of AHR•ARNT DNA binding heterodimers in vitro, reducing the formation or 
DNA binding ability of AHR•ARNT2 dimers, similar reductions in CYP1A1 following 
dosing with BAP or 3-MC may imply that these reductions are not caused by DNA 
binding of AHR•ARNT2 dimers, but through another undefined mechanism. 
 It is also possible that ARNT2 expressed in culture loses the ability to form AHR 
complexes capable of associating with DNA as evidenced by the lack of accumulation in 
nuclear lysates of TCDD treated cells expressing ARNT and ARNT2.  Such a mechanism 
could involve the interaction with tissue specific proteins yet to be defined that are not 
found in cytosolic fractions used in the in vitro activation assay, the formation of 
homodimers that limit the pool of ARNT2 that is available, the formation of a non-
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functional AHR•ARNT2 complex or compartmentalization or heterodimerization with 
ARNT.  Loss of ARNT2 function in vivo would be consistent with studies that have 
evaluated the function of ARNT2 in zebrafish.  In these studies, it has been shown that 
although ARNT2 is the predominate ARNT protein in aquatic species and can associate 
with AHR and bind DNA in vitro, knockdown of ARNT2 levels using antisense 
morpholino oligonucleotides in vivo does not reduce AHR-mediated signaling in this 
organism.  In contrast, reducing AHR or ARNT in zebrafish completely abolishes the 
effects of TCDD on the development of embryos indicating that zfARNT2 cannot 
compensate for the loss of ARNT in vivo (Bello et al., 2004; Carney et al., 2004; Prasch 
et al., 2004; Prasch et al., 2006; Prasch et al., 2003; Teraoka et al., 2003).   However, this 
does not address the results demonstrating that ARNT2 expressed in culture remains 
capable of interacting with the AHR and binding XREs when cytosolic extracts from 
cells are in vitro activated (Figure 4.19).  Thus, it is the presence of a component of the 
nuclear extract, a result of the preparation of the nuclear extract, or a result of the 
conditions for the in vitro activation that leads to the apparent inability of ARNT2 to 
function in AHR signaling.   
 Intriguingly, nuclear extracts prepared from cell lines expressing ARNT2 (either 
transiently or endogenously) exhibit a constitutive association of ARNT2 with nuclear 
structures in direct contrast to ARNT or AHR, which exhibit a ligand-dependent increase 
in nuclear extracts (Figures 4.24 and 4.26).  Thus, these results suggest a nuclear role for 
ARNT2 that may prevent ARNT2 from being accessible to the liganded AHR (Figure 
5.1).  If this were true, it may be pertinent to assess whether the addition of ARNT2 to 
nuclear extracts from NRK cells would generate AHR•ARNT2 dimers as seen with  
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Figure 5.1: Hypothetical model for lack of ARNT2 function in vivo.  Since the 
majority of ARNT2 appears to be constitutively associated with nuclear structures as 
previously described, it is possible that ARNT2 is constitutively associated with other 
PAS proteins or otherwise bound to DNA as a homodimer.  Such an association would 
potentially lead to ARNT2 being inaccessible to heterodimerization with the AHR 
following AHR activation. 
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cytosolic extracts in Figure 4.25.  If excess ARNT2 led to the formation of AHR•ARNT2 
dimers, this would further suggest that AHR remains capable of dimerizing with ARNT2 
and binding DNA in cell culture and that ARNT2 may have an endogenous function that 
impairs its ability to freely associate with the ligand activated AHR in the nucleus.  If 
another nuclear component is preventing the formation of AHR•ARNT2 dimers, then 
additional ARNT2 should eventually swamp out the competitor component allowing for 
heterodimerization with the AHR. Thus, further studies should be performed to assess the 
ability of ARNT2 isolated from nuclear extracts to function during AHR signaling and to 
further identify possible reasons for the difference between in vitro activated cytosolic 
ARNT2 to dimerize with the AHR versus ARNT2 from nuclear extracts. 
Therefore, it would also be important to assess whether protein•protein 
interactions or phosphorylation status of ARNT2 in nuclear extracts was impacting the 
ability of ARNT2 to associate with the AHR.  One of the best available tools to analyze 
the components of protein complexes is mass spectrometry analysis, especially where the 
potential components of these mixtures may be previously unknown.  However, the 
difficulty of such studies tends to stem from the availability or expense of mass 
spectrometry equipment and trained personnel and from the purification of the native 
proteins.  In an attempt to assess the potential interactions of ARNT2, ARNT2 protein 
complexes can be precipitated from cell extracts endogenously expressing ARNT2 either 
by immunoprecipitation techniques as previously described or through affinity 
chromatography, and the components assessed by mass spectrometry.   Tandem affinity 
purification (TAP) of proteins can be performed against proteins tagged with the “TAP” 
tag, which is composed of two IgG binding domains of the Staphylococcus aureus 
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protein A and a calmodulin binding peptide separated by a TEV protease cleavage site 
(Puig et al., 2001).  To achieve purification of ARNT2 complexes, TAP-tagged ARNT2 
from total cell lysates or nuclear extracts can be run through an affinity column coated 
with Staphylococcus aureus protein A IgG beads.  Elution of the proteins is subsequently 
triggered by treatment with TEV protease and the elutant subjected to a second round of 
purification using calmodulin beads and re-eluted following treatment with EGTA.  The 
use of this technique will allow for high yield of protein complexes in their native states.  
With the ability to generate large amounts of these purified complexes, functional studies 
can be performed using these complexes and mass spectrophotometry can be employed to 
identify components of ARNT2 containing complexes.  Furthermore, even without mass 
spectrophotometry, purified ARNT2 containing complexes can be denatured and the 
protein mixtures assessed for potential interactions by Western blotting, including the 
potential presence of AHR in TCDD-treated cells expressing ARNT and/or ARNT2.   
Since this purification technique allows for high-yield purification, this will also increase 
the sensitivity of the previously described studies.  2D-gel analysis or blue-native 2D gel 
analysis can also be used from these purified samples to assess the potential 
phosphorylation status of ARNT2 (or ARNT, AHR) to attempt to determine if such post-
translational modifications may also be playing a role in the regulation of ARNT2 in vivo. 
Additionally, little is known regarding the transformation of the liganded AHR 
complex to the AHR•ARNT dimer and whether the AHR component of an AHR•ARNT 
dimer can dynamically swap its partner protein is entirely unknown.  Since in vitro 
ARNT and ARNT2 have an equal ability to dimerize with TCDD-bound AHR, studies 
could be initiated to analyze the dynamics of AHR transformation using this model 
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system.   For these studies, in vitro activation reactions containing limiting AHR and 
ARNT could be run for 1.5-2 hrs at 30°C as usual; however, after time is allowed for 
initial AHR•ARNT dimerization, ARNT2 could then be added to the activation reactions 
at various time points for an additional 1-2 hours and portions of each activation reaction 
run on an EMSA as previously described using IgG against ARNT or ARNT2 to examine 
AHR•ARNT or AHR•ARNT2 DNA binding.  A portion of each sample could also be 
immunoprecipitated to examine the association of ARNT proteins with the AHR complex.  
In this manner, the question of whether preformed AHR•ARNT dimers could swap 
partners could be assessed, if the level of AHR•ARNT dimerization decreased over time 
in the presence of ARNT2.  However, if this swapping was truly dynamic (ie: AHR could 
dimerize with ARNT, swap with ARNT2, swap again with ARNT, etc.), it would be 
expected that an “equilibrium” would be reached wherein 50% of the total dimers were 
AHR•ARNT and 50% were AHR•ARNT2 as previously shown.  In contrast, if 
preformed dimers could not swap partners, the level of AHR•ARNT DNA binding seen 
initially would remain constant across all samples, and in the presence of limiting AHR, 
no ARNT2 dimerization would be seen.  If the AHR cannot swap partner proteins, it is 
certainly possible that ARNT2 does not associate with the AHR as a result of 
inaccessibility if ARNT2 is associated with other proteins. 
 Thus, the mechanism that underlies the lack of ARNT2 function in AHR-
mediated signaling in vivo is currently undefined.  However, Sekine et al., (2006) have 
hypothesized that ARNT2 does not dimerize with the AHR in vivo because it contains a 
proline and not a histidine residue at amino acid 352 within the PAS B domain.  This 
hypothesis is based on studies in which the histidine at amino acid 378 in the PAS B 
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region of ARNT was mutated to a proline (thus resembling the ARNT2 PAS B domain) 
causing the ARNT to have greatly reduced ability to function in AHR-mediated signaling 
that was similar to that observed with wild type ARNT2.  However, the studies did not 
directly evaluate the role of the P352 in ARNT2 function by converting it a histidine and 
producing a protein capable of functioning in AHR-mediated signaling.  However, 
Sekine et al., (2006) have hypothesized that ARNT2 does not dimerize with the AHR in 
vivo because it contains a proline and not a histidine residue at amino acid 352 within the 
PAS B domain.  This hypothesis is based on studies in which the histidine at amino acid 
378 in the PAS B region of ARNT was mutated to a proline that caused ARNT to have 
reduced ability to function in AHR-mediated signaling.  However, the studies did not 
directly evaluate the role of the P352 in ARNT2 function by converting it a histidine and 
producing a protein capable of functioning in AHR-mediated signaling.  The PAS B 
domain has been implicated in contributing to the heterodimerization potential and 
stability of ARNT and HIF-1α/HIF-2α through interactions occurring via the PAS B 
central B-sheet, and mutations in this region have been suggested to affect the 
transcriptional ability of the overall heterodimer (Card et al., 2005; Erbel et al., 2003).  
Importantly, mutation of P352 to histidine in the mouse ARNT2 did not cause the protein 
to function like ARNT in AHR-mediated signaling when transfected into LA-II cells.  
This may be due to the observation that the PAS A domain is also critical for DNA 
binding and protein-protein interactions and contributes directly to AHR•ARNT XRE 
binding (Chapman-Smith et al., 2004; Pongratz et al., 1998).  Thus, the findings that i) 
ARNT2 containing the P352 can dimerize and form functional complexes with the AHR 
in vitro and ii) ARNT2-H does not restore ARNT-like function in cells, indicate that the 
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reduced function of ARNT2 in vivo is unlikely to be solely related to P352 residue and, 
instead, is likely to involve regulatory mechanisms that are impacting the interaction of 
ARNT2 with the AHR.   
 Since the PAS B proline/histidine residue does not explain the differences 
between the ability of ARNT or ARNT2 to function in AHR signaling, it would also be 
pertinent to assess which domain(s) would.  Thus, swapping of functional domains 
between the ARNT proteins followed by their transfection into LA-II cells and evaluation 
of CYP1A1/reporter gene induction in cell culture following treatment with ligand may 
reveal more information about which regions of ARNT when placed into the ARNT2 
protein would allow ARNT2 to function in AHR mediated CYP1A1 induction.  In doing 
so, it is tempting to believe that the TAD of ARNT versus that of ARNT2 would be the 
key region since this domain shares <42% identity between ARNT proteins, while other 
functional domains share >80% identity.  With this in mind, it is evidently possible that 
ARNT2 may be capable of binding DNA, but not capable of recruiting the necessary 
cofactors for the subsequent transcription of CYP1A1.  However, as described in Chapter 
One, the ARNT domain appears to be dispensable for transactivation by the AHR•ARNT 
complex, though studies in this laboratory indicated that truncated ARNT proteins could 
not functionally substitute for full-length ARNT in LA-II cells (data not shown). 
However, it is also necessary to note that so far, CYP1A1 induction or reporter 
gene activity controlled by XREs from the CYP1A1 promoter have been the primary 
endpoints examined.  Thus, it remains possible that AHR•ARNT2 dimers function, even 
in cell culture, in the regulation of other target genes, perhaps even in the regulation of a 
different set of target genes than AHR•ARNT dimers.  While other AHR•ARNT targets 
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have been identified, such as CYP1A2, CYP1B1, and Glutathione S-transferase-ya, these 
targets are constitutively expressed and assessment of induction/repression is difficult.  
Therefore, an attempt should be made to identify other target genes of AHR•ARNT or 
AHR•ARNT2 dimers.  Such studies could involve microarray screening followed by 
Northern blotting of presumed targets, and subsequent protein evaluation. 
In order to further understand the possible physiological role of ARNT2, it is also 
necessary to evaluate its expression patterns and whether it is coexpressed with ARNT. 
Initial studies of the expression patterns of ARNT and ARNT2 mRNA in mouse 
suggested that ARNT2 had an expression pattern that was restricted to the kidneys and 
central nervous system and this would limit the function of the ARNT2 protein (Hirose et 
al., 1996; Jain et al., 1998).  However, the studies presented in Chapter Four demonstrate 
that while ARNT2 is expressed less ubiquitously than ARNT in the mouse, ARNT and 
ARNT2 protein can be detected in the several tissues including the brain, eye, and kidney, 
heart, spleen and thymus, and in many cell lines from the tissues indicating co-expression 
of these protein isoforms (Figure 4.22 A).  Indeed, a more sensitive antibody may reveal 
expression of ARNT2 in still other tissues.  Interestingly, ARNT2 has been demonstrated 
to be the predominant form of ARNT in several fishes including Fundulus heteroclitus 
and Danio rerio and more recently in the common cormorant, Phalacrocorax carbo (Lee 
et al., 2007; Powell et al., 1999; Tanguay et al., 2000).  Furthermore, ARNT2 protein 
from aquatic species has also been shown to be able to associate with the liganded AHR 
and bind XREs when synthesized in vitro including those from Fundulus heteroclitus, 
Danio rerio and Xenopus laevis, but does not appear to function in vivo (Powell et al., 
1999; Rowatt et al., 2003; Tanguay et al., 2000).  Collectively, these results reveal the 
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importance of studying the function of ARNT2 and demonstrate the ARNT2 protein is 
fully capable of associating with the AHR and binding DNA, but other unknown 
regulatory mechanism(s) or compartmentalization prevent these interactions from 
occurring.  The ability to now have model cell culture lines that for the first time show 
the endogenous co-expression of ARNT and ARNT2 in the same cell, will be key 
systems to further define the function and interaction of these proteins across different 
signaling pathways. 
While the studies described in Chapter Four have focused on the potential role of 
ARNT2 in AHR signaling, the endogenous role of ARNT2 is likely to involve its 
dimerization with other bHLH/PAS proteins.  Since the knockout of ARNT2 results in 
abnormalities of the hypothalamus in the failure to develop neuroendocrine lineages in 
the paraventricular and supraoptic nuclei, similar to the effects seen with knockout of the 
single-minded protein (SIM), the physiological role of ARNT2 appears to be as a 
dimerization partner with SIM (Hosoya et al., 2001; Michaud et al., 2000; Wines et al., 
1998).  Surprisingly, however, while the evaluation of the interactions between SIM and 
ARNT2 have been analyzed via immunoprecipitation, reporter gene studies, and two-
hybrid screens, the target genes regulated by these heterodimers remains unclear.  Since 
ARNT2 appears to play an essential role in development of the hypothalamus, it is 
important that these potential gene targets be assessed.  The first step in these studies 
would be to perform microarray analysis using mRNA extracted from the hypothalamic 
tissue from wild-type or ARNT2-/- mice between ED 8.5-PD 5, when expression of 
ARNT2 appears to be critical for proper development.  An attempt could then be made to 
correlate these changes in gene expression between these tissues to those genes 
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containing the CME enhancer that appears to bind ARNT2•SIM dimers.  Depending on 
the results, further studies could be performed using Northern analyses to examine 
specific gene expression changes or using quantitative real time PCR (qRT-PCR). 
ARNT2 also appears to play a role in hypoxic response, yet the potential 
differences between ARNT and ARNT2 in this role have not been evaluated.  Since 
many of the target genes regulated by HIF-1 are constitutive, particularly in cancer cell 
lines, an optimal means of studying gene regulation by HIF-1α•ARNT or HIF-
1α•ARNT2 dimers will be real time quantitative qRT-PCR.  A compilation of commonly 
used primer sets and specific antibodies used in immunofluorescence and 
immunohistochemical analysis of hypoxic response in several species has been culled 
from the literature base and is given in Appendix B focusing on studies that employed 
cell lines/model systems available to this laboratory.  Unlike gene regulation by 
ARNT2•SIM dimers, a variety of gene targets have been identified for HIF-1α•ARNT 
dimers.  Thus, the ability of ARNT2 to functionally substitute for ARNT or to 
heterodimerize with HIF-1α when co-expressed with ARNT can be evaluated using many 
of the resources available already in this laboratory.   
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Chapter Six 
Materials and Methods 
 
6.1 Materials 
2,3,7,8-tetracholorodibenzo-p-dioxin (TCDD) (≥98% stated chemical purity) was 
obtained from Radian Corp. (Austin, TX) and was solubilized in dimethyl sulfoxide 
(Me2SO).  Benzo[a]pyrene (BAP) (≥96% stated chemical purity) and 3-
methylcholanthrene (3-MC) (≥98% stated chemical purity) were purchased from Sigma 
(St. Louis, MO) and solubilized in dimethyl sulfoxide (Me2SO). 
 
6.2 Buffers 
Phosphate-buffered saline is 0.8% NaCl, 0.02%KCL, 0.14% Na2HPO4, 0.02% 
KH2PO4, pH 7.4.  Gel sample buffer (2X) is 125 mM Tris, pH 6.8, 4% SDS, 25% 
glycerol, 4 mM EDTA, 20 mM dithiothreitol, 0.005% bromophenol blue.  Tris-buffered 
saline is 50 mM Tris and 150 mM NaCl, pH 7.5.  TTBS is 50 mM Tris, 0.2% Tween 20, 
300 mM NaCl, pH 7.5.  TTBS+ is 50 mM Tris, 0.5% Tween 20, 300 mM NaCl, pH 7.5.  
BLOTTO is 5% dry milk in TTBS.  Lysis buffer (2X) is 50 mM HEPES, pH 7.4, 40 mM 
sodium molybdate, 10 mM EGTA, 6 mM MgCl2, and 20% glycerol.  Gel shift buffer (5X) 
is 50 mM HEPES, pH 7.5, 15 mM MgCl2 and 50% glycerol. MENG is MOPS, EDTA, 
NaN3, glycerol.  RIPA is 50 mM Tris, pH 7.4, 150 mM NaCl, and 0.2% NP40. 
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6.3 Cells and Growth Conditions 
Wild-type Hepa-1c1c7 (Hepa-1) mouse hepatoma cells, type II (LA-II) Hepa-1 
variants, human ARPE-19 retinal pigmented epithelium cells, B35 rat central nervous 
system cells, TCMK-1 mouse kidney cells, NRK-49F rat kidney cells, and A498 human 
kidney cells were purchased from the American Type Culture Collection (Manassas, VA).  
The Hepa-1, LA-II, and B35 cells were propagated in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 1.5 g/L sodium bicarbonate and 10% fetal bovine 
serum.  ARPE-19 cells were propagated in a medium containing a 1:1 mixture of DMEM 
and Ham’s F12 medium with 2.5 mM L-glutamine adjusted to contain 15 mM HEPES, 
0.5 mM sodium pyruvate, and 1.2 g/L sodium bicarbonate supplemented with 10% fetal 
bovine serum.  NRK-49F cells were propagated in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 1.5 g/L sodium bicarbonate and 5% bovine calf serum.  
TCMK-1 cells were propagated in Minimal Essential Medium (MEM) with 2 mM L-
glutamine with Earle’s BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-
essential amino acids and 1.0 mM sodium pyruvate with 10% fetal calf serum.  A498 
cells were propagated in RPMI medium with 10% fetal calf serum.  All cells were 
passaged at 3-4 day intervals and were used in experiments during a 2-month period at 
approximately 70-90% confluence.  For treatment regiments, TCDD was administered 
directly into growth medium for the indicated incubation times.  
 
6.4 Antibodies 
Specific antibodies against the AHR (A-1) and ARNT (R-1) were identical to 
those described previously (Holmes and Pollenz, 1997; Pollenz et al., 1994).  All 
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antibodies are affinity-purified IgG fractions.  Monoclonal mouse antibodies against the 
V5 epitope were purchased from Invitrogen (Carlsbad, CA). Polyclonal mouse antibodies 
against ARNT2 and CYP1A1 were purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA).  Polyclonal rabbit B-actin antibodies were purchased from Sigma (St. Louis, 
MO).   
 
6.5 Generation of Expression Constructs 
Numerous expression constructs were generated in order to obtain the results 
described in this report.  The primer sets that were used are listed below and are grouped 
according to the type of construct that was generated and are listed by primer name 
containing the species, target DNA sequence, direction of primer (5’ or 3’), and 
restriction site if applicable.  Mutagenesis primers are listed as mut for or mut rev (for 
forward or reverse).  TOPO cloning primers are listed as T/A.  Site-directed mutagenesis 
was performed using the Quikchange II XL site-directed mutagenesis kit as per the 
manufacturer's protocol (Stratagene). 
 
AHR NH-terminal tags 
 
HM mouse AHR 5’HindIII 5’-TTTTAAGCTTACCACCATGGGGGGTTCTCATCAT 
HM mouse AHR 5’MluI 5’-TTTTACGCGTACCACCATGGGGGGTTCTCATCAT 
GFP-mouse AHR 5’StuI 5’-TTTTAGGCCTGCCACCATGGTGAGCAAGGGCGA 
GGAG 
GFP-mouse AHR 3’ClaI 5’-TTTTATCGATTCAACTCTGCACCTTGCTTAGGAA 
TGC 
 
AHR constructs 
 
mouse AHR b2-3’ HindIII      5’-CAATAAGCTTCTACAGGAATCCACCAGG 
human AHR-3’ HindIII 5’-CAATAAGCTTTTACCAGGAATCCACTGGATG 
human AHR-5’ XhoI  5’-CAATCTCGAGCACCATGAACAGCAGCAGCGCC 
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rat AHR-3’ HindIII  5’-CAATAAGCTGAGCTACAGGAATCCGCTGGG 
rat AHR-5’ XhoI  5’-CAATCTCGAGGCACCATGAGCAGCGGCGCC 
rat/b1/b2 AHR-5’ XhoI 5’-CAATCTCGAGGCACCATGAGCAGCGGCGCCA 
ACATC 
mouse trAHR 5’XhoI  5’ATATCTCGAGCCACCATGGGGCTGAACACAGAG 
TTAGAC 
mouse AHR 5’HpaI  5’-CAATGTTAACCCACCATGAGCAGCGGCGCCAA 
CATC 
mouse AHR 3’XhoI  5’-CAATCTCGAGTCAACTCTGCACCTTGCTTA 
mouse AHR b2 3’XhoI 5’-CAATCTCGAGCTACAGGAATCCACCAGGTGT 
rat AHR 3’XhoI  5’-CAATCTCGAGCTACAGGAATCCGCTGGGTGT 
human AHR 5’HpaI  5’-CAATGTTAACCCACCATGAACAGCAGCAGCG 
CCAAC 
human AHR 3’XhoI  5’-CAATCTCGAGTTACAGAATCCACTGGATGT 
mouse AHR R39A mut for   5’-CAAATCCTTCTAAGCGACACGCAGACCGGCTGA 
ACACAGAG 
mouse AHR R39A mut rev     5’-CTCTGTGTTCAGCCGGTCTGCGTGTCGCTTAGAA 
GGATTTG 
mouse AHR b2 3’XhoI 5’-CAATCTCGAGTCAGCAGCGGCGCCAACATC 
mouse AHR b2 5’HindIII 5’-CAATAAGCTTTCAGCAGCGGCGCCAACATC 
mouse AHR b2/rat 5’HindIII 5’-CAATAAGCTTATGAGCAGCGGCGCCAACATC 
mouse AHR b2 3’ClaI 5’-CAATATCGATCTACAGAATCCACCAGG 
rat AHR 3’ClaI  5’-CAATATCGATCTACAGGAATCCGCTGG 
human AHR 5’HindIII 5’-CAATAAGCTTATGAACAGCAGCAGCGCC 
human AHR 3’ClaI  5’-CAATATCGATTTACAGGAATCCACTGGATG 
mouse AHR 5’AgeI  5’-CAATACCGGTATGAGCAGCGGCGCCAACATC 
mouse AHR 3’PacI  5’-CAATTTAATTAATCAACTCTGCACCTTGCTTAG 
mouse AHR b2 3’PacI 5’-CAATTTAATTAACTACAGGAATCACCAGGTGTG 
rat AHR 3’PacI  5’-CAATTTAATTAACTACAGGAATCCGCTGGGTGT 
G 
human AHR 3’PacI  5’-CAATTTAATTAATTACAGGAATCCACTGGATG 
 
 
ARNT and ARNT2 studies 
 
mouse AHR 3’T/A  5’-TCAACTCTGACACCTTGCTTAG 
mouse AHR 5’T/A  5’-ATGAGCAGCGGCGCCAACATC 
mouse ARNT2 5’-T/A 5’-GCAACCCCGGCCGCCGTCAAC 
mouse ARNT2 3’-T/A 5’-CTACTCAGAAAATGGAGGGAA 
mouse ARNT2 3’SalI  5’-TTTGTCGACCTACTCAGAAAATGGAGGGA 
mouse AHR b2 3’-T/A 5’-CTACAGGAATCCACCAGGTGT 
mouse AHR 3’Stu  5’-CAATAGGCCTTCAACTCTGCACCTTGCTTAG 
mouse AHR b2 3’Stu  5’-CAATAGGCCTCTACAGAATCCACCAGGTGT 
mouse ARNT2 5’XhoI 5’-CAATCTCGAGACCACCATGGCAACCCCGGCCG 
CCGTCAAC 
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mouse ARNT2 3’BamH1mut 5’-CAATGGATCCAATTCCGAAGGCAGATGACTG 
mouse ARNT2 5’BamHI mut 5’-CAATGGATCCAGCCACCCTTACCCGGCTGAC 
mouse ARNT2 3’HindIII 5’-CAATAAGCTTCTACTCAGAAAATGGAGGGAACA 
TGCCCAG 
mouse ARNT V5 2nd half  5’-CCTAACCCTCTCCTCGGTCTCGATTCTACGGCGG 
CGACTACAGCTAACCCAG 
5’Universal V5 half XhoI 5’-CAATCTCGAGCCACCATGGGTAAGCCTATCCCT 
AACCCTCTCCTCGGTCTC 
mouse ARNT2 V5 2nd half 5’-CCTAACCCTCTCCTCGGTCTCGATTCTACGGCAA 
CCCCGGCCGCCGTCAAC 
mouse ARNT 503 3’HindIII 5’-CAATAAGCTTCTAGCTGGCCAGCCCATCTCTTC 
CTG 
mouse ARNT 450 3’HindIII 5’-CAATAAGCTTTTACTGGCTAGAGTTCTTCACAT 
TGGTGTTGG 
mouse ARNT2 3’HindIII 5’-CAATAAGCTTCTACTCAGAAAATGGAGGGAACA 
TGC 
5’V5 Universal AgeI  5’-CAATACCGGTCCACCATGGGTAAGCCTATCCC 
TAAC 
mouse ARNT 3’EcoR1 5’-CAATGAATTCCTATTCGGAAAAGGGGGGAAAC 
ATAGTTAG 
mouse ARNT2 3’EcoR1 5’-CAATGAATTCCTACTCAGAAAATGGAGGGAACA 
TGC 
5’V5 Universal HindIII 5’-CAATAAGCTTGCACCATGGGTAAGCCTATCC 
mouse ARNT 3’ClaI  5’-CAATATCGATCTATTCGGAAAACGGTGGAAACA 
TAGTTAG 
mouse ARNT2 3’ClaI  5’-CAATATCGATCTACTCAGAAAATGGAGGGAAC 
ATGC 
V5 2nd half human ARNT 5’-CCTAACCCTCTCCTCGGTCTCGATTCTACGGC 
GGCGACTACTGCCAACC 
human ARNT 3’HindIII 5’-CAATAAGCTTCTATTCTGAAAAGGGGGGAAAC 
ATAGTTAG 
human ARNT 3’PacI  5’-CAATTTAATTAACTATTCTGAAAAGGGGGAAAC 
ATAGTTAG 
hARNT 378P mut for  5’-CTTCACTTTTGTGGATCCCCGCTGTGTGGCTA 
CTG 
hARNT 378P mut rev  5’-CAGTAGCCACACAGCGGGGATCCACAAAAGTG 
AAG 
mARNT2 352H mut for 5’-ACGTTTGTGGACCACAGATGCATCAGTGTG 
mARNT2 352H mut rev 5’-CACACTGATGCATCTGTGGTCCACAAACGTG 
 
For the mouse ARNT2 construct, no full length ARNT2 cDNA was available,  
however, two cDNA fragments were obtained one of which contained the carboxy-
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terminal portion of ARNT2 (Sogawa fragment) while one contained the full length 
ARNT2 with a 10 amino acid insertion contained within the carboxy-terminal region 
(Simon clone).  This second clone is believed to be an ARNT2 splice variant since a 
similar variant in the rat possesses an identical insert in this region (Drutel et al., 1996).  
To evaluate the full-length ARNT2 clone as published in GenBank, the amino terminal 
portion of the Simon clone was amplified using the following primers: mouse ARNT2 
3’BamH1mut 5’-CAATGGATCCAATTCCGAAGGCAGATGACTG and mouse 
ARNT2 5’BamHI mut 5’-CAATGGATCCAGCCACCCTTACCCGGCTGAC.  The 
amplicon was then ligated to the carboxy-terminal portion of the Sogawa clone after 
mutagenesis reactions were performed to create a BamH1 site within each construct.  
Using this BamH1 site, each amplified region was ligated together and cloned into 
pcDNA 3.1- for further studies.  The full-length ARNT2 construct was then sequenced to 
test for accuracy of the construct. 
For the V5-tagged constructs, each of the coding regions from ARNT and 
ARNT2 was ligated into a pcDNA 3.1(-) vector allowing each of the full-length untagged 
proteins to be expressed.  V5 tagged ARNTs were also generated.  For these expression 
constructs, the V5 epitope (GKPIPNPLLGLDST) was added to the coding region of each 
ARNT by sequential PCR along with XhoI and HindIII sites allowing the resultant PCR 
product to cloned into pcDNA 3.1(-).  The following forward primers were used for 
ARNT: 5'CCTAACCCTCTCCTCGGTCTCGATTCTACGGCGGCGACTACAGCTAA 
CCCAG and 5'CAATCTCGAGCCACCATGGGTAAGCCTATCCCTAACCCTCTCCT 
CGGTCTC. The reverse primer for ARNT was 5’CAATAAGCTTCTATTCGGAAAAG 
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GGGGGAAACATAGTTAG.  For the V5 tag of ARNT2, the following forward primers 
were used: 5’-CCTAACCCTCTCCTCGGTCTCGATTCTACGGCAACCCCGGCCGC 
CGTCAAC and 5’-CAATCTCGAGCCACCATGGGTAAGCCTATCCCTAACCCTCT 
CCTCGGTCTC. The reverse ARNT2 primer was 5’-CAATAAGCTTCTACTCAGAAA 
ATGGAGGGAACATGC.  Transcription start and stop sites are underlined. 
 
6.6 In Vitro Expression of Protein 
Recombinant protein was produced from expression constructs using the TNT 
Coupled Reticulocyte Lysate System essentially as detailed by the manufacturer 
(Promega, Madison, WI).  Upon completion of the 90-min reaction, a portion of the 
sample was combined with an equal volume of 2X gel sample buffer and boiled for 5 min 
for Western blotting and the remaining portion stored at -80°C for use in functional 
studies. 
 
6.7 Transient Transfection       
LA-II cells were seeded at 1.5-2.2x105 cells/well onto 35 mm dishes and 
propagated overnight.  A cocktail containing 3-6 μg ARNT expression vector and 22 μl 
LipofectAMINE™ (Gibco) transfection reagent was prepared in 1.3 mL of serum-free 
DMEM.  This volume was sufficient for transfecting 6 dishes with the same pool of 
DNA/transfection reagent and the transfection was carried out according to the 
manufacturer’s instructions.  After a 6-8 h transfection period, medium from each well 
was replaced with fresh medium containing FBS or an equal volume of 20% FBS 
medium was added to each well to yield an overall 10% FBS DMEM culture medium.  In 
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either case, cells were allowed to recover for 16 h prior to experimental treatments.  Cells 
were then harvested from plates and processed as detailed below.  WT Hepa-1 cells were 
similarly transfected using 3-6 μg expression vector and 15 μl LipofectAMINE™. 
 
6.8 Viral Infections and Selection. 
For stable cell generation, 1x105 PT67 viral packaging cells were plated onto 
35mm plates or 8.2x105 PT67 cells were plated onto 100mm plates and each well/plate 
transiently transfected with one of the retroviral constructs.  The cells were grown for 24 
hours during which time, the viral packaging cells created infectious, but replication-
incompetent virus, resulting in the creation of high-titer viral media.  After this time, the 
viral media was harvested, sterile filtered through a 0.45-um filter and aliquots of viral 
media used immediately for infection of target cells or frozen at -80°C for future 
experimentation.  Target cells plated at 7.5x104 – 1.0x105 cells on 35 mm plates or 6-
8x105 cells on 100mm plates in normal culture media were then washed and cultured 
with 1000ul of the viral media containing limiting amounts of packaged virus.  Based on 
infection efficiency judged by the number of colonies formed following infection, some 
repeated experiments included a second day of infection using another 1000ul of viral 
media.  In either case, 48 hours after the initial infection, the cells were harvested by 
trypsinization and plated onto 150mm plates in the presence of 800μg/ml of G418 for 
selection.  This concentration has already been confirmed as being fatal to the cultured 
cells being evaluated herein.  After 7-14 days of growth, colonies were chosen and 
harvested via sterile cloning disks onto 15mm culture plates still in the presence of G418 
selection media.  One disk was placed into each 15mm plate to allow for the growth of a 
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clonal population and the continued use of G418 will allow for a second round of 
selection.  At 90% confluence, the cells will be harvested and propagated onto 35mm 
plates and allowed to continue to propagate until cell populations can be frozen in liquid 
nitrogen and evaluated for expression of the gene of interest.  Previous experiments in the 
lab indicated that cells grown in this manner are typically a homogenous population in 
which >80% express the protein of interest.  Populations expressing inconsistent levels of 
the target protein in comparison to wild-type cells or inconsistencies in molecular mass 
were discarded.  If all lines exhibited identical responses, 1-2 lines were selected for the 
analyses listed.  Deviations among the cells resulted in characterization of other clones to 
identify the consensus response. 
 
6.9 Luciferase Reporter Studies   
 LA-II cells were transfected with the ARNT expression constructs as well as 
pSV- B-Galactosidase and GudLuc 1.1 plasmids and treated with Me2SO or TCDD for 6 
hours (Garrison and Denison, 2000).  The luciferase reporter assay was then performed 
according to the protocol dictated by the manufacturer (Promega, Madison, WI).  All 
luciferase values were then normalized to B-Galactosidase as a transfection efficiency 
control. 
 
6.10 RNA Interference 
 Annealed small interfering RNA (siRNA) complexes containing 21-bp regions of 
identity to regions of the murine XAP2 or an annealed 21-bp RNA to sequence not 
present in the mouse genome (siRNA control) were purchased from Ambion (Austin, TX). 
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siRNA (final concentration of 50–100 nM) was transfected into 35-mm dishes containing 
1–2 x 105/cells using LipofectAMINE™  reagent (Gibco). 36–48 h after transfection, cells 
were treated as detailed in the figure legends, and total cell lysates were harvested for 
Western blotting. The efficiency of siRNA gene knockdown was determined by Western 
blotting. Transfection efficiency was monitored by microscopy using fluorescein 
isothiocyanate-labeled RNA (Clontech). In general, transfection efficiency in all 
experiments was >85%. 
 
6.11 Immunofluorescence Staining and Microscopy 
 All immunohistochemical procedures (cell plating, fixation, and staining) were 
carried out as previously described (22-24). Dry, autoclaved coverslips were charged with 
0.01% sterile poly-lysine.  These coverslips were then placed in 35mm cell culture plates 
and cells were cultured directly onto the slips in appropriate medium.  The slips were 
then fixed with 4% paraformaldehyde (pH 7.4) and ice-cold methanol.  Slips were stained 
using the A-1A AHR IgG (2.8μg/ml) in BSA/PBS/Histidine buffer, washed with 
TTBS/TTBS+ and stained with a GAR-Rhodamine secondary antibody (1:200).  Cells 
were observed on an Olympus IX70 microscope. On average, 15–20 fields (5–20 cells 
each) were evaluated on each coverslip, and 3–4 fields were photographed with a digital 
camera at the same exposure time to generate the raw data. Nuclear fluorescence 
intensities of 25–50 cells in three distinct fields of view were obtained using MicroSuite 
image analysis software (Olympus America Inc.). 
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6.12 Preparation of Total Cell/Tissue Lysates 
After treatment, cell monolayers were washed twice with PBS and detached from 
plates by trypsinization (0.5% trypsin/0.5 mM EDTA).  Cell pellets were then washed 
with PBS and suspended in 50 to 100 μl of ice-cold 2X lysis buffer supplemented with 
Nonidet P-40 (0.5%), leupeptin (10 μg/ml), and aprotinin (20 μg/ml).  Cell suspensions 
were immediately sonicated for 5 s, supplemented with phenylmethylsulfonyl fluoride 
(PMSF, final concentration, 100 μM), and sonicated for an additional 5 s.  For total tissue 
lysates, frozen tissue samples were weighed and 200-750ul of 2x lysis buffer 
supplemented with Nonidet P-40 (0.5%), leupeptin (10 μg/ml), and aprotinin (20 μg/ml) 
was added to each sample depending on tissue sample size.  Samples were then sonicated 
for 10-20 s, supplemented with PMSF, and sonicated for an additional 10-20 s.  For either 
total cell or total tissue lysates, following sonication, a small portion of the lysate was 
then removed for protein determination, and the remainder was combined with an equal 
volume of 2X gel sample buffer, vortexed, and immediately heated for 5 min at 100°C.  
Samples were then sonicated for an additional 5 s and stored at -20°C or -70°C.  Protein 
concentrations were determined by the Coomassie Blue Plus assay (Pierce, Rockford, IL) 
with bovine serum albumin as the standard. 
 
6.13 Preparation of Cytosol and Nuclear Extracts   
Cell monolayers were washed twice with PBS and detached from plates by 
trypsinization (0.5% trypsin/0.5 mM EDTA).  Cell pellets were then washed with PBS 
and suspended in 1000 ul of ice-cold MENG. Lysis was carried out by homogenization in 
small glass dounce vessels using 30-50 strokes or by vortexing for 30 s in 1% Nonidet P-
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40 lysis buffer.  Samples were then centrifuged at 5,000 rpm for 2 min at 4°C.  The 
supernatant was then removed for protein determination or combined with an equal 
volume of 2X gel sample buffer and boiled for 5 min for Western blotting to assess 
protein expression. Nuclei were then washed twice with 0% Nonidet P-40 lysis buffer 
and extraction performed with MENG supplemented with 400 mM KCl for 30 min, 
vortexing periodically.  Samples were then centrifuged at 14,000 rpm for 15 min at 4°C.  
Nuclear extracts were then dialyzed in 4L of MENG at 4°C for 2 h in Slide-A-Lyzer® 
Mini Dialysis Units (Pierce) according to the manufacturer’s instructions.  The 
supernatant was then removed for protein determination or combined with 2X gel sample 
buffer and boiled for 5 min for Western blotting to assess protein expression.  The 
remaining sample was stored at -80°C until analysis.  Protein concentrations were 
determined by the Coomassie Blue Plus assay (Pierce, Rockford, IL) with bovine serum 
albumin as the standard.   
 
6.14 Western Blot Analysis and Quantification of Protein 
 Protein samples were resolved by denaturing electrophoresis on discontinuous 
polyacrylamide slab gels (SDS-PAGE) and were electrophoretically transferred to 
nitrocellulose.  Immunochemical staining was carried out with varying concentrations of 
primary antibody (figure legends) in BLOTTO buffer supplemented with DL-histidine 
(20 mM) for 1 hour at 22°C.  Blots were washed with three changes of TTBS or TTBS+ 
for a total of 45 min.  The blot was then incubated in BLOTTO buffer containing a 
1:10,000 dilution of goat anti-rabbit- or goat anti-mouse-HRP secondary antibodies for 1 
h at 22°C and washed in TTBS or TTBS+ as above.  Before detection, the blots were 
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washed in PBS for 5 min.  Bands were visualized with the enhanced chemiluminescence 
(ECL) kit as specified by the manufacturer (Amersham Biosciences, Piscataway, NJ).  
Multiple exposures of each set of samples were produced.  The relative concentration of 
target proteins were determined by computer analysis of the autoradiographs as detailed 
previously (Pollenz, 1996; Sojka et al., 2000). 
 
6.15 In Vitro Activation of AHR•ARNT Complexes and Electrophoretic Mobility Shift 
Assays 
50 ug of cytosol or approximately equal amounts of in vitro translated ARNT or 
ARNT2, as determined by quantitative Western blotting, were mixed with in vitro 
translated AHR and combined with 25 mM MOPS, 10 mM EDTA, and 10% glycerol 
buffer in a reaction of a total volume proportionate to the number of samples being 
evaluated such that each sample being evaluated was taken from a pooled total reaction 
and therefore represents identical samples.  Each sample was then supplemented with 
TCDD (170 nM), 3-MC (54 uM), BAP (1.7 uM) or Me2SO (0.5%) and incubated at 30°C 
for 2 h. To examine specificity of binding, 50-100 ng of antibodies against AHR, ARNT, 
or ARNT2 were also included in the activation reactions.  For EMSA, double-stranded 
fragments corresponding to the consensus XREs A, B, C, D, E and F of the murine 
CYP1A1 promoter have been described previously (Shen and Whitlock, 1992).  XRE 
duplexes corresponding to the six XREs of the murine CYP1A1 promoter as described by 
(Lusska et al., 1993) were purchased from Integrated DNA Technologies, Inc. (Coralville, 
IA). Approximately 4 ng of each 32P-labeled XRE was added to each sample, and the 
incubation continued for an additional 15 min at 22°C. The samples were then resolved 
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on 5% acrylamide/0.5% 45 mM Tris-borate and 1 mM EDTA gels, dried, and exposed to 
film.  A portion of the activated samples were also combined with an equal volume of 2X 
gel sample buffer and boiled for 5 min for Western blotting to assess protein expression.  
The relative DNA binding intensity of EMSA samples were determined by computer 
analysis of the EMSA autoradiographs as detailed previously (Pollenz, 1996; Sojka et al., 
2000). 
Oligo duplexes used in the EMSA reaction are given below showing the two 
guanine residue overhang used for [32P]-dCTP labeling.  Core sequences are bolded and 
mutated residues underlined. 
 
mXRE A 
5’-GGCCAAGCTCGCGTGAGAAGCG-3’ 
      3’-GGTTCGAGCGCACTCTTCGCGG-5’ 
 
mXRE B 
5’-GGGCTTGGCACGCACACAGGTT-3’ 
      3’-CGAACCGTGCGTGTGTCCAAGG-5’ 
 
mXRE C 
5’-GGGAGGCTAGCGTGCGTAAGCC-3’ 
      3’-CTCCGATCGCACGCATTCGGGG-5’ 
 
mXRE D wild-type 
5’-GGCCGGAGTTGCGTGAGAAGAG-3’ 
      3’-GGCCTCAACGCACTCTTCTCGG-5’ 
 
mXRE D mutant 
5’-GGCTCTTCTCGCGTAACTCCGG-3’ 
     3’-GAGAAGAGCGCATTGAGGCC-5’ 
 
mXRE E 
5’-GGAGTGCTGTCACGCTAGCTGG-3’ 
      3’-TCACGACAGTGCGATCGACCGG-5’ 
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mXRE F 
5’-GGCCGGGTTTGCGTGCGATGCT-3’ 
      3’-GGCCCAAACGCACGCTACGAGG-5’ 
 
E-box wild-type 
5’-GGCCCGGTCACGTGGCCTACG-3’ 
      3’-GGGCCAGTGCACCGGATGCGG-5’ 
 
E-box mutant 
5’-GGCCCGGTCGCATGGCCTACG-3’ 
      3’-GGGCCAGCGTACCGGATGCGG-5’ 
 
 
 
 
6.16 Immunoprecipitations 
  For the immunoprecipitations, 30 ul of in vitro translated AHR, ARNT, or 
ARNT2 were precipitated in RIPA buffer supplemented with bovine serum albumin (20 
μg/ml), histidine (20 mM), 1 μg specific or pre-immune IgG and 15 ul Protein A/G 
agarose (Pierce) for 2 hours at 4°C.  Pellets were washed with 800 ul TTBS three times 
for 10 minutes at 4°C and protein eluted by boiling in 30 ul SDS sample buffer.  Samples 
were centrifuged at 14,000 rpm and the supernatant resolved by SDS-PAGE and Western 
blotting as described above.  
 
6.17 Statistical Analysis 
Statistical analysis was carried out using InStat software (GraphPad Software Inc., 
San Diego, CA). 
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Appendix A: Endogenous AHRb-2 data 
 
 
The following figures (A-1 through A-7) were generated by Dr. Richard S. 
Pollenz and come from the publications: Pollenz RS, Wilson SE, Dougherty EJ (2006) 
Role of endogenous XAP2 protein on the localization and nucleocytoplasmic shuttling of 
the endogenous mouse Ahb-1 receptor in the presence and absence of ligand. Mol 
Pharmacol. 70:1369-79 and Pollenz RS, Dougherty EJ (2005) Redefining the role of the 
endogenous XAP2 and Carboxy-terminal hsp70-interacting protein on the endogenous 
Ah receptors expressed in mouse and rat cell lines. J Biol Chem. 280:33346-56.  These 
figures are included since they will aid the reader in interpreting the studies performed in 
Chapter Two, particularly in the comparison between endogenous Ahb-2 receptor function 
and that of Ahb-2 receptor in the Ahb-1 genetic background described in Chapter Two. 
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Appendix A: (Continued) 
 
 
 
Figure A-1: Analysis of AHR and XAP2 expression and association in Hepa-1, A7,  
and C2C12 cells. A, equal amounts of total cell lysates from the indicated cells were 
resolved by SDS-PAGE, blotted, and stained with A-1A rabbit IgG (1.0 µg/ml), -actin 
rabbit IgG (1:1000), hsp90 rabbit IgG (1:500), XAP2 mouse IgG1 (1:750), or p23 mouse 
IgG (1:1000). Reactivity was visualized by ECL with GAR-HRP or GAM-HRP IgG 
(1:10,000). B, cytosol was prepared from Hepa-1, A7, or C2C12 cells as detailed in 
Chapter Six.  800 µg of cytosol was precipitated with either affinity-pure A1-A IgG (5 µg) 
or affinity-pure preimmune rabbit IgG (5 µg) along with Protein A/G-agarose (25 µl) for 
2.5 h at 4 °C with rocking. Pellets were washed three times for 5 min each with TTBS 
supplemented with sodium molybdate (20 mM) and then boiled in 30 µl of SDS sample 
buffer. 15 µg of cytosol (input) or 15 µl of the eluted protein were resolved by SDS-
PAGE, blotted, and stained with A-1A IgG (1.0 µg/ml) or XAP2 mouse IgG1 (1:750). 
Reactivity was visualized by ECL with GAR-HRP or GAM-HRP IgG (1:10,000). He, 
Hepa-1; C2, C2C12; Ah, precipitated with A1-A IgG; Pi, precipitated with preimmune 
IgG. The numbers under the XAP2 blot represent the percentage of XAP in relation to the 
level in Hepa-1 (100%).  The precipitated IgG band is shown to demonstrate the 
uniformity of the precipitation across all samples.    
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Appendix A: (Continued) 
 
Figure A-2: Subcellular localization of AHR in Hepa-1, A7, C2C12, and 10T1/2 cells 
exposed to TCDD or LMB. Cells were grown on glass coverslips exposed to the 
compounds detailed below and then fixed as detailed previously (Holmes and Pollenz, 
1997; Pollenz, 1996; Pollenz et al., 1994). Coverslips were incubated with A-1 IgG (1.0 
µg/ml) and visualized with GAR-Rhodamine IgG (1:400). A–D, Hepa-1 cells exposed to 
methanol (0.5%) for 4 h (A), TCDD (2 nM) for 1 h (B), LMB (20 nM) for 2 h 
(C),orLMBfor 4 h (D). E–H, C2C12 cells exposed to methanol (0.5%) for 4 h (E), TCDD 
(2 nM) for 1 h (F), LMB (20 nM) for 2 h (G), or LMB for 4 h (H). Panels I–L, A7 cells 
exposed to methanol (0.5%) for 4 h (I), TCDD (2 nM) for 1 h (J), LMB (20 nM) for 2 h 
(K), LMB for 4 h (L). M–P, 10T1/2 cells exposed to methanol (0.5%) for 4 h (M), TCDD 
(2 nM) for 1 h (N), LMB (20 nM) for 2 h (O),or LMB for 4 h (P). Each set of four panels 
was exposed for identical times. Bar (A), 10 µm. 
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Appendix A: (Continued) 
 
 
 
 
Figure A-3: Reduction of endogenous XAP2 by siRNA knockdown in Hepa-1 cells. 
A, Hepa-1 cells were transfected with siRNA specific to XAP2 or control siRNA as 
detailed in Chapter Six. Forty-eight hours later, cytosol was prepared, and 600 µg was 
precipitated with either AHR (Ah-IgG) or preimmune IgG (Pi-IgG) as detailed in 
Chapter Six. Each of the precipitated samples as well as 15 µg of cytosol (input) was 
resolved by SDS-PAGE and blotted. Blots were stained with either 1.0 µg/ml A-1A IgG 
or XAP2 mouse IgG1 (1:750), and reactivity was visualized by ECL with GAR-HRP or 
GAM-HRP IgG (1:10,000). The IgG bands are presented to show the consistency of the 
precipitations. C, cells transfected with control siRNA; X, cells transfected with XAP2 
siRNA. B, computer densitometry was used to determine the relative level of AHR or 
XAP2 protein present in the precipitated samples presented on the blot in A. Each 
column represents the relative densitometry units of an individual band and shows that 
the ratio of XAP2/AHR has changed in the siXAP samples. Ah, level of AHR protein; 
mX, level of XAP2 protein. 
 
 
 
 
 
 270
Appendix A: (Continued) 
 
 
 
Figure A-4: Subcellular localization of AHR in cells with reduced levels of XAP2. 
Hepa-1 cells were transfected with siRNA specific to XAP2 or control siRNA along with 
FITC-labeled RNA (BLOCK-IT) as detailed in Chapter Six. Forty-eight hours later, cells 
were treated with either 0.1% methanol or 1 nM LMB for 4 h and either fixed for 
immunofluorescence microscopy or harvested for the preparation of total cell lysates. A, 
Western blot of AHR and XAP2 expression in total cell lysates prepared from cells 
transfected with siCON or XAP2 siRNA (siXAP). B, cells were visualized for AHR. 
Fixed cells were stained with 1.0 µg/ml A-1 IgG and visualized with GAR-RHO IgG 
(1:400). The FITC-labeled panels represent the exact fields presented to the left and 
illustrate the transfection efficiency of the experiment. Scale bar, 10 µm. 
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Figure A-5: Association of endogenous XAP2 with AHR in Hepa-1 cells transfected 
with hXAP2 expression vectors. Hepa-1 cells were transfected with pCI-hXAP2 or 
control vector pcDNA3.1 as detailed in Chapter Six. After 24 h, populations of cells were 
harvested, and cytosol was generated for immunoprecipitation experiments. A, 600 µg of 
cytosol from the indicated samples was precipitated in duplicate with either AHR (AHR-
IgG) or preimmune IgG (Pi-IgG) as detailed in Chapter Six. Each of the precipitated 
samples as well as 15 µg of cytosol (input) was resolved by SDS-PAGE and blotted. 
Blots were stained with either 1.0 µg/ml A-1A IgG or XAP2 mouse IgG1 (1:750), and 
reactivity was visualized by ECL with GAR-HRP or GAM-HRP IgG (1:10,000). mXAP2, 
endogenous mouse XAP2; hXAP2, exogenous human XAP2; and AHR (AHR). The IgG 
bands are presented to show the consistency of the precipitations. C, samples from cells 
transfected with pcDNA3.1; X, samples from cells transfected with pCI-hXAP2. B, 
computer densitometry was used to determine the relative level of AHR or XAP2 protein 
present in the precipitated samples presented on the blot in A. Each column represents the 
relative densitometry units of an individual band and can be used to evaluate differences 
in the ratio of XAP2/AHR in the different samples. However, because of the difference in 
the sensitivity of each antibody for its target protein, the ratio does not represent the 
absolute number of protein molecules. Note that the XAP2/AHR ratio is essentially 
unchanged in all the samples.  The precipitated IgG band is shown to demonstrate the 
uniformity of the precipitation across all samples.    
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Figure A-6: Localization of endogenous Ahb-1 receptor in Hepa-1 cells expressing 
hXAP2. Hepa-1 cells were transfected with pCI-hXAP2 along with FITC-labeled RNA 
(BLOCK-IT), pEYFP-XAP2-FLAG, or control vector pCDNA3.1 as detailed in Chapter 
Six. After 24 h, populations of cells were either harvested for the generation of total cell 
lysates or fixed for immunocytochemical staining. A, equal amounts of the indicated 
samples were resolved by SDS-PAGE and blotted. Blots were stained with either 1.0 
µg/ml A-1A IgG, XAP2 mouse IgG1 (1:750), or anti-actin IgG (1:1000), and reactivity 
was visualized by ECL with GAR-HRP or GAM-HRP IgG (1:10,000). Con, cells 
transfected with pcDNA3.1; +XAP, cells transfected with pCI-hXAP2 and BLOCK-IT; 
+Y-XAP, cells transfected with pEYFP-hXAP2-FLAG. B, exact Hepa-1 populations that 
were transfected as detailed in A were fixed and stained for the AHR with 1.0 µg/ml A-1 
IgG and visualized with GAR-RHO IgG (1:400). Con AHR, AHR staining pattern in 
cells transfected with pcDNA3.1; AHR + hXAP2, AHR staining pattern in cells 
transfected with pCI-hXAP2 and BLOCK-IT; FITC, FITC labeling of the exact field 
presented to the left to illustrate the transfection efficiency of the experiment; YFP-XAP2, 
pattern of the expressed EYFP-XAP2-FLAG; AHR, AHR staining pattern of the exact 
field presented to the left. The arrows indicate cells that are not expressing the EYFP-
XAP2-FLAG protein. Scale bar, 10 µm. 
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Figure A-7: Western blot analysis of AHR in Hepa-1, A7, and C2C12 cells exposed 
to TCDD. A, Hepa-1, A7, and C2C12 cells were exposed to Me2SO (0.1%) for 2 h or 
TCDD (2 nM) for the indicated times. Equal amounts of total cell lysates were then 
resolved by SDS-PAGE, blotted, and stained with A-1A IgG (1.0 µg/ml) and -actin IgG 
(1:1000). Reactivity was visualized by ECL with GAR-HRP IgG (1:10,000), and bands 
were quantified and normalized as detailed (Holmes and Pollenz, 1997; Pollenz, 1996; 
Pollenz et al., 1994). B, the level of AHR protein at each time point was divided by the 
corresponding level of actin, and the average ± S.E. of the three independent samples was 
plotted as a function of the time 0 control. The error bars on some of the later time points 
are within the symbol used to show the data point. *, statistically different from the  
Hepa-1  
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Appendix B: Hypoxia qRT-PCR Primer sets 
 
 
 
The following lists qRT-PCR primer sets (forward and reverse) and antibodies 
that have been used in analyzing hypoxic response in several cell lines.  These data were 
complied from several publications, whose references are listed above each data set, and 
are further subdivided by the species and cell line being examined.  Amplicon sizes for 
PCR products are given where known.  Target genes are abbreviated as follows: HIF-1α, 
hypoxia-inducible factor-1 α; VEGF, vascular endothelial growth factor; NMDA-R1, N-
methyl D-aspartate receptor subtype 1; eNOS, endothelial nitric oxide synthase; iNOS, 
inducible NOS; nNOS, neuronal NOS; ANG, angiopoietin, GLUT1, glucose transporter 1; 
PGK, phosphoglycerate kinase; GluR2/3, glutamate receptor subunit; GFAP, glial 
fibrillary acidic protein; GAPDH, glyceraldehydes 3-phosphate dehydrogenase. 
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HUMAN (ARPE-19 cells) 
 
Matsuda, S, Gomi, F, Katayama, T, Koyama, Y, Tohyama, M, and Yasuo Tano (2006). 
Induction of Connective Tissue Growth Factor in Retinal Pigment Epithelium Cells by 
Oxidative Stress.  Jpn J Ophthalmol 50:229–234 
 
 
CTGF  
Forward 5’-CGGCTTACCGACTGGAAGAC 
Reverse 5’-CGTCGGTACATACTCCACAG 
 
VEGF 
5’-CAGCGCAGCTACTGCCATCCAATCGAGA 
5’-GCTTGTCACATCTGCAAGTACGTTCGTTTA 
 
human or mouse β-actin  
5′-TCCTCCCTGGAGAAGAGCTA 
5′-TCCTGCTTGCTGATCCACAT 
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RAT (corpus collosum from brains of rats in hypoxic environment) 
 
Kaur C, Sivakumar V, Ang LS and Sundaresan A (2006). Hypoxic damage to the 
periventricular white matter in neonatal brain: role of vascular endothelial growth factor, 
nitric oxide and excitotoxicity. J Neurochem. 98:1200-16. 
 
 
Primer                                                  Amplicon size 
 
HIF-1α 
Forward: 5’-TCAAGTCAGCAACGTGGAAG  
Reverse: 5’-TATCGAGGCTGTGTCGACTG   198 bp 
 
VEGF  
5’-AGAAAGCCCAATGAAGTGGTG  
5’-ACTCCAGGGCTTCATCATTG      177 bp 
 
NMDA-R1  
5’-AACCTGCAGAACCGCAAG 
5’-GCTTGATGAGCAGGTCTATGC     333 bp 
 
eNOS  
5’-TGGCAGCCCTAAGACCTATG  
5’-AGTCCGAAAATGTCCTCGTG     243 bp 
 
iNOS  
5’-CCTTGTTCAGCTACGCCTTC  
5’-GGTATGCCCGAGTTCTTTCA      179 bp 
  
nNOS  
5’-AACCTGCAGAACCGCAAG  
5’-GCTTGATGAGCAGGTCTATGC     617 bp 
 
β-actin  
5’-TCATGAAGTGTGACGTTGACATCCGT  
5’-CCTAGAAGCATTTGCGGTGCAGGATG    285 bp 
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RAT (retinas) 
Kaur C, Sivakumar V, and Foulds WS (2006). Early response of neurons and glial cells 
to hypoxia in the retina. Invest Ophthalmol Vis Sci. 47:1126-41 
 
Primer        Amplicon Size 
 
HIF-1α 
Forward: 5’-TCAAGTCAGCAACGTGGAAG  
Reverse: 5’-TATCGAGGCTGTGTCGACTG     198  
 
VEGF  
5’-AGAAAGCCCAATGAAGTGGTG  
5’-ACTCCAGGGCTTCATCATTG       177  
 
NMDA-R1  
5’-AACCTGCAGAACCGCAAG  
5’-GCTTGATGAGCAGGTCTATGC      333  
 
GluR2  
5’-CTATTTCCAAGGGGCGCTGAT  
5’-CAGTCCAGGATTACACGCCG      539  
 
GluR3  
5’-CGCAGAGCCATCTGTGTTTA  
5’-GTTGCCACACCATAGCCTTT       180   
 
eNOS  
5’-TGGCAGCCCTAAGACCTATG  
5’-AGTCCGAAAATGTCCTCGTG      243  
 
iNOS  
5’-CCTTGTTCAGCTACGCCTTC  
5’-GGTATGCCCGAGTTCTTTCA       179  
 
nNOS  
5’-AACCTGCAGAACCGCAAG  
5’-GCTTGATGAGCAGGTCTATGC      617  
 
β -Actin (96% identity with mouse) 
5’-TCATGAAGTGTGACGTTGACATCCGT  
5’-CCTAGAAGCATTTGCGGTGCAGGATG     285 
 
 
 278
Appendix B: (Continued) 
 
 
 
MOUSE 
 
Shao G, Gao C, and Lu G (2005). Alterations of hypoxia-inducible factor-1 alpha in the 
hippocampus of mice acutely and repeatedly exposed to hypoxia. Neurosignals 14:255–
261. 
 
GAPDH primers:  
Forward 5’-CCCTTCATTGACCTCAAC-3  
Reverse: 5’-TTCACACCCATCACAAAC-3  
 
HIF-1α primers: 
5’-TATAAACCTGGCAATGTCTCC-3 
5’-GATGCCTTAGCAGTGGTCGT-3 
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MOUSE (Used C57Bl mice) 
 
Kociok N, Krohne TU, Poulaki V, and Joussen AM (2006). Geldanamycin treatment 
reduces neovascularization in a mouse model of retinopathy of prematurity. Graefe’s 
Arch Clin Exp Ophthalmol. 245:258-66. 
 
VEGF:  
Forward 5′-CAG CTA TTGCCG TCC GAT TGA GA-3′ and 
Reverse 5′-TGC TGG CTT TGG TGA GGT TTG AT-3′ 
 
ANG1:  
5′-CTG ATG GAC TGG GAA GGG AAC C-3′ and 
5′-CGC AGA AAT CAG CAC CGT GTA AG-3′ 
 
ANG2:  
5′-GAA GGA CTG GGA AGG CAA CGA-3′ and 
5′-CCA CCA GCC TCC TGA GAGCAT C-3′ 
 
GAPDH: 
5′-AAC TTT GTG AAG CTC ATT TCC TGG TAT-3′ and  
5′-CCT TGC TGG GCT GGG TGG T-3′ 
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MOUSE (Used C57Bl mice) 
Lazovic JL, Basu A, Lin H, Rothstein, RP, Krady K, Smith MB, and Levison SW (2005). 
Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 
type 1 receptor-deficient mice conferring neuroprotection. Stroke. 36:2226-31. 
 
iNOS  
Forward 5'-CCCTTCCGAAGTTTCTGGCAGCAGC-3'  
Reverse 5'-GGCTGTCAGAGCCTCGTGGCTTTGG-3'  
 
eNOS  
5'-TTCCGGCTGCCACCTGATCCTAA-3'  
5'-AACATATGTCCTTGCTCAAGGCA-3'  
 
Cyclophilin  
5'-CCATCGTGTCATCAAGGACTTCAT-3'  
5'-TTGCCATCCAGCCAGGAGGTCT-3' 
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MOUSE (Used primary mouse hepatocytes) 
 
Allena JW, Johnsonb RS, Bhatia SN (2005).  Hypoxic inhibition of 3-
methylcholanthrene-induced CYP1A1 expression is independent of HIF-1alpha. 
Toxicology Letters 155, 151–159. 
 
VEGF   
Forward 5’-AGTCCCATGAAGTGATCAAGTTCA  
Reverse 5’-ATCCGCATGATCTGCATGG 
 
PGK  
5’-CAAATTTGATGAGAATGCCAAGACT 
5’-TTCTTGCTGCTCTCAGTACCACA 
 
GLUT-1  
5’-GGGCATGTGCTTCCAGTATGT  
5’-ACGAGGAGCACCGTGAAGAT  
 
CYP1A1 
5’-AAAACACGCCCGCTGTGAA  
5’-TGAATCACAGGAACAGCCACC  
 
β-Actin 
5’-AGGCCCAGAGCAAGAGAGG  
5’-TACATGGCTGGGGTGTTGAA 
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MOUSE: Antibodies used for immunohistochemistry and immunofluorescence 
 
Kaur C, Sivakumar V, Ang LS and Sundaresan A (2006). Hypoxic damage to the 
periventricular white matter in neonatal brain: role of vascular endothelial growth factor, 
nitric oxide and excitotoxicity. J Neurochem. 98:1200-16. 
 
Antibodies         Dilution 
 
VEGF  
Rabbit-polyclonal Santa Cruz Biotechnology (Santa Cruz, CA, USA)      1: 200 
 
NMDA-R1  
Rabbit-polyclonal Chemicon International Inc. (Temecula, CA, USA)      1: 200 
 
eNOS  
Mouse-monoclonal BD Biosciences (Franklin Lakes, NJ, USA)      1: 250 
 
iNOS  
Mouse-monoclonal BD Biosciences (Franklin Lakes, NJ, USA)    1: 1000 
 
nNOS  
Rabbit-polyclonal BD Transduction (Franklin Lakes, NJ, USA)      1: 500 
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RAT (retinas) 
Kaur C, Sivakumar V, and Foulds WS (2006). Early response of neurons and glial cells 
to hypoxia in the retina. Invest Ophthalmol Vis Sci. 47:1126-41 
 
Antibodies         Dilution 
 
VEGF  
Rabbit polyclonal Santa Cruz Biotechnology, Santa Cruz, CA    1:200  
 
GluR2/3  
Rabbit polyclonal Chemicon International Inc., Temecula, CA   1:200  
 
NMDA-R1  
Rabbit polyclonal Chemicon International Inc., Temecula, CA    1:200  
 
eNOS  
Mouse monoclonal BD Biosciences, San Diego, CA     1:250  
 
iNOS  
Mouse monoclonal BD Biosciences, San Diego, CA    1:1000  
 
nNOS  
Rabbit polyclonal BD Transduction Labs, San Jose, CA     1:500  
 
GFAP 
Mouse monoclonal Chemicon International Inc., Temecula, CA   1:1000   
 
Glutamine synthetase  
Rabbit polyclonal Sigma-Aldrich, Ann Arbor, MI      1:600 
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